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8Chapter 1
Between the year 1856 and 1863 Gregor Mendel, a monk from Austria, cultivated 
thousands of plants to study how specific traits, such as the shape and colour of the 
flowers, are inherited from one generation to the next. Mendel hypothesized there 
had to be specific factors or hereditary units that resulted in inherited features. Based 
on the observations from the cultivating studies, Mendel hypothesised that I) every 
organism contains two factors for each trait, II) factors are passed independently from 
the parent to the offspring, and III) one factor could mask the contribution of the second 
factor at the hereditary units where the first factor is dominant over the second.1
It would take many decades before Mendel’s laws of inheritance would be widely 
accepted by the scientific community and to unravel how the factors (or hereditary units) 
hypothesised by Mendel resulted in inherited features. Now we know that the heredity 
information is stored in the deoxyribonucleic acid (DNA), and we know that this DNA 
consists of four bases: adenine (A), cytosine (C), guanine (G) and thymine (T) (Figure 1). 
Furthermore, the human DNA is stored in 46 chromosomes and forms 23 chromosomes 
pairs where each factor of each trait is, as hypothesised by Mendel, present twice (i.e. 
diploid). Alterations in these bases, called mutations, can occur (in the sperm and eggs) 
and these can be passed on from generation to generation and in this way normal traits, 
but also pathogenic traits (diseases), can be passed on to the offspring.
The studies of Mendel are the foundation for our current understandings of 
single-gene traits in human, For this reason, single-gene traits are now termed 
Mendelian disorders and Gregor Mendel is referred to as the “father of modern 
genetics,” acknowledging his contribution to inheritance and genetics. In humans, the 
phenotype can be diverse and can vary in physiological and pathogenic ways. Medical 
genetics studies the mechanisms, diagnosis, and management of genetic disorders. 
The impact of Mendel’s work on current day medical genetics is illustrated by the 
3,874 genes in which mutations are currently known to lead to a disease phenotype 
in humans. This database has the suitable name: “Online Mendelian Inheritance in 
Man” (OMIM) 2. Conversely, there are 6,153 phenotypes for which the molecular basis 
is known (mutations in some genes can result in multiple phenotypes).
However, Mendelian inheritance does not do justice to the full complexity of 
genetics. Most traits are not the result of a single alteration in the DNA. Traits may 
show complex, multifactorial, and polygenic inheritance, implicating an effect resulting 
from lifestyle3, environmental factors4, in combination with alterations in multiple 
genes5. Skin pigmentation is an example of a trait that is the result of the genetic 
composition and environment. The pigmentation of the skin is highly inheritable, 
affected by multiple genes, and is strongly influenced by a non-genetic factor, exposure 
to ultra violet light 6. This complex interaction between genes and the environment 
makes it difficult to unravel the underlying mechanisms of many common traits.
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Figure 1. Illustration of a cell and different DNA structures. DNA consists of four base pairs (A, C, 
G, and T) and forms a complementary, double-stranded helix structure. The DNA strand is tightly 
wrapped around histones to form nucleosomes. The nucleosomes form chromatin structures. By 
tightly stacking up chromatins, chromosomes are formed. The nucleus of a human cell contains 
46 chromosomes. (Figure adapted from 7)
The central  dogma of molecular biology
Based on the plant breeding studies, Mendel hypothesized that there have to be 
certain factors that resulted in inherited features. However, it remained unclear 
what these hereditary units were and how they would result in a trait. It took roughly 
100 years before Francis Crick in 1958 explained how the genetic information flows 
within a biological system: from DNA to RNA to protein. This is defined as the “central 
dogma of molecular biology” 8,9.
The human genome consists of 20,000 protein-coding genes that account for 1-2% 
of the human genome10,11. These regions translate into functional protein molecules. 
First, the sequence is entirely transcribed into a complimentary copy of the DNA in the 
form of pre-messenger ribonucleic acid (pre-mRNA). The pre-mRNA sequence consists 
of exons, introns and untranslated regions (UTR). Splice sites indicate the boundaries 
between the introns and exons. When the pre-mRNA sequence is processed into a 
mature mRNA molecule, introns are removed from the pre-mRNA sequence leaving 
only the exons present in the mRNA. The mRNA is transported outside of the nucleus 
into the in the cytosol of the cell where the ribosomes are located.
1
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Figure 2. Illustration of how genetic information flows within a biological system. The DNA se-
quence is transcribed into pre-messenger RNA (pre-mRNA). The pre-RNA is processed into ma-
ture-mRNA by the removal of the 5’ UTR, 3’ UTR, intronic sequences, and the addition of a 5’ cap 
and a poly-A-tail. The codons of the mRNA will be translated into a protein sequence until a stop 
codon is encountered.
Once the mRNA arrives at the ribosomes, the protein-translation process can be 
initiated. During this process, the mRNA molecule will be translated into a sequence 
of amino acids that will form a protein molecule. The mRNA is translated based 
on the sequence of a codon. A codon consists of three mRNA bases (a triplet) and 
codes for a specific amino acid. The translation process is initiated by the chain-
initiation codon (or start codon) “ATG” which will be translated into the amino acid 
“Methionine.” From this point on the amino acid sequence will be elongated by 
one of the 20 amino acid based on the triplet-codon. The synthesis process will be 
terminated when a stop codon (TAG, TAA or TGA) is reached and the amino acid 
sequence will be released (and a protein will be formed).
The central dogma of molecular biology describes in detail how information of 
the DNA sequence is transferred into protein and explains how genetic variation 
results in physical traits. Small alterations in the DNA-sequence can have a variety 
of effects on the functioning of a protein.
A codon consists of three nucleotides, which means there are 64 codons possible 
with the four bases A, C, T, and G. Three codons contain a termination sequence 
and a total of 61 codons code for 20 different amino acids. This means a certain 
redundancy is present in the codon sequence. Different codons can be translated 
into the same amino acid. Synonymous variants are alterations in the DNA sequence 
11
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that change the codon while leaving the encoded amino acid unchanged. These 
changes usually occur in the third position of the codon. For example, there are 
four codons that translate into the amino acid Glycine (GGA, GGC, GGG, and GGT). 
Any change in the last position of the codon will result in the same amino acid being 
incorporated in the protein sequence at that position.
Figure 3. DNA variants can alter the flow of genetic information. A. In this example, the alteration 
of the wild-type cytosine (C) can have different effects on the amino acid sequence: I) A synonymous 
variant, changing the C into a thymine (T) does not change the amino acid sequence. II) A missense 
variant, changing the C into a guanine (G) substitutes the amino acid cysteine (Cys) into a Tryptophan 
(Trp). III) A nonsense mutation, changing the C into an adenine (A) creates a premature stop codon. 
B. In an exon, unless the length of the indel is divisible by three, will produce a frame-shift (IV). An 
in-frame indel occurs when the reading frame is not altered by the indel (V).
However, changing a single nucleotide can lead also to a change in a codon that alters 
one amino acid in the protein (i.e. non-synonymous). The incorporation of an amino 
acid with different chemical properties is called a missense variant and this can have 
severe consequences for the structure and functioning of the protein. A special case of 
a non-synonymous substitution is a nonsense variant in which a codon that encodes 
one of the amino acids, changes into one of the three stop codons. This results in a 
premature truncation of the produced mRNA that will be degraded by the nonsense-
mediated decay (NMD) pathway, and no protein product is formed12,13. The insertion or 
deletion of nucleotides can alter the reading frame, resulting in a completely different 
translation from the original, and typically resulting in a premature stop-codon, again 
giving rise to NMD. However, when the inserted or deleted sequence is divisible by 
three, the reading frame does not alter. Such in-frame insertions and deletions can, 
nevertheless, lead to an abnormal protein product14. Figure 3 and Figure 4 provides 
an overview of variants and the effect on the mRNA and protein level.
1
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Figure 4. The effect of splice-site mutations. Exon sequence (illustrated by the yellow rectangle) is 
flanked by specific base pair splice sites, which are required for splicing. Alterations located in the 
3’acceptor site (I) and 5’ donor site (II) disrupt the correct formation of mRNA during the maturation 
of the mRNA.
Genetic Variat ion
The average proportion of the DNA that differs from person to person is estimated 
to be between 0.1% – 0.4%15. Based on the thousand genomes project, where the 
complete DNA (i.e., the genome) of 2,504 individuals was determined, a typical 
genome differs on 4.1 – 5.0 million locations to the human reference genome16. In 
almost all (>99.9%) variation consists of single nucleotide variants (SNV) or small 
insertions and deletions (indels). A recent study of 60,706 individuals detected a total 
of 7,4 million high-quality variants in the protein-coding regions corresponding to an 
average of one variant for every 8 base pairs (bp) within the exome intervals17. This 
study revealed that 99% of identified variants is present in less than 1% of individuals 
and 54% of variants are observed only once in the data set, illustrating the variability 
within the protein-coding regions of the human genome. Given that the human 
genome consists of 3 billion nucleotides, one variant is present on average every 
600 bases in any individual. The protein-coding regions make up only 1-2% of the 
entire genome and on average have about 22,000 variants.
In addition to single nucleotide variants, the genome can vary in its structure. 
These variations are called structural variations and include copy-numbers 
variations (CNVs) and inversions of stretches of DNA. CNVs are variants for which 
extra bases are inserted (i.e. insertions) or deleted (i.e. deletions) from the DNA. 
In the case of a duplication, the genome has an extra copy of a genomic region 
in addition to the two copies already present, whereas in the case of a deletion 
one copy of a genomic region is lost. In the case of an inversion, a DNA segment is 
reversed end to end. This type of DNA rearrangement does not have to result in a 
change of the total amount of genetic material. An average human genome harbours 
an estimated 2,100 to 2,500 structural variations affecting more bases of sequence 
(about 20 million) than SNVs and small indels16.
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Molecular mechanisms of disease
As illustrated by the previous paragraphs and in Figure 3, the downstream impact 
of variants in the DNA sequence can vary from being benign to severely affecting 
mRNA and protein synthesis potentially disrupting crucial cellular processes thereby 
causing disease or even lethality. There are multiple mechanisms known through which 
mutations (i.e. pathogenic variants) can give rise to disease. Gregor Mendel already 
realized during his plant breeding experiments the importance of a diploid genome, 
meaning that for every gene on the autosomes a backup copy exists in case one copy 
becomes non-functional as the result of a mutation. Many genes, however, require two 
functional copies for normal development and for maintaining normal cell function. 
Such genes are called haploinsufficient because a reduction in the amount of protein 
that they encode for will result in disease. Other mechanisms include gain-of-function 
mechanisms (the function of the protein is altered, resulting in disease) or dominant-
negative mechanisms (a mutation in one copy of the gene also affects the other copy, for 
example, because the resulting protein interacts with itself to form homo-oligomers).
Sequencing
The publication of all 5,386 nucleotides of the bacteriophage φX174 in the year 
1977 marked the sequencing of the first complete genome of an organism18. In that 
same year, the method used to sequence the genome of the bacteriophage φX174 
was published by the group of Frederick Sanger19. The technique, known as “Sanger 
sequencing,” is considered a breakthrough for the scientific community and allowed 
rapid and accurate sequencing of long stretches of DNA. In the year 2001, 24 years after 
the genome of the bacteriophage φX174, the completion of the Human Genome Project 
(HGP) was announced during a White House press conference, marking the next 
breakthrough in human genetics. 13 years, 3.4 billion US dollars, and an international 
collaboration of around 200 labs located in more than 18 countries managed to 
determine the three billion bases of the human genome20,21. With the publication of the 
complete human genome, predictions were made that most genetic diseases would 
be unravelled within the next ten years. However, understanding the link between the 
genome and disease was far more complex than most scientists imagined.
Next-generat ion sequenc ing
In the wake of the completed HGP, the sequencing price started to drop significantly22. 
The introduction of the Massive Parallel Sequencing (MPS) techniques marked the 
start of the “next-generation sequencing” (NGS) era. NGS is based on the concept 
of massively parallel sequencing in a single reaction. Next-generation sequencing 
techniques have shown rapid development and made a significant impact on 
1
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how genetic research is conducted. They have allowed us to look at mutations in 
all genes or even the entire genomes in a single experiment. There are now two 
relatively unbiased NGS approaches that are very popular for detecting genetic 
variation within an individual: exome and genome sequencing. Currently, there are 
sequencing platforms available that claim to read an entire human genome within 
days for a price of 1,000 US Dollars, making this technique affordable for research 
and diagnostic applications around the world23.
Genome sequenc ing
Genome sequencing (GS or whole genome sequencing; WGS) is the process where 
variation in all the base pairs of the genome are determined in a single experiment. 
GS is considered to be the most comprehensive genetic test so far24. GS serves 
as a single genetic test to reliably identify and characterize the comprehensive 
spectrum of genetic variation. One single GS experiment provides a comprehensive 
overview of all SNVs and structural variants of a person that in the past would have 
required multiple different experiments. At this stage, GS is still under development, 
especially structural variants are difficult to comprehensively detect with short-read 
sequencing approaches which now are the most affordable.
Exome sequenc ing
Protein-coding regions harbour an estimated 85% of the mutations that have 
significant effects on disease-related traits25. Exome sequencing (or whole exome 
sequencing; WES) targets the 1% of the genome that encode for proteins (the exons 
of the genes). Exome sequencing utilises a specialized protocol that selects protein-
coding DNA regions followed by sequencing on an MPS platform. Although GS 
represents the ultimate genetic experiment, exome sequencing offers advantages 
regarding costs, speed, and ease of data storage and analysis. Chapter 6 provides 
a comprehensive comparison of the ability of WES and WGS technologies to achieve 
sufficient coverage in the protein-coding regions of the human genome, to reliably 
detect of variation.
Bioinformat ics
The introduction of NGS has increased the scale at which genomic data is being 
generated and that has created new challenges on how to efficiently store, analyse 
and interpret data of this magnitude. Solutions from other fields, such as computer 
science and statistics, had to be introduced to tackle the challenges in data analysis, 
firmly establishing a role for bioinformatics within the field of genetics.
15
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Bioinformatics has been central to the analysis and interpretation of NGS data. 
Bioinformatic workflows involve quality control and mapping of the sequencing 
reads to the reference genome, variant calling, variant annotation, and (long-
term) storage on data systems. Chapter 2 of this thesis discusses in detail the 
bioinformatic analysis and challenges of sequencing data and the directions where 
the field is moving.
Diagnosis and de novo  mutat ions
The widespread adoption of NGS technologies by the genetics community and the 
rapid decrease in costs per base, allowed exome sequencing to become a standard 
within the repertoire of diagnostics. The introduction of exome sequencing has 
made a significant impact on the diagnostic sequencing yield26. In addition, the 
technique allowed for the detection of de novo mutations using patient-parent trio 
sequencing (See Figure 5). De novo mutations are alterations present in the genome 
of the offspring that are not inherited from the parents. Upon fertilization, a human 
zygote inherits half of its genome from the mother via the oocyte and the other 
half from the father through the sperm. De novo mutations occur either during 
the formation of the gametes or post-zygotically27-29. In addition to the genetic 
information passed on from generation to generation, each of us is born with 
45-60 de novo mutations in the germline27,28. De novo mutations can explain why 
early onset diseases with severely reduced fecundity, such as intellectual disability, 
remain frequent in the human population30,31.
Figure 5: A family-tree showing a de novo mutation. Squares indicate indexes of the male sex and 
circles indicate females. Both parents (Generation I) have wild-type alleles and have two children 
(generation II). One of the children has wild-type alleles and one has a de novo variant, which is 
depicted as a red stroke on the schematic chromosomal representation.
1
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Gene -disease ident i f icat ion in inte l lectual disabil i ty
De novo mutations were identified to be the cause of many recognizable syndromes 
involving severe congenital neurodevelopmental disorders such as intellectual 
disability. In 2010, the genes for Schinzel Giedion32 (SETPB1) and Kabuki syndrome33 
(MLL2) were identified by exome sequencing of a surprisingly low number of 
respectively 4 and 14 probands. Patient selection based on well-characterized 
overlapping phenotypes turned out to be the key to the success of these studies, 
as this allowed for the identification of recurrently mutated genes. For non-
syndromic forms of intellectual disability, the extreme genetic heterogeneity would 
complicate a similar approach, and therefore scientists decided to sequence not 
only the patient’s exome but also that of his/her parents, in order to identify de novo 
mutations as a potential cause of the intellectual disability.
The first systematic trio-based exome sequencing study of patients with 
unexplained intellectual disability (ID) identified a possible causal de novo 
mutation in six of the ten patients studied31. This study corroborated a de novo 
paradigm for intellectual disability and hypothesized that together with de novo 
copy number variation, de novo point mutations could explain the majority of all ID 
cases in the population, something that was later confirmed in the first trio-based 
genome sequencing study in ID34. Similarly, a substantial contribution of de novo 
mutations was found for other disorders, such as autism spectrum disorders35 
(ASD), schizophrenia36 (SZ) and epileptic encephalopathies37 (EE) supporting a large 
contribution of de novo mutation in neurodevelopmental disorders. The results of 
currently the largest trio study of de novo mutations in patients with unexplained 
ID will be discussed in chapter 3 of this thesis.
Chal lenges: the c l in ical  heterogenei ty of  intel lectual  d isabi l i ty
The clinical heterogeneity of ID is reflected by extreme genetic heterogeneity. 
Currently, there are over 1,500 genes associated with developmental disorders and 
ID [chapter 3 and chapter 4]. A recent publication estimated that developmental 
disorders, including ID, have an average prevalence of 1 in 213 to 1 in 448 births. 
Given current global demographics, this equates to almost 400,000 children born 
per year 38. Most of these disorders are caused by de novo mutations. 34,38,39
An understanding of the genetic cause of intellectual disability can benefit 
patients and their families. A diagnosis potentially provides information on the 
disease-prognosis, appropriate therapy, and averts further costly and unnecessary 
testing. Family members may benefit from the knowledge of the risk of recurrence, 
reproductive counselling, and possible prenatal diagnosis30. Furthermore, the 
17
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identification of disease genes contributes to our understanding of gene functions 
and biological pathways underlying health and disease in general40,
Currently, for 31-42% of patients with neurodevelopmental disorders and ID a 
genetic diagnosis can be made based on the mutations identified by next-generation 
sequencing techniques 34,38,39. This raises the question of what are the causes of 
the developmental disorders in the other 58-69% of patients. It is expected that 
there are many more pathogenic, coding mutations in these undiagnosed patients 
are present, although compelling evidence is currently lacking. The discovery of 
the remaining disease genes requires larger studies and novel, more powerful, 
analytical strategies for a disease gene association that leverage gene-specific 
patterns 38,39. Chapters 3, 4, and 5 show how novel computational methods applied 
to large cohorts of patients can be used to identify new disease genes.
1
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AIM AND SCOPE OF THIS THESIS
The introduction of next-generation sequencing had accelerated disease gene 
identification for rare monogenic ID based on commonly affected genes in patients 
with clinically well-defined syndromes or based on recurrent de novo mutations in 
small series of non-syndromic diseases. The aim of this thesis was to develop and 
apply novel computational methods to identify novel candidate disease genes for 
intellectual disability in exome data of large patient cohorts.
In chapter 2 I discuss bioinformatic challenges in the analysis of exome 
sequencing data, the recent developments in this field, and the directions that these 
are taking us to.
Chapter 3 presents a meta-analysis of de novo mutations of 2,104 patients with 
intellectual disability and neurodevelopmental disorders. In this chapter, I describe 
how we discovered ten novel candidate genes based on the statistical enrichment 
of de novo mutations in genes.
Chapter 4 describes how clusters of missense de novo mutations can be 
exploited to identify novel disease genes. We developed a method to accurately 
identify genes with significant spatial clustering patterns of de novo mutations 
in large patient cohorts. Application of the method to a large cohort of patients 
identified three novel candidate genes for intellectual disability.
In chapter 5 we investigate the use of mutational burden analysis to identify 
novel genes in a variety of patient cohorts, including intellectual disability.
In chapter 6 I explore the extent to which whole-genome sequencing could offer 
improved coverage of protein-coding region compared to whole exome sequencing.
Chapter 7 Provides a general discussion of the thesis and perspectives for future 
research.
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ABSTRACT
With the widespread adoption of next-generation sequencing technologies by the 
genetics community and the rapid decrease in costs per base, exome sequencing 
has become a standard within the repertoire of genetic experiments for both 
research and diagnostics. Although bioinformatics now offers standard solutions 
for the analysis of exome sequencing data, many challenges still remain; especially 
the increasing scale at which exome data are now being generated has given rise 
to novel challenges in how to efficiently store, analyze and interpret exome data 
of this magnitude. In this review we discuss some of the recent developments in 
bioinformatics for exome sequencing and the directions that this is taking us to. 
With these developments, exome sequencing is paving the way for the next big 
challenge, the application of whole genome sequencing.
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INTRODUCTION
Bioinformatics has been central to the analysis and interpretation of exome sequencing 
data. Initial bioinformatics challenges concerned quality control; short read-mapping 
1,2, variant calling 3-5, and variant annotation 6-9. Most of these challenges have now 
been tackled to a degree that bioinformatic workflows are available to analyze and 
interpret exomes in a standard fashion and provide workable results 10,11. Some of the 
original hurdles have simply become less relevant with the progression of technology 
giving rise to more and higher quality sequence data and longer sequence reads 
(e.g. the ambiguous alignment of very short sequencing reads). Nevertheless, quality 
control of exome sequencing data still remains a necessity in order to guarantee 
reliable downstream results. This task has now become fairly routine through the 
development of several software packages that facilitate the assessment of standard 
quality control measures for exome sequencing 3,5,12,13.
With the widespread adoption of next-generation sequencing (NGS) technologies 
by the genetics community and the rapid decrease in costs per base, exome 
sequencing has become a standard within the repertoire of genetic experiments for 
both research and diagnostics 14,15. Although whole genome sequencing represents 
the ultimate genetic experiment, exomes still offer advantages in terms of costs, 
speed and ease of data storage and analysis. The steady increase of sequencing 
capacity and the widespread application of exome sequencing has allowed the 
sequencing of thousands of individuals and studies with hundred thousands 
of exomes are already in progress 16-19. As an example, the Exome Aggregation 
Consortium (ExAC) collected a dataset of over 60,000 individuals and will grow 
even larger in the nearby future 20. This scale at which exome data are now being 
generated has given rise to novel challenges in bioinformatics to store, analyze and 
interpret exome data of this magnitude 21. In this review we will discuss some of the 
recent developments in bioinformatics for exome sequencing. We have summarized 
some of the tools that we believe may be of interest to the reader in Table 1.
More data ,  more storage
With growing datasets, simply storing data becomes a challenge that all laboratories 
will at some point need to face. Sequencing instruments typically generate FASTQ files 
containing all individual sequencing reads. After alignment the resulting reads are 
stored in the Sequence Alignment/Map (SAM) format that describes where sequence 
reads are mapped onto the reference genome. SAM files are usually compressed into 
the binary SAM (BAM) format that reduces the file size 3-4 times 5. The BAM format 
is currently the de facto standard format for aligned reads and can be used by a large 
variety of downstream analysis and visualization tools 5,12,22. Genomic variants that are 
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subsequently identified based on the BAM file are then stored in a variants call format 
(VCF) 23. The typical size of a single exome BAM file is within the range of Gigabytes 
whereas the VCF file is usually no more than 100 Megabytes.
Storing less
The most straightforward method for reducing data storage needs is by simply 
storing less data, or by removing data as soon as possible. As an example, sequencing 
instruments currently only store raw images of the sequencing process a limited time 
for trouble-shooting after which they are discarded. Similarly, many labs no longer keep 
the original raw sequencing reads (FASTQ file) after alignment since modern sequence 
aligners also include reads in the BAM file that are not aligned to the genome. This 
adds a little bit to the size of the BAM files but there is no longer any need for storing 
FASTQ files, since raw reads can now be regenerated from the alignment files by tools 
like Picard24 and SAMtools5. This potentially reduces storage requirements by half. In 
addition to this, several clinical guidelines have been proposed that allow diagnostic 
laboratories to remove the alignment files after 1 or 2 years 25,26. However, although 
VCF files contain the primary result of the experiment it is worthwhile to keep BAM 
files for future analysis since they contain much more information than VCF files. For 
example the identification of CNVs 27, somatic mutations 28, and mitochondrial DNA 
variation 29. It is not uncommon that reanalysis of FASTQ or BAM files can identify 
additional variants that were initially missed 30.
Compression
An alternative to the straightforward removal of large files to save space is data-
compression. This has already been introduced for raw sequence files that are now 
by default compressed with gzip.
Although the SAM/BAM format is convenient in the sense that it contains 
almost all information of the original reads and all details about the alignment 
in an intuitive fashion, it was not designed for efficient storage 5. Since BAM files 
are already in binary format, ordinary compression algorithms cannot significantly 
reduce their size. However, specialized compression tools use various techniques 
to further reduce the size of BAM files. First of all non-essential information, e.g. 
read identifiers, can be removed. Secondly, the majority of the exome will be the 
same as the reference genome and can be stored more efficiently: Reference-
based compression encodes reads based on a reference sequence and stores only 
positions that differ from the reference sequence 31,32. For regions where there are 
no differences to the reference genome, only coordinates and depth information are 
retained. Lastly, individual base quality scores (or Q scores) are typically encoded 
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as PHRED-like scores within a range of 0-40 33. These quality scores are used to 
optimize read-mapping and variant calling. However, the scale of quality scores 
is very fine-grained and encoding Q scores into bins reduces storage space 34,35. 
Binning quality scores often results in compression with some loss of information 
(lossy compression), where the original quality scores lose precision during 
compression. The lost precision does, however, not necessarily result in significant 
loss of accuracy for variant calling 36.
Based on these approaches, alternative formats such as Goby 37, SlimGene 38, CRAM 
31 and DEEZ 39, have been introduced that attempt to keep as much of the original 
information yet at a lower cost of disk space than BAM. In particular, the CRAM format 
has gained a lot of traction. Compression of a BAM file to CRAM format with the 
Scramble tool resulted in file reductions of 38-55% with a compression time of a few 
minutes 40. CRAM compression has already been applied to tackle storage-capacity 
problems in large databases such as Sequence Read Archive (SRA) 41 and the 1000 
Genomes project42. The CRAM format is now supported by some widely used genomic 
analysis tools such as SAMtools, Picard and GATK 3,5. With the increasing support for 
the CRAM format, it may well replace the use of BAM files in the near future.
With ever growing datasets containing variants of thousands of individuals, it 
becomes worthwhile to compress the relatively small VCF files as well. The Tabix 
format offers a convenient compression format for large VCF files. This reduces file 
sizes roughly 3-5 times, and also supports indexing to perform efficient querying of 
genome positions 43. Some common resources are already available in Tabix format 
such as dbSNP 44 and Combined Annotation-Depended Depletion (CADD) scores 45. 
Another option is to use the recently published Genotype Query Tools (GQT) to index 
and compress large number of VCF files. This tool also facilitates fast querying. GQT 
was used to compress the Exome Aggregation Consortium (ExAC) VCF file, consisting 
of 9.36 million exonic variants for 60,706 individuals, from 14.1 TB to 28 GB 46.
All in all, the growing need to reduced storage space is leading to new data formats 
for alignment and variant files and smarter algorithms to query these efficiently.
Cloud-based solut ions
Compression of data is an easy and efficient way to reduce storage needs, but in the 
end the reduction in data sizes is limited. An alternative is to store large amounts of 
genomics data in the cloud. Cloud storage offers several out-of-the-box advantages 
to local storage: it is scalable, has default access control policies, protects against 
data loss, allows for auditing, data encryption, easy sharing, and automation by 
programmable interfaces 47,48. Currently, there are multiple commercial providers of 
cloud services of which Amazon Web Services49 (AWS), Microsoft Azure50 and Google 
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cloud platform51 are the largest. In addition there are non-profit organizations 
offering cloud-computing solutions such as Open Cloud Consortium52.
Cloud storage is based on a “pay as you go” monetary model whereby one only 
pays for used storage that can be expanded ad hoc. Although cloud storage itself is 
relatively inexpensive with less than $100 for storing 1 TB of data per month, there 
are some additional costs to consider 53. While transferring data into the cloud 
storage is usually free of costs, analyzing and downloading data from the cloud 
can be relatively expensive. For example, downloading 1TB of data from the cloud 
costs approximately $120 per TB 53. This makes it worthwhile not only to keep data 
in the cloud but also to perform the analysis there and only download smaller result 
files. Special software is, however, needed to make efficient use of the scalability 
of the cloud-computing platform. Currently there are already a variety of tools for 
cloud-based mapping of sequence reads, 54,55, genotyping 56, variant annotation 
57 as well as complete cloud-based exome sequencing pipelines 58,59. Fusaro et al. 
showed that the alignment of the entire genome (4 billion paired reads, 35pb long) of 
a person in 48 h costing approximately $48 of cloud resources 48. According to Stein 
et al. the International Cancer Genome Consortium (ICGC) analyzed 500 genomes 
in the cloud for a price of $18 per sample whereas the authors estimate this would 
require $200 on standard computer systems 60.
Data stored into the cloud can also provide a solution for effective public and 
private data sharing. For example, the Amazon Web Services (AWS) contains 1000 
Genomes Project data 61 and accommodates 1,200 whole genome sequences of the 
ICGC. In addition, data from Ensembl and GenBank are being hosed in AWS and data 
transfer between AWS instances is free of charge 48. Furthermore, the US National 
Cancer Institute is exploring how the cloud could facilitate a cost-effective platform 
to store and share large amounts of tumor data62.
The uptake of cloud-based solutions by academic and non-academic hospital 
laboratories has been slow, likely because of practical concerns, unfamiliarity, as well 
as ethical and legal concerns of storing patient DNA data in the cloud 63. Although 
data storage in the cloud is relatively inexpensive, transferring vast quantities of 
sequencing data via the Internet from and into the cloud may be a considerable 
cost and a time-consuming process due to low network bandwidth 47,64. In addition, 
moving genetic data of patients to a third-party server introduces issues concerning 
security and privacy 65. This has limited the use of cloud-based storage solutions for 
most clinical NGS applications so far. However, given the advantages and a future 
of routine genome sequencing, it may well be unavoidable that all genomics data 
end up in the cloud for analysis and for patients and their physicians to access.
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Name Description Website
Data compression
CRAMtools
Framework to compress BAM files into CRAM 
format
https://github.com/
enasequence/cramtools
Scramble C implementation of CRAM to compress BAM into 
CRAM format for faster encoding
http://sourceforge.net/
projects/staden/files/
io_lib/
TABIX
Tool to index and query bgzip-compressed VCF 
formatted files, available via SAMtools
http://sourceforge.net/
projects/samtools/files/
tabix/
Genotype 
Query Tools
Toolset to compress and query VCF files. 
Designed to compress large scale cohorts
https://github.com/
ryanlayer/gqt
Cloud tools
CloudBurst
Cloud-based parallel read-mapping algorithm to 
map sequence reads to a reference
http://sourceforge.net/
projects/cloudburst-bio/
Cloud Aligner
Cloud-based Hadoop MapReduce-based 
approach mapping of sequence reads
http://cloudaligner.
sourceforge.net/
Crossbow
Cloud-computing software tool that combines 
read-mapping and the SNP genotyping
http://bowtie-bio.
sourceforge.net/
crossbow/index.shtml
VAT
Variant Annotation Tool (VAT) is a Cloud based 
platform to functionally annotate variants
http://vat.gersteinlab.
org/
Mercury
A whole exome sequencing analysis workflow 
deployed In the Amazon Web Services (AWS) cloud
https://www.hgsc.bcm.
edu/software/mercury
Variant prioritization tools
CADD
Combined 63 annotations into one meta-score 
(C-score) for the entire genome based on a SVM 
http://cadd.
gs.washington.edu/
Eigen
Spectral approach to the functional annotation of 
genetic variants in coding and noncoding regions. 
http://www.columbia.
edu/~ii2135/eigen.html
DANN
DANN used the same feature set and training data as 
CADD to train a deep neural network (DNN).
https://cbcl.ics.uci.edu/
public_data/DANN/
FitCons
Predictions of pathogenicity for the entire 
genome based on evolutionary conservation and 
functional data
http://compgen.cshl.edu/
fitCons/
SPANR/SPIDEX
Trained a model optimized for the prioritization of 
splice site variants with a deep learning approach
http://www.
deepgenomics.com/spidex 
HAL
Prioritization of splice site variants based on their 
effect of (alternative) RNA splicing
http://splicing.
cs.washington.edu
PHIVE
Analysis of exome variants by computing 
phenotype similarity between human disease 
phenotypes and phenotype information from 
knock-out experiments in model organisms
http://www.sanger.ac.uk/
resources/databases/
exomiser
RVIS
The Residual Variation Intolerance Score or RVIS 
is a gene based score to prioritize disease genes 
based on intolerant to genetic variation
http://genic-intolerance.
org/
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Name Description Website
CNV detection
CoNIFER
Detects rare CNVs in exome data based on 
sequence read-depth
http://conifer.
sourceforge.net/
XHMM
Uses principal-component analysis (PCA) to 
normalize exome read depth and a hidden 
Markov model (HMM) to detects CNVs
https://atgu.mgh.
harvard.edu/xhmm/
Codex
Normalization and CNV calling procedure for 
whole exome sequencing data
http://www.bioconductor.
org/packages/devel/bioc/
html/CODEX.html
Phenotypes
Phenotips
A software tool for collecting and analyzing 
phenotypic information for patients with genetic 
disorders.
https://phenotips.org/
PhenoDB
A software tool to store and analyze standardized 
phenotypic information.
http://phenodb.net
Phenominer A tool to extract structured phenotypes from text http://phenominer.mml.
cam.ac.uk/
Data sharing
ExAC
60,706 unrelated individuals sequenced as 
part of various disease-specific and population 
genetic studies
http://exac.
broadinstitute.org/
DECIPHER
Database contains data from 18,533 patients 
who have given consent for broad data-sharing
https://decipher.sanger.
ac.uk/
Café Variome
Platform to share genetic variant and phenotype 
data on a global scale
http://www.cafevariome.
org/
GeneMatcher
Online platform designed to connect clinicians 
and researchers from around the world who 
share an interest in the same gene or genes
https://genematcher.org/
RD-connect
Platform that links up data used in rare disease 
research into a central resource for researchers 
worldwide.
http://rd-connect.eu/
PhenomeCentral
Repository for secure data sharing targeted 
to clinicians and scientists working in the rare 
disorder community
https://www.
phenomecentral.org/
MatchMaker 
Exchange
Platform enabling matching of cases with similar 
phenotypic and genotypic profiles though a 
number of databases
http://www.
matchmakerexchange.
org/
Table 1. Overview of some of the novel bioinformatics tools related to the storage, analysis or 
interpretation of exome sequencing data.
Variant ident i f icat ion
To some extent, challenges for calling variants have become less urgent with improved 
exome enrichment assays, increasing sequence quality and read length and reduced 
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sequencing prices, allowing for higher coverage sequencing of the exome in individual 
patients. Whereas early comparisons of whole exome capture kits showed that 
around 80% of the human protein-coding sequence regions were captured at a 
minimal coverage of 20x 66, current exome capture kits and sequencing at minimal 
100x median average coverage capture more than 95% of the coding regions with a 
minimal coverage of 20x 67. Due to the increased coverage and improved sequencing 
quality for modern exomes, variant calling has become more reliable. Several studies 
have even demonstrated the identification of somatic mutations for rare syndromes 
28,68,69, which is only possible with high coverage. These improvements in exome 
quality have led some laboratories to reconsider the validation of sequencing variants 
by the gold standard Sanger sequencing. A recent validation study found that all single 
nucleotide variants with a Genome Analysis Toolkit (GATK) 3 quality score above 500 
were confirmed by Sanger sequencing and estimated that only validating variants with 
a quality score below this threshold would reduce the Sanger confirmation workload 
by 70–80% 70. Overall the significant improvements in exome sequencing quality 
may indeed eliminate the need for validation of high-quality variants. However, the 
detection of SNVs in NGS data has not been fully resolved and results from different 
variant callers remain inconsistent 11,71,72. In addition, small insertions/deletion (indels) 
are still particularly problematic to identify accurately 73. Highly accurate genotypes 
across the genome of a single individual as for example provided by the “Genome in 
a Bottle Consortium” may help resolve these issues in the future 72.
Detect ion of  copy number variants
From SNVs attention has moved towards the identification of other types of variants 
in exome sequencing data. In particular, the identification of copy number variation 
(CNV) from exome data poses an attractive possibility as CNVs are an important 
cause of disease 74. Genomic microarray platforms such as the SNP-array and Array 
CGH are the de facto standard to detect CNVs 75, whereas whole genome sequencing 
will likely be the preferred platform for the detection and characterization of CNVs 
as well as other structural variants 76. In contrast to microarrays and whole genome 
sequencing, exome sequencing targets only 1-2% of the protein-coding regions of the 
genome. The sparse and fragmented nature of exome data makes it more difficult 
to identify CNVs and methods rely mostly on depth-of-coverage approaches. For 
these approaches a normalized read count in a genomic window of a single individual 
is compared to that of other exomes. Normalization of read counts is required to 
counteract technical issues such as poor read mapability, GC bias, and batch effects 
between sequencing experiments 77. Many different algorithms have been devised 
based on read-depth methods, such as CODEX, Convex, Conifer, and XHMM 27,78-
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80. Comparisons of CNV algorithms for exome data have shown that none of the 
algorithms performed well in all situations and that the resolution is limited to at 
least three exome targets 27,80,81. Although this does not equal the sensitivity of high-
resolution microarrays, it is comparable to that of medium resolution microarrays 
that are still commonly used. Studies describing the large-scale application of 
CNV detection only based from exome data are, however, still limited 82, which 
may perhaps hint at some of the underlying difficulties to obtain robust CNV calls 
from exome data. The possibility to detect copy number variants in exome data is, 
however, a great benefit of exome sequencing that should not be ignored as CNVs 
contribute significantly to disease. The identification of other types of structural 
variants such as inversions, and the accurate prediction of CNV breakpoint remains 
challenging and whole genome sequencing is likely needed for this 83.
Variant interpretat ion
Sequencing the protein-coding regions of a patient typically yields tens of thousands 
of variants of which the majority is likely to be benign and only one or perhaps 
two variants contribute to the disease phenotype 84,85. The most effective way 
of distinguishing benign from pathogenic variants is based on using population 
frequencies of variants. For this approach all variants occurring in the population at 
higher frequencies than the disease prevalence are considered as benign. Databases 
with collections of exome variants of individuals without clear disease phenotypes 
have therefore been tremendously helpful to prioritize variants in Mendelian disease. 
This has given rise to several initiatives for large-scale variant databases with exome 
data 16,86. The largest of these, thus far, is the Exome Aggregation Consortium (ExAC) 
database, containing variants of more than 60,000 exomes 20. These large databases 
are instrumental to the interpretation of future exomes for Mendelian disease gene 
identification. In addition, a need for population-specific databases of variation will 
remain, especially for those populations that are poorly represented in the large 
public databases 87. Interpretation based on population frequency information from 
databases should be done with care because of the possibility of false positives 88, 
founder mutations 89, somatic or tissue-specific variants 90.
Coding mutat ions
Although accurate population frequencies are a necessity for the interpretation 
of exomes, this will only reduce the number of possible candidate mutations to a 
couple of hundred or so 84. Further prioritization of pathogenic variants remains a 
challenging task, in particular for missense variants. Various tools such as Polyphen2 
91, SIFT 92 and PhyloP 93, have long been used in the pathogenicity assessment of 
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these protein-coding variants based on evolutionary conservation. Unfortunately, 
these prioritization methods lack specificity and sensitivity to sufficiently reduce the 
large number of candidate mutations from exome sequencing on their own 84. This 
becomes even more apparent when considering the prioritization of non-coding 
variation from whole genome sequencing experiments.
However, in the last few years, novel tools have been published that are expected to 
offer better sensitivity and specificity compared to the traditional prioritization tools. The 
availability of genome-wide functional annotations of coding and non-coding variants in 
combination with algorithmic improvements resulted in novel tools adapted to prioritize 
both coding and non-coding variants. These novel tools can broadly be divided into two 
groups. The first group focuses on the prediction of deleterious variation by computing 
a functional meta-score based on integrating a variety of genome-wide annotations. 
Combined Annotation-Depended Depletion (CADD) is the most well-known example of 
such a framework that applies a support vector machine (SVM) to integrate 63 sources 
of functional and evolutionary data into a relative pathogenicity score 45. Eigen 94 and 
DANN 95 are other examples using a different algorithmic approaches to combine large 
varieties of annotations into one pre-computed meta-score trained to distinguish 
between benign and deleterious variants. Fitness consequence (FitCons) 96 is different 
in the sense that it compares patterns of divergence between the human population 
and primates to assess functional sites that emerged quite recently. The second group 
of tools attempts to specifically predict non-coding regulatory variants. DeepSEA 97 and 
DeltaSVM 98 are examples of such tools and were trained on a variety of annotations 
of non-coding annotations mainly derived from the ENCODE project 99. Notably, the 
DeepSEA method was based on a Deep learning algorithm, which is a form of machine 
learning that is increasingly being applied to biological problems 100,101.
In spite of the potential of these tools, it remains unclear how well they perform 
in clinical practice because independent validation studies for these novel tools are 
still lacking. Moreover, such studies are hampered by a lack of sufficient validation 
data that have not already been used in the development of the prediction software 
or original benchmark 102. Van der Velde et al. demonstrated the practical utility 
of CADD for the interpretation of variants. The authors applied CADD to a set of 
2,210 variants that were manually assessed by an expert panel and found that, 
beside a relatively small number of discrepancies in favor of the expert, CADD scores 
proved valuable for the prioritization of pathogenic variants. 103. However, a recent 
validation of CADD and other prediction tools using in vivo mouse models, found 
that about half of the assessed mutations that were predicted to be deleterious had 
little impact on the clinical phenotype 104. This once again highlights the importance 
of functional validation of potential pathogenic variants.
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Spl ice s i te mutat ions
Due to the increased read lengths, exome sequencing typically captures a large part 
of the extended splice site at sufficient coverage for variant identification. However, 
mutations in the extended splice site are typically excluded during the prioritization 
step because variation within these regions is more prevalent but also more difficult 
to interpret. Existing algorithms for splice sites such as MaxEntScan 105 and NNSplice 
106 were not designed to offer predictions for the large numbers of variants from 
exome sequencing 107. Like for coding variants recent developments in algorithms 
has improved the ability to interpret this type of variants.
The SPANR (Splicing-based analysis for variants) tool is another example of a 
“deep learning” computational model scoring the effect of variants on the mRNA-
splicing. The SPANR model is trained on 1,393 sequence features extracted from 
10,689 alternatively spliced exons and their corresponding mRNA expression levels 
in 16 human tissues and offers predictions up to 300bp within the intron 108. The 
authors found that SPANR correctly predicted the direction of change in expression 
of the exon for 73 out of 99 (74%) splice site mutations. Another novel splice site 
prediction tool called Hexamer Additive Linear (HAL) is a model, trained on nearly 
two million synthetic alternatively spliced mini genes, to predict the effect of 5’ 
and 3’ mutations on exon skipping 109. In a set of 286 variants within three genes 
(CTFR, BRCA2 and SMN2) the prediction accuracy ranged from 86 to 90%. These 
improvements in splice site prediction programs may open up new avenues for the 
interpretation of variants in exomes.
Gene priori t izat ion
For the interpretation of exome data it is not sufficient to only determine whether 
a variant is likely to impair normal gene function, but also whether the function of 
a mutated gene is actually relevant for the disease 110. Two novel approaches for 
the interpretation of gene function have gained a lot of traction.
Phenotypic Interpretation of Variants in Exomes (PHIVE) is an algorithm that 
computes phenotype similarity between human disease phenotypes and phenotype 
information from knockout experiments in model organisms. This gene-level 
information is then combined with variant pathogenicity predictions and thereby 
achieves better rankings of pathogenic variants in exome data 111. A totally different 
approach to predict deleteriousness for genes is based on the use of population 
variation to determine how intolerant genes are to normal variation. Two studies 
independently showed that human disease genes are much more intolerant to 
genetic variation than other genes 112,113. Several studies have already successfully 
used this approach to prioritize genes with likely pathogenic mutations 76,114.
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Overall, algorithm development has leveraged the availability of genome-wide 
datasets such as Exome Sequencing Project (ESP) 16, Encyclopedia of DNA Elements 
(ENCODE)99 and the International Mouse Phenotype Consortium (IMPC) 115 to 
provide improved pathogenicity predictions for variants and to cope with exome-
sized variant datasets. These novel algorithms represent our first steps to the 
next big challenge, the interpretation of non-coding variation from whole genome 
sequencing experiments. In the meanwhile, technologies for high-throughput 
functional assays are under development that may produce the high-throughput 
functional validations needed to improve in silico variant predictions 116.
Finding recurrent mutat ions
Besides the interpretation of variants and genes, progress has also been made 
in the approaches to provide proof of pathogenicity for novel candidate genes. 
While functional proof of pathogenicity remains crucial, it is time-consuming 
and expensive to obtain, and requires specific expertise. An additional layer of 
evidence for pathogenicity of a mutation in a candidate disease gene can be 
obtained by identifying multiple patients with mutations in the same gene and 
a similar phenotype. Two different approaches for finding recurrently mutated 
candidate genes have emerged, depending on whether the disorder is either rare 
and monogenic or more common and genetically heterogeneous.
Genotype-centric approach for common genet ical ly heteroge-
neous d isorders
For genetically heterogeneous disorders, it is not possible to select specific subsets 
of patients based on their phenotype to perform a targeted analysis of the candidate 
gene. Therefore, screening of a large cohort of patients for additional mutations 
within the same candidate gene is typically performed 117,118. When costs allow, it is 
even more efficient to immediately screen the entire cohort by exome sequencing, 
rather than start with a small number of selected samples 19,119,120. In such a set-
up, however, the probability of random findings becomes very large and rigorous 
statistics are required. Statistical methods do not only protect against potential 
false positive findings but are also able to take into account factors like reduced 
penetrance, modifiers, and multigenic effects 121. The first large-scale exome 
sequencing studies already relied on different statistical approaches based on 
estimates of genome-wide mutation rates to identify genes enriched for de novo 
mutations 119,120. An improved statistical framework was proposed by Samocha 
et al. 122 which was first applied by the DDD project which performed large-scale 
trio sequencing of 1,133 trios with developmental disorders 19. After identifying 
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de novo coding mutations in this a cohort, a statistical approach was used based 
on estimates of the gene-specific mutation rate to identify 12 novel genes that 
were enriched for de novo mutations. The same group also used a novel statistical 
framework for the identification of recessive genes in a cohort of 4,125 families with 
developmental disorders 123. In this case a model was constructed to estimate the 
probability of drawing n unrelated families with similar biallelic genotypes by chance 
from the general population. Estimates of population allele frequencies for rare 
loss-of-function and missense variants were obtained from the Exome Aggregation 
Consortium data set 20. Although in both studies the cohorts are considered to be 
very large, statistical power was still limited and the authors emphasize that this 
should motivate data-sharing through international databases.
Phenotype-centric approach for rare monogenic d isorders
For many Mendelian diseases the phenotype is very rare, and individual groups 
do not have more than a few cases making it impossible to perform large-scale 
screening. The alternative is then to take a phenotype-centric approach where 
one finds additional patients with the same, or similar, distinct phenotype. Once 
more patients have been identified with overlapping phenotypes specific testing 
of candidate genes can be performed. Alternatively, there is the opposite approach 
in which first patients with matching genotypes are identified and final evidence 
of pathogenicity comes from the matching of patient phenotypes. In both cases 
additional evidence is obtained not just by the common genotype, but also by 
the shared specific phenotype of patients with mutations. This approach is now 
facilitated by various data-sharing initiatives for rare diseases such as DECIPHER 
124, Café Variome 125, GeneMatcher 126, RD-connect 127, and PhenomeCentral 128, see 
Brookes & Robinson for an overview of data-sharing initiatives and databases 129. 
The matchmaker exchange is a recent initiative to integrate the information from all 
of these databases by providing a single interface for queries together with match-
making algorithms 130. A nice example of a phenotype-centric approach is a recent 
paper on the identification RSPRY1 by which the authors identified an additional 
case with the same phenotype by using the Care4Rare Canada matchmaker 131. This 
should hopefully inspire more researchers to contribute to these databases and 
facilitate the identification of the genetic cause for their patients. By contributing 
these data to public databases they do not only become available to researchers 
and physicians but also to the patients themselves 132,133. A nice illustration of 
this is the case of Massimo Damiani who suffered from an unclassified form of 
leukoencephalopathy and whose parent’s efforts resulted in the genetic diagnosis 
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134. The authors argue that these patient-led efforts have the potential to increase 
the value of matchmaking networks.
Structured phenotypes
The probability of success for matchmaking increases with the availability of good 
phenotype information. A long-standing challenge with phenotype descriptions 
is the lack of standardization. This presents several problems such as the use 
of different clinical nomenclature for similar phenotypes, the uncertainty 
whether phenotypes are absent or not assessed, and the fact that it is unclear 
how phenotypes are related to each other, which makes it difficult to perform 
computational analyses 135. For some years these issues have been tackled by 
the introduction of standardized phenotype vocabularies and ontologies. Several 
ontologies have been developed but one of the most used is the human phenotype 
ontology (HPO)135. HPO currently consists of more than 250,000 phenotypic 
annotations 136. The practical benefits of using HPO have been demonstrated by 
the development of novel tools that facilitate the prioritization of exome variants 
(as discussed in the previous section), but also by a recent study of the DDD-project. 
Akawi et al. used structured phenotype information to statistically quantify the 
phenotypic similarity of patients with developmental delay for which rare mutations 
were identified in the same gene 123. Although the added value of the integrated 
phenotypes in the statistical assessment was limited, this will likely improve when 
phenotype information becomes more comprehensive. Obtaining comprehensive 
structured phenotypes, however, is difficult and time-consuming. The DDD project 
mandated the availability of phenotype information in HPO format for all of their 
samples 137. Such criteria are not easily imposed for most other projects and several 
tools have been developed to encourage and facilitate the use of phenotype 
information. PhenoDB 138 and PhenoTips 139 are platforms that allow clinicians to 
enter, store and analyze structured phenotypic data. Phenominer is a tool able 
to extract phenotype contexts from simple text to identify relationships between 
human diseases described in OMIM and literature 140. In the future even the actual 
measuring of phenotypes may be automated leading to more robust and objective 
phenotypes that will also take less time of physicians to administrate 141, and 
allowing bioinformaticians to use these data for interpretation of exome variants.
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CONCLUSIONS
Here we have discussed some of ongoing bioinformatic developments that have 
the potential to impact the way we currently analyze and interpret exome data. It 
is clear that many developments in bioinformatics are still needed with respect 
to exome sequencing and that this is still a very active field of development. This 
requires a high degree of flexibility and adaptiveness from those working in this 
field. Especially since new challenges are already on the horizon with the anticipated 
large-scale application of whole genome sequencing.
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ABSTRACT
To identify candidate genes for intellectual disability, we performed a meta-analysis 
on 2,637 de novo mutations, identified from the exomes of 2,104 ID patient-parent 
trios. Statistical analyses identified 10 new candidate ID genes: DLG4, PPM1D, RAC1, 
SMAD6, SON, SOX5, SYNCRIP, TCF20, TLK2 and TRIP12. In addition, we show that these 
genes are intolerant to nonsynonymous variation and that mutations in these genes 
are associated with specific clinical ID phenotypes.
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INTRODUCTION
Intellectual disability (ID) and other neurodevelopmental disorders are in part due to 
de novo mutations affecting protein-coding genes.1-4 Large scale exome sequencing 
studies of patient-parent trios have efficiently identified genes enriched for de novo 
mutations in cohorts of individuals with ID compared to controls2 or on the basis of 
expected gene-specific mutation rates.5
Here we sequenced the exomes of 820 patients with ID and their parents as 
part of routine genetic testing at the Radboud University Medical Center (RUMC) 
in the Netherlands. We identified 1,083 de novo mutations (DNMs) in the coding 
and canonical splice site regions affecting 915 genes (Supplementary Tables 1-2, 
Supplementary Figs. 1-4). In our cohort we detected an increased number of Loss-
of-function (LoF) mutations compared to controls (Fisher’s exact test p=9.38x10-12, 
Supplementary Methods) and enrichment for recurrent gene mutations (observed 
versus expected, p<1×10-5, Supplementary Fig. 5).
Using an established framework of gene specific mutation rates6, we calculated 
for each gene the probability of identifying the observed number of LoF or functional 
DNMs in our cohort (Methods). To validate this approach we first performed the 
analysis on the complete set of 820 ID patients. After Benjamini-Hochberg correction 
for multiple testing, 18 well-known ID genes were significantly enriched for DNMs 
(Supplementary Tables 3 and 4). To optimize our analysis for the identification 
of novel candidate genes in the RUMC cohort, we excluded all individuals with 
mutations in any of the known ID genes (Methods and Supplementary Fig. 6). 
Repeating the analysis for mutation enrichment, we identified four genes (DLG4, 
PPM1D, SOX5, TCF20) that were not, to our knowledge, previously associated with 
ID and that were significantly enriched for DNMs in our cohort (Figure 1, Table 1, 
Supplementary Table 5). To achieve the best possible power for the identification 
of candidate ID genes, we next added data from four previously published family-
based sequencing studies (Supplementary Table 1). The combined cohort 
included 2,104 patient-parent trios and 2,637 DNMs across 1,990 genes. After again 
excluding individuals with mutations in known ID genes, this cohort consisted of 
1,471 individuals with 1,400 DNMs in 1,235 genes (Methods and Supplementary 
Fig. 6). Meta-analysis on this combined cohort identified ten candidate ID genes 
with more LoF DMNs or more functional DNMs than expected a priori. These ten 
genes included the four novel candidate ID genes previously identified in the RUMC 
cohort, as well as RAC1, SMAD6, SON, TLK2, TRIP12 and SYNCRIP (Figure 1, Table 1 
and Supplementary Table 6).
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Figure 1. Genes enriched for LoF and functional DNMs in a cohort of 2,104 ID trios from multiple 
studies. The y-axes shows the -log10-transformed corrected P-value of the DNM enrichment as listed 
in Table 1. Corrected P-values based on LoF mutations are blue and corrected P-values based on 
functional mutations are colored green. Only genes with a corrected P-value (LoF, functional, or 
both) less than the significance threshold (red dotted line, 0.05) are shown.
To further evaluate the identification of the ten candidate ID genes, we compared 
the phenotypes of the 18 RUMC individuals with DNMs in these genes. We observed 
strong phenotypic overlap for some of these genes (Figure 2, Supplemental case 
reports, Supplementary Table 7). Additional genes that were close to statistical 
significance, such as SETD2, show phenotypic similarities suggestive for a shared 
genetic cause consistent with previous case reports7,8 (Supplementary Fig. 7, 
Supplemental Case reports).
Studies have shown that genes involved in genetic disorders exhibit strongly 
reduced tolerance to genetic nonsynonymous genetic variation compared to non-
disease genes. This is particularly evident for ID.3 We found that a large set of well-
known dominant ID genes (n = 444), along with the ten candidate ID genes, are highly 
intolerant to LoF variation9 (median probability of being LoF-intolerant (pLI) of 0.95; 
P < 1x10-5 and 0.99; P < 1x10-5 respectively; (Methods, Supplementary Fig. 8 and 
Supplementary Table 8). We noted that those ID genes harbor only missense variants 
(‘missense-only’ genes) are among the most intolerant ID genes (median pLI of 0.99; P < 
1x10-5 ; Supplementary Fig. 8). Additionally, we found that mutations in missense-only 
genes are more likely to cluster than mutations in genes for which we also identified 
LoF mutations (P = 0.01, Fisher’s exact test; Methods and Supplementary Table 9).
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Gene
RUMC cohort ID cohort
Gene description
LoF Functional LoF Functional
DLG4 q 1.13E-04 0.086 7.69E-06 8.02E-04 Required for synaptic plasticity 
associated with NMDA receptor 
signaling. Depletion of DLG4 changes 
the ratio of excitatory to inhibitory 
synapses in hippocampal neurons.
p 6.56E-09 7.50E-06 2.24E-10 4.66E-08
NM_001365.3 c (n=3) (n=3) (n=4) (n=5)
PPM1D q 0.047 0.764 8.22E-04 0.174 Ser/Thr phosphatase that mediates 
a feedback regulation of p38-p53 
signaling thereby contributing to 
growth inhibition and suppression of 
stress induced apoptosis.
p 5.45E-06 2.56E-04 9.57E-08 3.03E-05
NM_003620.3 c (n=2) (n=2) (n=3) (n=3)
RAC1 q
n.d.
0.217
n.d.
0.020 Plasma membrane-associated 
small GTPase involved in many 
cellular processes. In the synapses, 
it mediates the regulation of F-actin 
cluster formation by SHANK3.
p 3.80E-05 1.75E-06
NM_018890.3 c (n=2) (n=3)
SMAD6 q
n.d. n.d.
0.037 1 Mediates TGF-beta activity and the 
BMP-SMAD1 signaling. Functions as 
a transcriptional co-repressor.
p 8.29E-06 7.50E-04
NM_005585.4 c (n=2) (n=2)
SON q 1 1 0.003 1 Component of the spliceosome 
with pleiotropic roles during mitotic 
progression. Functions in efficient 
cotranscriptional RNA processing.
p 0.086 0.005 4.12E-07 1.67E-03
NM_138927.1 c (n=1) (n=1) (n=3) (n=3)
SOX5 q 0.016 1 0.038 0.216 Member of Transcription factors that 
regulate embryonic development. 
Plays a critical role in neuronal 
progenitor development by regulating 
the timing of differentiation.
p 1.39E-06 3.98E-04 8.79E-06 5.83E-05
NM_006940.4 c (n=2) (n=2) (n=2) (n=3)
SYNCRIP q 1 1 0.028 1 Heterogeneous nuclear 
ribonucleoprotein (hnRNP) 
functioning in the CRD-mediated 
mRNA stabilization complex and the 
SMN complex, and the apoB RNA 
editing-complex.
p 0.001 0.019 4.94E-06 1.24E-03
NM_006372.4 c (n=1) (n=1) (n=2) (n=2)
TCF20 q 6.22E-06 0.035 1.24E-04 0.174 Transcriptional activator of 
matrix metalloproteinase 3 and 
(co)activator of various other 
transcriptional activators.
p 1.81E-10 1.00E-06 7.21E-09 3.71E-05
NM_005650.1 c (n=4) (n=4) (n=4) (n=4)
TLK2 q 0.100 1 0.347 5.86E-04 Ser/Thr kinase regulating chromatin 
assembly. Involved in DNA 
replication, transcription, repair and 
chromosome segregation.
p 1.44E-05 4.20E-04 9.09E-05 1.70E-08
NM_005650.1 c (n=2) (n=2) (n=2) (n=5)
TRIP12 q 0.273 1 2.35E-04 0.174 E3 ubiquitin-protein ligase involved in 
ubiquitin fusion degradation pathway. 
Guards excessive spreading of 
ubiquitinated chromatin at damaged 
chromosomes in DNA repair.
p 5.55E-05 0.003 2.05E-08 4.05E-05
NM_001284214.1 c (n=2) (n=2) (n=4) (n=4)
Table 1. Novel candidate ID genes. All genes listed reached statistical significance after Benjamini-
Hochberg correction for enrichment of functional and/or loss-of-function (LoF) DNM in the RUMC or ID 
cohort. For each gene the Benjamini-Hochberg corrected p-value (q), uncorrected p-value (p) and the raw 
counts (c) are shown. n.d. (not defined) indicates genes without observed DNMs in the RUMC or ID cohort.
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There is considerable overlap of genes and molecular pathways involved in 
neurodevelopmental disorders (NDDs), such as autism spectrum disorder, 
schizophrenia, epileptic encephalopathy and ID.10 Therefore, we performed a third 
analysis including 12 published family-based sequencing studies of various NDDs 
(Supplementary Table 1 and Supplementary Fig. 6). Repeating our analysis in 
this NDD cohort, we identified seven genes significantly enriched for either LoF 
or functional DNMs (Supplementary Fig. 9 and Supplementary Table 10). In line 
with our hypothesis, five of the identified genes were also identified in our previous 
analyses with individuals with ID only, whereas two genes (SLC6A1 and TCF7L2) only 
reached significance in the NDD meta-analysis as a result of additional mutations in 
patients with phenotypes other than ID (Supplementary Table 11). Specifically, for 
two of the five candidate ID genes (TLK2 and TRIP12) additional DNMs were identified 
in individuals with autism spectrum disorder and schizophrenia, suggesting that 
DNMs in these genes may lead to a broader phenotype than ID alone. For TRIP12, a 
similarly broad phenotype has been reported previously.4
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Figure 2. TLK2 protein (Q86UE8) with de novo mutations localized to the serine/threonine catalytic 
domain. Two individuals in the RUMC cohort were found to have a DNM in TLK2; they showed over-
lapping clinical features including facial dysmorphisms (Supplemental Case reports).
In summary, we identified ten candidate ID genes via a meta-analysis of whole exome 
sequencing data on 2,104 ID trios. The statistical framework used here differs from 
other methods based on gene-specific mutation rates, by removing all trios with 
mutations in known disease genes, and by applying Benjamini-Hochberg correction 
for multiple testing. Our study underscores the impact of DNMs on a continuum 
of neurodevelopmental phenotypes, that impinge on a broad range of processes, 
including chromatin modifiers (TRIP12 and TLK2), Fragile X Mental Retardation 
Protein (FMRP) target and synaptic plasticity genes (DLG4; Supplementary Fig. 
10) and embryonically expressed genes (PPM1D and RAC1)2. Data from a similar 
systematic study of DNMs in neurodevelopmental disorders suggest that many, and 
possibly most, genes whose DNM causes severe developmental disorders are now 
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known11. Yet only TCF20 and PPM1D are shared between the 10 candidate genes in 
our study and the 14 genes identified by McRae et al.11. Thus, a large number of rare 
dominant developmental disorder genes may remain to be identified.
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METHODS
Recrui tment of  ind ividuals wi th ID
The Department of Human Genetics from the Radboud University Medical 
Center (RUMC) is a tertiary referral center for clinical genetics. Approximately 350 
individuals with unexplained intellectual disability (ID) are referred annually to our 
clinic for diagnostic evaluation. Since September 2011 whole exome sequencing 
(WES) is part the routine diagnostic work-up aimed at the identification of the 
genetic cause underlying disease.12 For individuals with unexplained ID, a family-
based WES approach is used which allows the identification of DNMs as well as 
variants segregating according to other types of inheritance, including recessive 
mutations and maternally inherited X-linked recessive mutations in males.13 For 
this study, we selected all individuals with ID who had family-based WES using the 
Agilent SureSelect v4 enrichment kit combined with sequencing on the Illumina 
HiSeq platform in the time period 2013-2015. This selection yielded a set of 820 
individuals, including 359 females and 461 males. The level of ID ranged between 
mild (IQ 50-70) and severe-profound (IQ<30).
Families gave informed consent for both the diagnostic procedure as well as for 
forthcoming research that could result in the identification of new genes underlying 
ID by meta-analysis, as presented here. Explicit consent for photo-publication was 
sought and granted by a subset of families.
Diagnost ic whole exome sequenc ing
The exomes of 820 patient-parent trios were sequenced, using DNA isolated from 
blood, at the Beijing Genomics Institute (BGI) in Copenhagen. Exome capture was 
performed using Agilent SureSelect v4 and samples were sequenced on an Illumina 
HiSeq instrument with 101-bp paired-end reads to a median coverage of 75x. 
Sequence reads were aligned to the hg19 reference genome using BWA version 
0.5.9-r16. Variants were subsequently called by the GATK unified genotyper (version 
3.2-2) and annotated using a custom diagnostic annotation pipeline. Base pair 
resolution coverage of the regions enriched by the SureSelect V4 kit are computed 
by BEDTools based on the regions as provided by the manufacturer. An average 
98.9% of Agilent SureSelect V4 enriched targets was covered by 10 or more reads 
for the RUMC cohort of 820 ID patients (Supplementary Fig. 1).
Ident i f icat ion of  DNMs in 820 ind ividuals wi th ID
The diagnostic WES process as outlined above only reports (de novo) variants that can 
be linked to the individuals’ phenotype. In this study, we systematically collected all 
DNMs located in the coding sequence (RefSeq) and/or affected canonical splice sites 
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(canonical dinucleotides GT and AG for donor and acceptor sites; Supplementary 
Fig. 4), as identified in 820 individuals with ID irrespective of their link to disease, 
to evaluate the potential relevance of genes for ID in an unbiased fashion using a 
statistical framework. DNMs were called as described previously.13 Briefly, variants 
called within parental samples were removed from the variants called in the child. 
For the remaining variants pileups were generated from the alignments of the child 
and both parents. Based on pileup results variants were then classified into the 
following categories: “maternal (for identified in the mother only)”, “paternal (for 
identified in the father only)”, “low coverage” (for insufficient read depth in either 
parent), “shared” (for identified in both parents)”, and “possibly de novo” (for absent 
in the parents). Variants classified as possibly de novo were included in this study.
We applied various quality measures to ensure that only the most reliable calls 
were included in the study: (i) all samples had less than 25 possibly de novo calls; 
(ii) each variant had at least 10x coverage in either parent (for example, high prior 
probability of being inherited); (iii) the location was not known in dbSNP version137 
(for example, a possible highly mutable genomic location) and (iv) each variant was 
called in a maximum of 5 samples in our in-house variant database (which eliminated 
variants that occur too frequent to be disease-causing given the incidence of ID in 
combination with the sample size of our in-house database); (v) each variant showed 
a variant read percentage >30%, or alternatively, >20% with >10 individual variant 
reads and (vi) each variant had a GATK quality score of >400. For de novo variants 
called within a 5-bp window of each other within the same individual, variant calls 
were manually curated and merged into a single call (when occurring on the same 
allele). This set of criteria resulted in the identification of 1,083 potential DNMs in 
820 individuals with ID.
Val idat ion and categorizat ion of  DNMs
In a separate (unpublished) in-house study, we recently determined the predictive 
value for GATK quality scores in terms of the variant being validated by Sanger 
sequencing. A set of 840 variants called by the same version of GATK was 
retrospectively analyzed for the quality scores and validation status of each variant 
in the set. Based on this assessment, we determined that a GATK quality score 
≥500 resulted in 100% of variants being validated by Sanger sequencing (data 
not shown). In addition to our in-house study, two other studies also found 100% 
Sanger validation rates for variants with a GATK quality score of ≥500.14 Based on 
these results, we considered all variants with a GATK Q-score of ≥500 (n = 1,039) 
to be true DNMs. Nonetheless, a random set of 141 potential DNMs with GATK 
Q-scores of ≥500 were all confirmed by Sanger sequencing. All potential de novo 
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variants with GATK Q-scores between 400 and 500 (n = 40) were subsequently 
validated by Sanger sequencing, and all were confirmed. All 20 DNMs of the reported 
candidate genes were confirmed by Sanger sequencing (Supplementary Table 2 
and Supplementary Fig. 2-4).
For further downstream statistical analysis (see below), DNMs were categorized 
by mutation type: (i) LoF DNM (n = 211), including nonsense (n = 77), frameshift 
(n = 97), canonical splice site (n = 27), start loss (n = 2), stop loss (n = 1) and premature 
stop codon resulting from an indel (n = 7); (ii) functional DNM (n = 872), including all 
LoF mutations (n = 211), in-frame insertion/deletion events (n = 23) and all missense 
mutations (n = 638) (Supplementary Fig. 4). For variants within the same individual 
and within the same gene but more than 5bp apart, the variant with the most severe 
functional effect was considered for the per-gene statistics (see below).
Evaluat ing the number of  recurrent ly LoF and funct ional  de novo 
mutated genes
We simulated the expected number of recurrently mutated genes by redistributing 
the observed number of mutations at random over all genes based on their specific 
LoF and functional mutation rates (see “Statistical enrichment of DNMs” below) 
as described by Samocha et al.6 Based on results from 100,000 simulations, we 
calculated how many times the number of recurrently mutated genes was the 
same or exceeded the observed number of recurrently mutated genes in the RUMC 
data set. We performed the simulation separately for LoF and functional DNMs 
(Supplementary Fig. 5). P-values were then calculated by taking the number of 
times the number of recurrently mutated genes exceeded the observed number of 
recurrently mutated genes and dividing by the number of simulations. In addition 
the z-values were computed by subtracting the mean value of the simulations from 
the observed value and dividing by the s. d. of the simulations.
Genes previously impl icated in ID et io logy
To evaluate whether the genes identified by our meta-analyses have been previously 
implicated in ID, we used two publicly available repositories of genes known to be 
involved in ID. First, we used our list of 707 genes, routinely used by our diagnostic 
setting to interpret WES results of individuals with ID.15 Second, we downloaded a 
list of 1,424 genes associated with developmental disorders from the DDG2P16; the 
list was compiled and curated by clinicians as part of the Deciphering Developmental 
Disorders (DDD) study to facilitate clinical feedback of likely causal variants5. In 
total the two lists compromised 1,537 unique genes. In this manuscript, the list of 
unique gene entries is referred to as “known ID genes” (Supplementary Table 4).
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Stat ist ical  enrichment of  DNMs
In our meta-analysis for ID and neurodevelopmental disorders we only included 
studies with minimum of 50 trios. For each gene, and each of the functional classes 
(LoF and functional), we used the corresponding gene specific mutation rate 
(GSMR) as published by Samocha et al.6 to calculate the probability of the number 
of identified DNMs in our cohort. For genes for which no GSMR was reported, we 
used the maximum GSMR of all reported genes (i.e. the GSMR of the gene TTN). We 
then calculated specific mutation rates for the two defined functional classes (LoF, 
functional). The GSMR for LoF DNMs was calculated by summing the individual 
GSMR for nonsense, splice site and frameshift variants; the GSMR for functional 
DNMs was calculated by summing the GSMR for the LoF variants with the missense 
mutation rate; and for genes for which variants from different functional classes 
were identified, we used the overall GSMR. For the stop-loss and start-loss mutations 
we used the LoF-rate and for in-frame indels, the functional rate. Null hypothesis 
testing was done using a one-sided exact Poisson test based on a sample size of 
820 individuals with ID, representing 1,640 alleles for autosomal genes, and 1,179 
alleles for genes on the X chromosome (461 males).
For DNMs on chromosome X the correct mutation rate depends on the patient’s 
gender as the mutation rates for fathers is higher than for mothers. Estimates show 
a 4:1 ratio of paternal to maternal DNMs17. Hence, male offspring, receiving their 
chromosome X exclusively from the mother, have therefore a lower mutation rate 
on chromosome X than estimated by the GSMR. This correction could however only 
be performed for the RUMC cohort, as information of gender was not available for 
all studies included in the ID cohort. Noteably, not correcting for this bias in male 
individuals for DNM in genes on the X chromosome will lead to less significant 
P-values for genes on the X chromosome, thereby potentially underestimating the 
significance of candidate ID genes located on the X-chromosome. When a patient 
was found to have two DNMs in the same gene we ignored one of the two DNMs for 
the statistical enrichment analysis to avoid false positive results. In such cases the 
severity of the DNM protein effect was a factor in the choice which DNM to ignore. 
For example, if a patient has one missense and one nonsense DNM in the same 
gene, the missense mutation was ignored in the statistical analysis.
The gene specific P-values were corrected for multiple testing based on the 
18,730 genes (present in the Agilent V4 exome enrichment kit) times the number 
of tests (2), using the Benjamini-Hochberg procedure with an FDR of 0.05. In our 
cohort of 820 individuals with ID, conclusive diagnoses were already made based 
on DNMs in genes previously implicated in disease. The use of a multiple testing 
correction with a FDR of 0.05, in combination with a potential large number of DNMs 
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in known ID genes, may cause the artificial increase the significance of other genes 
because of an increasingly lenient correction for the least significant genes18. To 
verify that the identification of candidate ID genes was not inflated by this effect, 
we performed the analysis after removing all individuals with a DNM in one of 
the known genes (potential other DNMs in such individuals were also removed for 
further analysis). Incidentally, this also increased our statistical power. The mode of 
inheritance was not taken into account when removing individuals with a DNM in a 
known gene (for example, samples with a DNM in a recessive gene were excluded). 
This correction left 584/820 individuals with ID in the RUMC cohort, with 627 DNMs 
across 584 genes. Similarly, for the ID and neurodevelopmental cohort, we removed 
all individuals with a DNM in a known ID gene (and other DNMs in these individuals). 
For the ID cohort, 1,471 samples remained with 1,400 DNMs in 1,235 genes. For the 
neurodevelopmental cohort, 4,944 samples remained with 4,387 DNM across 3,402 
genes (For the complete overview see Supplementary Fig. 6). We corrected for 
testing 34,386 genes (i.e. all 18,730 genes minus the 1,537 known ID genes multiplied 
by two for testing the LoF and functional categories).
Val idat ion of  the stat ist ical  approach by analys is of  DNMs in a 
contro l  cohor t
To further confirm the validity of our statistical approach, we applied the same 
analyses to a set of DNMs identified in trios of healthy individuals and unaffected 
siblings. For this purpose, we downloaded and reannotated all DNMs identified in 
1,911 unaffected siblings of individuals with ASD from Iossifov et al.2 together with 
DNMs in controls (Supplementary Table 12). In total the control set contained 2,019 
coding DNMs found in 2,299 trios. Notably, the protein-coding de novo mutation rate 
in the control cohort was markedly lower than observed in the individuals with ID 
(0.91 DNMs versus 1.32 DNMs, respectively). Additionally, we observed no significant 
enrichment of recurrently mutated genes for LoF or functional mutations (P = 0.60 
and P = 0.12, respectively, Supplementary Fig. 11).
For the control cohort we performed the statistical analysis as described above 
and identified only one gene that was significantly enriched for functional DNMs. 
For YIF1A (FDR corrected P-value = 0.01) we identified a total of three missense and 
one frame-shift DNM (Supplementary Table 13 and 14). YIF1A may be involved 
in transport between the endoplasmic reticulum and the Golgi, and has a pLI 
of 2.08x10-8 indicating this gene is a LoF-tolerant gene .We note that the control 
cohort consists mostly of healthy siblings from individuals with ASD, and, as such, 
may still have minor enrichments for mutations that lead to susceptibility for 
neurodevelopmental disorders.
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Increased number of  LoF mutat ions in RUMC cohor t  compared 
to contro ls
To reduce the impact of the enrichment kit used in the control set studies and RUMC 
cohort, we computed the intersection of all enrichment kits (Agilent SureSelect 
37Mb ∩ Agilent SureSelect 50Mb ∩ Agilent SureSelect V4 ∩ Nimblegen SeqCap V2; 
Supplementary Table 12) using the i´ntersect´ function of BEDTools. Only the LoF 
DNMs present in the 28,189,737-Mb intersection of the four enrichment kits were 
used in the analysis. The Fisher’s exact test on the enrichment kits normalized LoF 
DNMs yielded a significant difference with P = 9.38x10-12 (RUMC: 157 LoF DNMs of 
a total of 805 DNMs; controls: 137 LoF DNMs of a total of 1,485 DNMs; OR = 2.38; 
CI: 1.85-3.07). The coverage and other relevant technical information of the control 
studies are listed in Supplementary table 12. We note it is important to consider 
the coverage and false negative rates of all sequencing studies. So far, only a single 
study has attempted to provide a false negative rate (for example, mutations that 
are there but were not identified) for exome sequencing, and this was predicted 
to be <5%2.
Attribut ing pLI for  a l l  protein-coding genes
To determine the intolerance to LoF variation for each gene, we used the LoF 
intolerance (pLI), which is based on data from the Exome Aggregation Consortium 
(ExAC) version 0.3.1 providing exome variants from 60,706 unrelated individuals9. 
The pLI is based on the expected versus observed variant counts to determine the 
probability that a gene is intolerant to LoF variants and is computed for a total of 
18,226 genes. The closer a pLI is to 1 the more intolerant a gene is to LoF variants. 
The authors consider a pLI >= 0.9 as an extremely LoF-intolerant set of genes. The 
pLIs for the genes used in this study can be found in Supplementary Table 8. 
Intolerance to LoF variation was evaluated for the available pLIs of four gene sets 
(1) 170 LoF-tolerant (LoFT) genes19, (2) 404 Housekeeping genes, involved in crucial 
roles in cell maintenance20, (3) 1,359 genes with functional DNMs from the healthy 
control dataset (Supplementary Table 14), and (4) 444 Well-known dominant ID 
genes (Supplementary Table 4).
Gene set based evaluat ion of  pLI
We evaluated the pLI by computing the expected median pLI for each gene set based 
on randomly drawing n pLI values from the complete set of 18,226 pLI annotated 
genes and calculating the median (where n is the number of genes in the gene 
set). By repeating this random sampling process 100,000 times, we computed the 
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likelihood of the observed median pLI of a gene set compared to the expected 
median pLI by calculating the empirical p-value:
where m is the median pLI of one simulation, mobserved is the observed median pLI 
and N is the total number of performed simulations (N = 100,000). In addition, the 
z-values were computed as described in the section “Evaluating the number of 
recurrently LoF and functional de novo mutated genes”.
Based on the simulations we identified a significant lower median pLI for the 
LoFT genes, which is in line with the LoFT nature of this gene set (observed 9.33 x 
10-9 distribution simulations: μ = 0.04, σ = 0.03; empirical P < 1 x 10-5; z = 1.25). For 
the healthy control set, the observed median pLI matched the simulated distribution 
of median pLI (observed 0.03; distribution simulations: μ = 0.03, σ = 0.01; empirical 
P = 0.31; z = 0.39). For the housekeeping and dominant ID gene sets, the observed 
median pLI was significantly higher than the simulated distribution of median pLI 
(HK genes: observed: 0.87; simulated distribution: μ = 0.03, σ = 0.02; empirical P < 
1 x 10-5; z = 54.05 and dominant ID genes: observed: 0.95; simulated distribution: 
μ = 0.03, σ = 0.01; empirical P < 1 x 10-5; z = 61.54). In addition, the median pLI of the 
housekeeping gene approximates (median pLI = 0.87) and the dominant ID gene set 
(median pLI = 0.95) surpasses the extremely LoF-intolerant threshold of 0.9, which 
is in line with the LoF-intolerant nature for of housekeeping and dominant ID genes 
(Supplementary Fig. 12).
The set of ten novel candidate ID genes has a median pLI of 0.99 (observed 0.99; 
simulated distribution: μ = 0.14, σ = 0.20; empirical P < 1 x 10-5; z = 4.28) which is, 
as observed for the dominant ID genes, above the extremely LoF-intolerant gene 
threshold of 0.9 (Supplementary Fig. 8). For the missense-only genes (with at least 
three missense mutations in the absence of LoF mutations, all of which were known 
dominant ID genes), we observe the highest median pLI of 0.9999 (observed: 0.9999; 
simulated distribution: μ = 0.09, σ = 0.14; empirical P < 1 x 10-5; z= 6.70) illustrating 
that those known and candidate dominant ID genes that harbor only missense 
variants are among the most LoF-intolerant ID genes (Supplementary Fig. 8).
Attributing Residual Variation Intolerance Score (RVIS) for all genes
In addition, the residual variation intolerance score (RVIS) was assessed in the 
same fashion as described for the pLI. The RVIS ranks genes based on whether 
they have more or less common functional genetic variations relative to the 
genome-wide expectation. The initial RVIS gene scores were computed based on 
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the NHLBI-ESP6500 data set21 and recently recomputed based on the ExAC v0.3 
dataset22 .The genes from our study were annotated with RVIS scores based on 
ExAC (Supplementary Table 8).
RVIS scores for gene sets were compared in the same way as for the pLI 
(Supplementary Fig. 13). Again, we found the new candidate ID genes to be 
significantly more intolerant than any random set of genes found (observed median 
RVIS: 8.47, distribution simulations: μ = 50.05, σ = 15.08; empirical P = 4.60 x 10-4; z: 
-2.76), like the known dominant ID genes (Supplementary Fig. 13). For the dominant 
missense-only genes we again observe the lowest median RVIS of 3.56 (distribution 
simulations: μ = 50.02, σ = 10.42; empirical P < 1 x 10-5; z: -4.46; Supplementary 
Fig. 13).
Est imat ing c lustering of  DNMs
The spatial distribution of missense, frameshift and nonsense DNMs were 
analyzed for clustering within the respective gene they occurred based on 100,000 
simulations. The locations of observed DNMs were randomly sampled over the 
coding exons of the gene and the distances (in base pairs) between the mutations 
were normalized for the total coding size of the respective gene. The geometric 
mean (the nth root of the product of n numbers) of all mutation distances between 
the DNMs was taken as a measure of clustering. A pseudocount (adding 1 to all 
distances and 1 to the gene size) was applied to avoid a mean distance of 0 when 
there were identical mutations.
Based on the prior distance distribution of the 100,000 simulations, we computed 
a gene-based empirical probability of the observed distance for dominant ID genes 
with 3 or more DNMs (n = 64 genes) in the ID set of 2,104 trios. A total of 21 genes 
contained only missense mutations (missense-only group) and 43 genes contained 
frameshift, nonsense or a combination of frameshift, nonsense and missense DNMs 
(“LoF + Functional” group). In 21 genes of the missense-only group, 5 genes had 
empirical probabilities below the significant threshold of 0.05/64, whereas only one 
of the 43 LoF + Functional genes had an empirical probability below the significant 
threshold (Supplementary Table 9). Fisher’s exact test was used to compute the 
statistical significance (P = 0.012; OR = 12.56; CI: 1.26-632.65).
Cl in ical  evaluat ion of  selected pat ients
All patients were referred by clinical geneticists for diagnostic evaluation and 
overall patient characteristics were comparable to those of a previously published 
cohort13. To confirm the identification of the candidate ID genes, we compared the 
phenotypes of individuals with a DNM in any one of the ten candidate genes and 
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two genes (SLC6A1 and TCF7L2) significantly enriched in the neurodevelopmental 
cohort. Comparison of phenotypes was only possible for 8 of 12 genes in which 
at least 2 individuals with ID were in the RUMC cohort (7 of10 candidate ID genes, 
and 1 of 2 candidate NDD genes). A table listing these clinical details is provided in 
Supplementary Table 7. Detailed clinical data for other published individuals is 
mostly not available. For TLK2 and SETD2 a more detailed phenotypic comparison 
was performed (see Supplementary data for case reports).
Stat ist ics
Statistical significance was calculated using R statistical computing software 
version 3.1.0. Two-tailed Fisher’s exact tests (significance level α of 0.05) were used 
to analyze statistical significance between groups for the number of LoF DNMs 
and number of clustered DNMs. The gene-specific analysis of excess numbers of 
LoF and functional DNMs was performed using a one-sided exact Poisson test 
with gene-specific mutation rates taken from the Samocha et al. study6. The gene 
specific P-values were corrected for multiple testing based on the 18,730 genes 
present in the Agilent V4 exome enrichment kit times the number of tests (2; LoF 
and functional), using the Benjamini-Hochberg procedure with an FDR of 0.05. Data 
distribution was assumed to be normal, but this was not formally tested.
For the statistical testing based on random sampling we used the “sample” and 
“sample.int” functions (without replacement) from the R version 3.1.0 with a random 
sample size n of 100,000. By comparing the observed value to the distribution of 
the random samples, the empirical P-value was computed. In addition the z-value 
was computed by subtracting the mean value of the simulations from the observed 
value and dividing by the standard deviation of the simulations.
A Supplementary Methods Checklist is available.
Code avai labi l i ty
We used code to perform the statistical analysis in a systematic manner to reduce 
mistakes are available from the corresponding author upon request.
Data avai labi l i ty
The data supporting the findings of this study are available within the article and its 
supplementary information files. Additional clinical information of patients included 
this study are available from the corresponding author upon request.
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SUPPLEMENTARY DATA
Supplemental Case repor ts
TLK2
Pat ient 17
This male is the second of three children of consanguineous parents of Turkish 
ancestry. His father had learning difficulties and was illiterate. He was born after 
40+3 weeks of gestation with a birth weight of 3415 gram (0 SD), length of 50 cm 
(-2 SD) and head circumference of 35 cm (0 SD). Delivery was uncomplicated. Both 
motor and language development were delayed. He started walking at the age of 
2 years. At the age of 20 years, psychological assessment revealed a TIQ level of 56 
(WISC-III). He followed special education as a child, but after finishing this, he was not 
able to work due to severe psychiatric problems with frequent tantrums and periods 
of hyperventilation. Several psychiatric medications turned out to be insufficient. 
Ophthalmologic examination revealed myopia (-2.5/-3.5 dioptre) and strabismus of 
the left eye. He was treated for oesophagitis and had frequent diarrhea. Because 
of his delayed development, he was referred to a clinical geneticist. Physical 
examination at the age of 16 years showed a normal height of 171 cm (-0.5 SD, 
based on normal values for Turkish children23 and normal weight of 50.3 kg (-0.5 SD). 
He had facial dysmorphisms including short forehead, upward slanting palpebral 
fissures, mild epicanthal folds, hypertelorism, ptosis, flat mid-face, thin upper lip 
and pointed chin. Thoracal kyphosis and scoliosis were noticed. His hands showed 
contractures of the proximal interphalangeal joints of the fourth fingers and absence 
of flexion creases of the distal interphalangeal joints of the second till fourth fingers. 
Previous investigations, comprising of karyotyping, fragile X screening and SNP array 
analysis were normal. Metabolic screening and brain MRI scan, performed at age 
16 years, showed no abnormalities. Using whole exome sequencing, a de novo TLK2 
mutation was identified: Chr17(GRCh37):g.60678182G>T; NM_006852.3:c.1720+1G>T 
(p.(r.spl?)).
Pat ient 439
This male patient is the second of two children of nonconsanguineous parents of 
Dutch ancestry. There were no developmental problems reported in the family. 
Prenatal ultrasound showed a single umbilical artery. He was born after 40 weeks of 
gestation with a birth weight of 3170 gram (-1 SD) after an uncomplicated delivery. As 
neonate, he had feeding difficulties and low weight. His development was delayed. 
He started walking at the age of 18 months. He spoke the first words at normal age, 
but further language development was delayed and he speaks with hoarse voice. 
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Psychological assessment at the age of 5 years showed a borderline TIQ level of 
80 and at the age of 7.5 years a mild intellectual disability with a TIQ level of 67 
(SON-R 6-40). He was recently diagnosed with multiple complex developmental 
disorders, with severe problems in regulation of emotions and anxiety. Treatment 
with Abilify and Cipramil has been started to alleviate the symptoms. The boy 
had severe constipation, requiring laxatives. Physical examination at the age of 
7 years showed a short stature, with a height of 11.5 cm (-2.5 SD), normal weight 
of 21 kg (0 SD) and normal head circumference of 50 cm (-1 SD). He had facial 
dysmorphisms including upward slanting palpebral fissures, blepharophimosis, 
ptosis, full nasal tip and pointed chin. His hands showed brachydactyly and single 
flexion crease of the second and third finger. Previous investigations, consisting 
of fragile X screening and SNP array, were normal. Metabolic screening showed 
no abnormalities. Using whole exome sequencing a de novo TLK2 mutation was 
identified: Chr17(GRCh37):g.60689765C>T; NM_006852.3:c.2092C>T (p.(Arg698*)).
SETD2
Pat ient 162
This male patient is the first child of three children of non-consanguineous parents 
of Dutch ancestry. There were no developmental problems reported in the family. 
He was born after 36+4 weeks of gestation which was complicated by maternal 
hypertension and HELLP syndrome. Delivery was uncomplicated. His birth weight 
of 2625 gram (-1.5 SD) was normal. There was normal motor development, but 
delayed development of language, with the first words at the age of 3 year. At the 
age of 7 years, psychological assessment showed mild ID with TIQ of 54 (WISC-III). 
As child, he received surgery for bilateral inguinal hernia. He needed glasses to 
correct myopia (-2/-2.5 dioptre). Physical examination at the age of 11 years showed 
macrocephaly with a head circumference of 59.5 cm (+4 SD), high-normal height of 
164.4 cm (+2 SD) and low-normal weight of 45 kg (-2 SD). He had facial dysmorphisms 
including small and protruding ears, broad forehead, hypertelorism, downward 
slanting and narrow palpebral fissures. A shawl scrotum was present. There were 
no abnormalities of the extremities observed. At age of 4 years, brain MRI and 
metabolic screening showed no abnormalities. Previous investigations, consisting 
of karyotyping, MLPA analysis, fragile X screening, 250k SNP array and sequence 
analysis of multiple genes (SOS1, NRAS, SHOC2, NF1, SPRED1, NSD1, KCNQ1OT1, H19, 
NFIX, EZH2, BRAF, MAP2K1, KRAS, PTPN11, RAF1) were normal. Using whole exome 
sequencing a de novo SETD2 mutation was identified: Chr3(GRCh37):g.47161721dup; 
NM_014159.6:c.4405dup (p.(Met1469fs)).
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Pat ient 716
This male patient was the second of two children of non-consanguineous parents 
of Dutch ancestry. His older brother needed special education because of severe 
behavior problems. Further family history was not contributory. He was born 
after 40 weeks of gestation with a birth weight of 3000 gram (-1.5 SD). Delivery 
was uncomplicated. In the first year, no problems were noticed, but after his first 
year, both motor and language development were delayed. He walked the first 
steps at the age of 19 months. As young child, he was aggressive to other children, 
but this improved from the age of 8 years. He was referred to a clinical geneticist 
because of developmental delay, tall stature and macrocephaly. From age 9 years, 
he eats unrestrained and gains weight. Physical examination at the age of 9 years 
showed tall stature with height of 162.5 cm (+2.5 SD), macrocephaly with head 
circumference of 57.8 cm (+3 SD) and normal weight of 55.5 kg (+1.5 SD). He had facial 
dysmorphisms including high forehead, deep set eyes and downward slanting of 
palpebral fissures. There was clinodactyly of his second and third toes and he had a 
mastocytoma on his right leg. Brain MRI at the age of 9 years showed a subarachnoid 
cyst left temporal. Analysis of growth hormones showed no abnormalities, but 
hand films revealed advanced carpal and phalangeal bone age of 11 years at the 
age of 9 years. Previous investigations, consisting of karyotyping, fragile X and 
Sotos screening were normal. Using family-based whole exome sequencing a de 
novo mutation in SETD2 was identified: Chr3(GRCh37):g.47155435_47155437del; 
NM_014159.6:c.4644_4646del (p.(Gln1548del)).
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SUPPLEMENTARY TABLES
Supplementary Tables 2-6, 8-10 and 14 were not included in this thesis and can de 
found online at the following link: https://www.nature.com/articles/nn.4352
Study # Trios Disorder Coding Functional LoF
RUMC 820 ID 1,083 872 211
Gilissen, C., et al.3 50 ID 84 65 15
Rauch, A., et al.24 51 ID 84 76 21
de Ligt, J., et al. 13  50* ID 57 46 12
Deciphering Developmental Disorders Study.5 1,133 ID 1,337 1,073 235
Neale, B.M., et al.25 175 ASD 170 120 18
Iossifov, I., et al.2 2,508 ASD 2,738 2,103 389
Epi4K Consortium.26 356 EE 412 333 53
Xu, B., et al.)27 53 SCZ 34 32 0
McCarthy, S.E., et al.28 57 SCZ 64 50 9
Gulsuner, S., et al.1 105 SCZ 99 67 12
Xu, B., et al.29 231 SCZ 132 106 19
Fromer, M., et al.30 617 SCZ 639 483 63
Total 6,206 6,933 5,426 1,057
Supplementary Table 1. Meta-study cohort composition. Columns indicate (from left to right) the study 
name, the number of trios in the studied cohort, the disorder that was studied (ID: Intellectual disability, 
SCZ: Schizophrenia ASD: autism spectrum disorder, EE: epileptic encephalopathy), the number of coding, 
functional, and loss-of-function (LoF) mutation. *Of the 100 samples in de Ligt et al. 50 samples overlap 
with Gilissen et al. Overlapping DNMs are removed from the de Ligt et al. DNM list.
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Gene
Patient key
Intellectual 
Disability
Seizures
Motor delay
Language delay
Hypotonia
Behaviour 
problems
Structural brain 
abnormalities
Facial 
dysmorphisms
Neonatal 
feeding 
difficulties
Visual 
impairment
Urogenital 
abnormalities
Gastointestinal 
abnormalities
Congenital 
heart defect
Skeletal 
abnormalities
Abnormal birth 
weight
Abnormal OFC
Abnormal 
height
Abnormal 
weight
Other major 
abnormalities
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Gene ASD EE ID SCZ LoF* Functional* Biology
DLG4 0 0 5 0 7.65×10-4 0.115
Required for synaptic plasticity 
associated with NMDA receptor 
signaling. Depletion of DLG4 changes 
the ratio of excitatory to inhibitory 
synapses in hippocampal neurons.
PPM1D 0 0 3 0 0.025 1
Ser/Thr phosphatase which mediates 
a feedback regulation of p38-p53 
signaling thereby contributing to 
growth inhibition and suppression of 
stress induced apoptosis.
SLC6A1 3 0 2 0 1 0.033
Encodes a GABA transporter which 
removes GABA from the synaptic cleft 
by its high affinity sodium-dependent 
reuptake info presynaptic terminals. 
Mutations in SLC6A1 been associated 
with epilepsy with myoclonic-atonic 
seizures)31.
TCF20 0 0 4 0 0.010 1
Transcriptional activator of matrix 
metalloproteinase 3 and (co)activator 
of various other transcriptional 
activators. Previous case reports 
suggested a stronger link with ASD32.
TCF7L2 2 0 3 0 0.025 0.033
High mobility group (HMG) box-
containing protein that participates 
in the Wnt signaling pathway where it 
modulates Myc expression, acts as a 
repressor of CTNNB1 and as activator 
in its presence.
TLK2 1 0 5 1 0.075 3.14×10-4
Ser/Thr kinase regulating chromatin 
assembly. Involved in DNA replication, 
transcription, repair and chromosome 
segregation.
TRIP12 3 0 4 0 7.65×10-4 0.033
E3 ubiquitin-protein ligase involved 
in ubiquitin fusion degradation 
pathway. Guards excessive spreading 
of ubiquitinated chromatin at damaged 
chromosomes in DNA repair.
Supplementary Table 11. All significant genes in the neurodevelopmental cohort Genes with a significant 
enrichment for de novo mutations identified in the complete cohort of neurodevelopmental trios. Genes 
in bold were not identified in the ID cohort analysis. Columns show, from left to right, the gene name, 
number of cases found in Autism Spectrum Disorder (ASD) cohorts, in Epileptic Encephalopathy (EE) 
cohorts, in intellectual disability (ID) and Schizophrenia (SCZ). *Corrected p-value for loss-of-function 
(LoF) and functional mutations, respectively.
69
Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability
St
ud
y
# 
Tr
io
s
D
is
or
de
r
Co
di
ng
Fu
nc
ti
on
al
Lo
F
Se
qu
en
ce
r
En
ri
ch
m
en
t 
K
it
Co
ve
ra
ge
Io
ss
if
ov
, I
., 
et
 a
l.2
1,
91
1
A
SD
 /
 
Si
b
s.
1,
78
0
1,
30
9
17
5
C
SH
L:
 H
is
eq
20
00
Se
q
C
ap
 E
Z 
v2
.0
(4
4 
M
b)
80
%
 e
n
ri
ch
ed
 t
ar
ge
ts
 
at
 2
0x
 c
ov
er
ag
e
U
W
: H
is
eq
20
00
Se
q
C
ap
 E
Z 
v2
.0
(4
4 
M
b)
YA
LE
: H
iS
eq
20
00
Se
q
C
ap
 E
Z 
v2
.0
(4
4 
M
b)
G
en
om
e 
of
 t
h
e 
N
et
h
er
la
n
d
s 
C
on
so
rt
iu
m
.3
3
25
0
C
on
.
13
7
97
7
H
iS
eq
20
00
n
on
e 
(W
G
S)
A
ve
ra
ge
 1
3x
R
au
ch
, A
., 
et
 a
l.2
4
20
ID
 /
 C
on
.
19
12
2
H
iS
eq
20
00
Su
re
Se
le
ct
 X
T 
H
u
m
an
 
al
l e
xo
n 
50
 M
b 
ki
t
M
e
d
ia
n
 
co
ve
ra
g
e
: 
11
2
x.
 9
0
%
 e
n
ri
ch
ed
 
ta
rg
et
s 
at
 2
0x
G
u
ls
u
n
er
, S
., 
et
 a
l.1
84
ID
 /
 S
ib
s.
66
48
11
G
en
o
m
e 
A
n
al
yz
er
 
IIX
Se
q
C
ap
 E
Z 
v2
.0
 (4
4 
M
b)
M
e
d
ia
n
 
co
ve
ra
g
e 
>1
0
0x
. 
93
%
 e
n
ri
ch
ed
 
ta
rg
et
s 
at
 1
0 
x
Xu
, B
., 
et
 a
l.2
9
34
SC
Z 
/ 
C
on
.
17
12
1
H
iS
eq
20
00
Su
re
Se
le
ct
 3
7M
b
M
e
d
ia
n
 
co
ve
ra
g
e
: 
65
.2
x.
 >
80
%
 e
n
ri
ch
ed
 
ta
rg
et
s 
at
 2
0x
To
ta
l
2,
29
9
2,
01
9
1,
47
8
19
6
Su
pp
le
m
en
ta
ry
 T
ab
le
 1
2.
 C
on
tr
ol
 c
oh
or
t c
om
po
si
tio
n.
 F
or
 e
ac
h 
of
 th
e 
co
ho
rt
s 
us
ed
 to
 c
on
st
ru
ct
 th
e 
co
nt
ro
l s
et
 th
e 
nu
m
be
r 
of
 s
am
pl
es
 a
nd
 d
e 
no
vo
 m
ut
at
io
ns
 is
 
sh
ow
n.
 C
ol
um
ns
 in
di
ca
te
 (f
ro
m
 le
ft
 to
 r
ig
ht
) t
he
 s
tu
dy
 n
am
e,
 th
e 
nu
m
be
r o
f t
ri
os
 in
 th
e 
st
ud
ie
d 
co
ho
rt
, t
he
 d
is
ea
se
 th
at
 w
as
 s
tu
di
ed
 in
 th
e 
co
nt
ex
t o
f t
he
 c
on
tr
ol
 c
oh
or
t 
(ID
: I
nt
el
le
ct
ua
l d
is
ab
ili
ty
, S
CZ
: S
ch
iz
op
hr
en
ia
 A
SD
: a
ut
is
m
 s
pe
ct
ru
m
 d
is
or
de
r, 
EE
: e
pi
le
pt
ic
 e
nc
ep
ha
lo
pa
th
y)
 a
s 
w
el
l a
s 
w
he
th
er
 s
am
pl
es
 w
er
e 
un
re
la
te
d 
he
al
th
y 
co
nt
ro
ls
 
(C
on
.) 
or
 u
na
ff
ec
te
d 
si
bl
in
gs
 (S
ib
s.
), 
th
e 
nu
m
be
r 
of
 c
od
in
g,
 fu
nc
tio
na
l a
nd
 lo
ss
-o
f-f
un
ct
io
n 
(L
oF
) m
ut
at
io
n,
 th
e 
se
qu
en
ci
ng
 p
la
tf
or
m
 u
se
d,
 th
e 
st
ud
y 
of
 G
ul
su
ne
r 
et
 a
l. 
us
ed
 th
e 
Ill
um
in
a 
G
en
om
e 
An
al
yz
er
 II
X 
w
he
re
 th
e 
ot
he
r 
fo
ur
 s
tu
di
es
 u
se
d 
th
e 
Ill
um
in
a 
H
iS
eq
20
00
 p
la
tf
or
m
, t
he
 e
nr
ic
hm
en
t, 
en
ri
ch
m
en
t k
it
s 
us
ed
, c
ov
er
ag
e,
 r
ep
or
te
d 
co
ve
ra
ge
 a
s 
st
at
ed
 in
 th
e 
pu
bl
is
he
d 
pa
pe
r.
3
70
Chapter 3
Gene Genomic variant cDNA mutation Protein effect
YIF1A Chr11(GRCh37):g.66052251G>A NM_020470.2(YIF1A):c.739C>T p.Arg247Cys
YIF1A Chr11(GRCh37):g.66052363G>A NM_020470.2(YIF1A):c.716C>T p.Ser239Leu
YIF1A Chr11(GRCh37):g.66055332G>A NM_020470.2(YIF1A):c.299C>T p.Ala100Val
YIF1A Chr11(GRCh37):g.66055553del NM_020470.2(YIF1A):c.242del p.Glu81Glyfs*8
Supplementary Table 13. List of DNMs in genes significantly enriched in the control cohort. The four 
de novo mutations in the control cohort of the gene YIF1A are from Iossifov et al.2.
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Supplementary Figure 1. Overview of the percentage of on target coverage by 10 or more reads. A 
scatter plot of the percentage of on target coverage by 10 or more reads shown for the 820 samples 
of the RUMC cohort. In this figure the samples are ordered ascending based on the percentage of 
on target coverage. The median percentage of 98.9% on target coverage by 10 or more reads of the 
RUMC cohort is depicted by the black thick line.
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 Supplementary Figure 2. Distribution of de novo mutations (DNM) over patients in the RUMC 
cohort. In total, 619 of 820 patients had at least one de novo mutation.
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Supplementary Figure 3. Distribution of de novo mutations per gene in the RUMC cohort. In 
total, 915 different genes have had at least one de novo mutation.
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Supplementary Figure4. Schematic representation of the location of de novo mutations identified 
in the RUMC cohort and their presumed effect on protein function. *Premature Termination Codon 
(PTC); an insertion or deletion does not introduce a frameshift event, but directly creates a PTC.
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Supplementary Figure 5. Simulations of recurrent mutated genes of the RUMC cohort. The two 
panels show the distribution of recurrently mutated genes based on 100,000 simulations resam-
pling the 211 LoF and 872 functional de novo mutations of the 820 ID patients in the RUMC-cohort. 
Simulations are based on the gene specific mutation rates of Samocha et al.6. The colored boxes 
indicate the interquartile range; the whiskers indicate the full interval and the orange diamond 
indicate the observed number of recurrent de novo mutated genes in the RUMC cohort. a. For the 
loss-of-function simulations the observed number of recurrently mutated genes (N = 23, depicted 
by the diamond) does statistically differ from the simulations. (LoF simulations in orange boxplot: 
μ = 2.31, σ = 1.49; empirical P-value: <1.00×10-05, Z-value = 13.90) b. For the functional simulations 
the observed number of recurrently mutated genes (N = 85, depicted by the diamond) does sta-
tistically differ from the simulations (functional simulations in green boxplot: μ = 34.98, σ = 5.40; 
empirical P-value: <1.00×10-05, Z-value = 9.26).
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Supplementary Figure 6. Flow chart of cohort construction for statistical analysis. Based on 
the presence of de novo mutations (DNMs) in 1,537 known ID genes (Supplementary table 4) the 
patients were divided among two groups for a) the RUMC cohort (820 trios) b) the combined ID 
cohort (2,104 trios) and c) the neurodevelopmental cohort (6,206 trios). The group on the left side 
in the color red indicate the patients with DNMs found in known ID genes. On the right, in the green 
color, is the group of patients without DNMs present in the 1,537 known ID genes. The statistical 
analysis was performed on the cohort consisting of patients without DNMs in known genes. The 
number of trios and DNMs present in genes is shown for each group.
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Supplementary Figure 7. Schematic overview of de novo mutations found in SETD2. SETD2 
(Q9BYW2) with de novo mutations in individuals with ID and ASD. Individuals show similar over-
growth phenotype including macrocephaly, tall stature and facial dysmorphisms (Supplemental 
Case reports).
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Supplementary Figure 8. Intolerance to Loss-of-function (LoF) variation for ID genes. The box plots 
indicate the distribution of median pLI (probability LoF intolerant) based on 100,000 permutations 
of equal sized gene sets (see Online Methods). Gene sets analyzed include genes with at least one 
functional de novo mutation in healthy control set (pink box; N=1,300), dominant ID genes (blue box; 
N=423), and novel candidate ID genes (green box, N=10). In orange, all genes (n=21, all known domi-
nant ID genes) were used for which we observed at least three amino missense DNM - and no loss-of-
function - mutations, suggestive for genes with gain-of-function and/or dominant-negative effect. The 
red diamonds show the observed median pLI per category. The closer a pLI is to 1 the more intolerant 
a gene is to LoF variants. A pLI >= 0.9 is considered as an extremely LoF intolerant set of genes9. For 
the control genes, the observed median pLI matched the simulated distribution of median pLI (Ob-
served: 0.03; simulated distribution: μ=0.03, σ=0.01; empirical p-value: 0.31; Z-value = 0.39). For the 
set of dominant ID genes and ten novel candidate ID genes, the observed median pLI is significantly 
higher than the simulated distribution of median pLI (Dominant ID genes: observed: 0.87; simulated 
distribution: μ=0.03, σ=0.01; empirical p-value <1x10-5; Z-value: 61.54 and Novel candidate ID genes: 
Observed 0.99; simulated distribution: μ= 0.14, σ= 0.20; empirical p-value <1x10-5; Z-value = 4.28). 
For the dominant ‘missense only’ genes (with at least three missense mutations in the absence of 
LoF mutations). We observed the highest median pLI of all evaluated gene sets (Observed: 0.9999; 
simulated distribution: μ=0.09, σ=0.14; empirical p-value <1x10-5; Z-value = 6.70)
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Supplementary Figure 9. Genes enriched for LoF and functional de novo mutations in the cohort 
of 6,206 individuals with neurodevelopmental disease. The y-axes shows the -log10(P) value of the 
mutation enrichment. Corrected P-values based on LoF mutations are colored in blue and corrected 
P-values based on functional mutations are colored green. Only genes with a corrected P-value 
(LoF, functional, or both) less than the significance threshold (red dotted line, 0.05) are shown.
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Supplementary Figure 10. Schematic representation of a synapse, with special focus on the 
postsynaptic density (PSD). Proteins playing an essential role in the PSD for signaling cascades and/
or receptor trafficking are schematically depicted, as well as the AMPA Receptor (AMPAR), NMDA 
receptor (NMDAR), metabolic Glutamate receptor (mGluR), Calcium and Potassium channels (Ca2+ 
and K+ respectively) (Iasevoli, F., Tomasetti, C. & de Bartolomeis, A. Neurochem Res 38, 1-22 (2013)). 
An overlay was made between all DNMs identified in the NDD meta-analysis and the genes playing 
essential roles in the PSD, as well as with the list of known ID genes. Known ID genes are indicated 
by an asterisk. For genes in blue, we identified at least one DNM in the ID cohort, whereas the genes 
in orange were restricted to carry DNMs in the EE, SCZ and/or ASD patients. For genes in green, 
we identified DNMs in our meta-analysis both the ID and (at least one of the) NDD cohorts. Genes 
listed in black play a role in e.g. complex formation of the AMPAR or NMDAR, but in have not been 
identified to carry DNM in our current ID/NDD cohort. Importantly, three of ten genes which we 
identified as novel candidate ID gene play a role in the PSD and its downstream processes. DLG4, 
encoding post-synaptic density protein 95 (PSD95), is one of the core PSD proteins34, whereas RAC1 
and TCF7L2 are important in downstream signaling cascades, including Rho- and Wnt signaling 
respectively (novel candidate ID are underlined and highlighted in red).
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Supplementary Figure 11. Simulations of recurrent mutated genes of the control cohort. The two 
panels show the distribution of recurrently mutated genes based on 100,000 simulations resam-
pling the 196 LoF and 1,478 functional de novo mutations of the 2,299 control cohort. Simulations 
are based on the gene specific mutation rates of Samocha et al6. The colored boxes indicate the 
interquartile range; the whiskers indicate the full interval and the orange diamond indicate the 
observed number of recurrent de novo mutated genes in control cohort. a. For the loss-of-function 
simulations the observed number of recurrently mutated genes (N = 2, depicted by the diamond) 
does not statistically differ from the simulations (simulations in orange boxplot: μ = 2.00, σ = 1.39; 
empirical P-value: 0.60; Z-value = 2.69×10-3) b. For the functional simulations the observed number 
of recurrently mutated genes (N = 103, depicted by the diamond) does not statistically differ (simu-
lations in green boxplot: μ=93.17 σ=8.33; empirical P-value: 0.13; Z-value = 1.39).
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Supplementary Figure 12. Gene set based evaluation of pLI. The box plots indicate the distri-
bution of median pLI (probability Loss-of-function intolerant) based on 100,000 permutations of 
equal sized gene sets (see Online Methods). Gene sets analyzed include LoFT tolerant genes with 
(light blue; N=163), genes with at least one functional de novo mutation in healthy control set (pink 
box; N=1,300), Housekeeping (HK) genes (yellow box; N=398), and dominant ID genes (N=423). 
The red diamonds show the observed median pLI per category. The closer a pLI is to 1 the more 
intolerant a gene is to LoF variants. A pLI >= 0.9 is considered as an extremely LoF intolerant set 
of genes9. The median pLI for the loss-of-function tolerant genes was significantly lower than the 
simulated distribution of median pLI (observed 9.33x10-9; simulated distribution: μ= 0.04, σ= 0.03; 
empirical p-value: <1x10-5; Z-value=1.25). For the gene set with DNM in healthy controls, the observed 
median pLI matched the simulated distribution of median pLI (observed 0.03; simulated distribution: 
μ= 0.03, σ= 0.01; empirical p-value: 0.31; Z-value=0.39). For the “house-keeping” and dominant ID 
gene sets, the observed median pLI is significantly higher than the simulated distribution of median 
pLI (HK genes: observed: 0.87; simulated distribution: μ= 0.03, σ= 0.02; empirical p-value <1x10-5; 
Z-value = 54.05 and Dominant ID genes: Observed: 0.95; simulated distribution: μ= 0.03, σ= 0.01; 
empirical p-value <1x10-5; Z-value = 61.54).
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Supplementary Figure 13. Gene set based evaluation of RVIS. The box plots indicate the distribu-
tion of median RVIS (Residual Variation Intolerance Score) based on 100,000 permutations of equal 
sized gene sets (see Methods). Gene sets analyzed include loss-of-function tolerant (LoFT) genes 
(light blue; N=161), genes with at least one functional de novo mutation in healthy control set (pink 
box; N=1,262), House-keeping (HK) genes (yellow box; N=397), dominant ID genes (blue box; N=412), 
and novel candidate ID genes (green box, N=9). In orange, all genes (N=21, all known dominant ID 
genes) were used for which we observed at least three amino missense DNM - and no loss-of-func-
tion - mutations, suggestive for genes with gain-of-function and/or dominant-negative effect. The 
red diamonds show the observed median RVIS per category. Based on the simulations, depicted by 
the boxplots, we could identify a significant higher median RVIS for the LoFT genes, which is in line 
with the tolerant nature of this gene set (Observed: 85.04; simulated distribution: μ=50.01, σ=2.48; 
empirical p-value: <1x10-5; Z-value: 14.14). For the healthy control set the observed median RVIS was 
significantly lower than the expected median RVIS (observed: 37.05; simulated distribution: μ=50.01, 
σ=1.36; empirical p-value: <1x10-5; Z-value=-9.56). For the House-keeping and dominant ID gene sets 
the observed median RVIS is significantly lower than the simulated distribution of median RVIS (HK 
genes: observed: 32.80; simulated distribution: μ=50.01, σ=2.48; empirical p-value <1x10-5; Z-value: 
-6.95; and Dominant ID genes: observed: 18.92; simulated distribution: μ=50.02, σ=2.43; empirical 
p-value <1x10-5; Z-value: -12.82). The set of novel candidate ID genes has an observed median RVIS 
of 8.47 (simulated distribution: μ=50.05, σ=15.08; empirical p-value = 4.60x10-4; Z-value: -2.76). For 
the 21 dominant ‘missense only’ genes (with at least 3 missense mutations in the absence of LoF 
mutations) we observe the lowest median RVIS of 3.56 (simulated distribution: μ=50.02, σ=10.42; 
empirical p-value <1x10-5; Z-value: -4.46) again illustrating that those known and novel candidate 
dominant ID genes that harbor only missense variants are among the most intolerant ID genes.
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ABSTRACT
Haploinsufficiency (HI) is the best characterized mechanism through which 
dominant mutations exert their effect and cause disease. Non-haploinsufficiency 
(NHI) mechanisms, such as gain-of-function and dominant-negative mechanisms, 
are often characterized by the spatial clustering of mutations, thereby affecting 
only particular regions or base pairs of a gene. Variants leading to haploinsufficency 
might occasionally cluster as well, for example in critical domains, but such clustering 
is on the whole less pronounced with mutations often spread throughout the gene. 
Here we exploit this property and develop a method to specifically identify genes 
with significant spatial clustering patterns of de novo mutations in large cohorts. We 
apply our method to a dataset of 4,061 de novo missense mutations from published 
exome studies of trios with intellectual disability and developmental disorders (ID/
DD) and successfully identify 15 genes with clustering mutations, including 12 genes 
for which mutations are known to cause neurodevelopmental disorders. For 11 out 
of these 12, NHI mutation mechanisms have been reported. Additionally, we identify 
three candidate ID/DD-associated genes of which two have an established role in 
neuronal processes. We further observe a higher intolerance to normal genetic 
variation of the identified genes compared to known genes for which mutations lead 
to HI. Finally, 3D modeling of these mutations on their protein structures shows that 
81% of the observed mutations are unlikely to affect the overall structural integrity 
and that they therefore most likely act through a mechanism other than HI. 
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INTRODUCTION
De novo mutations affecting protein-coding genes are a major cause of intellectual 
disability (ID) and other developmental disorders (DDs).1,2 Several whole exome 
sequencing (WES) studies have identified ID syndromes molecularly characterized 
by very specific spatial clustering of de novo missense mutations.3-6 Similarly, large-
scale WES studies of individuals affected by ID/DD have recently leveraged this 
phenomenon as supporting evidence of the involvement of a gene in disease.7,8 
This spatial clustering of de novo mutations (DNMs) is typical for missense 
mutations in genes without clear, or limited numbers of, truncating mutations 
subsequently degraded by nonsense-mediated mRNA decay, suggesting that these 
clustered mutations act through a different mechanism than haploinsufficiency 
(HI).9 Alternative pathophysiological mechanisms that may underlie (de novo) 
mutation clustering are gain-of-function or dominant-negative effects, resulting 
in the alteration or impairment of specific protein function.10,11 We note that while 
spatial clustering is commonly taken to indicate a mechanism different from loss-
of-function,12 this is not an absolute rule, and a loss-of-function mechanism cannot 
be excluded without functional evidence.13 Here, we developed a method to identify 
genes with spatially clustered DNMs and applied this to DNMs identified in a large 
cohort of individuals with ID/DD.14 
We downloaded all DNMs occurring in individuals with ID/DD from denovo-db 
version 1.314 identified through WES and whole genome sequencing which were then 
re-annotated with our in-house variant annotation pipeline. The de novo mutations 
included in the analysis were previously validated by a second independent method 
or showed a high validation rate for a subset of de novo mutations. In addition, 
we added 1,183 de novo variants identified in the exomes of a in-house ID cohort 
that was previously published.8 To further reduce the risk of including sequencing 
artifacts and/or genotyping errors, we excluded all de novo variants that were 
present more than once in the ExAC dataset (Table S1).15 These efforts resulted in 
6,495 protein-coding DNMs, including 4,061 missense mutations, in 5,302 individuals 
with ID/DD (Table S2). 
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Gene name Transcript ID # de novo missense
Median 
distance (bp) P-value
Adj.
p-value
ACTL6Ba ENST00000160382 3 0 5.70E-07 1.10E-02
ALG13 ENST00000394780 3 0 1.50E-07 2.89E-03
CDK13 ENST00000181839 12 273 <1.00E-08 <1.93E-04
COL4A3BP ENST00000380494 6 18 2.60E-07 5.01E-03
GABBR2a ENST00000259455 3 0 9.00E-08 1.74E-03
GRIN2B ENST00000609686 11 354 1.57E-06 3.03E-02
KCNH1 ENST00000271751 7 65 1.00E-07 1.93E-03
KCNQ2 ENST00000354587 20 301 5.00E-08 9.64E-04
KIF5C ENST00000435030 3 0 1.40E-07 2.70E-03
PACS1 ENST00000320580 9 0 <1.00E-08 <1.93E-04
PACS2a ENST00000458164 3 0 1.50E-07 2.89E-03
PCGF2 ENST00000360797 3 0 1.11E-06 2.14E-02
PPP2R1A ENST00000322088 4 5 4.60E-07 8.87E-03
PPP2R5D ENST00000485511 16 10 <1.00E-08 <1.93E-04
SMAD4 ENST00000398417 4 6 1.60E-07 3.08E-03
Table 1. List of identified genes with clustering de novo missense mutations. P-values are based on a 
permutation test (N=1.00E+08). Adj. p-values are corrected by Bonferroni correction. The three identified 
genes that have not yet been implicated in ID/DD are indicated by an a.
We set out to determine for any gene whether the observed de novo missense 
mutations cluster more than expected compared to random permutations. Hereto, 
we selected for each the longest representative transcript (i.e. part of the GENCODE 
basic set)16 and calculated the geometric mean distance δg over all missense DNMs 
on cDNA. δg Was calculated by taking the mean distance normalized for transcript 
length l over all (M) combinations of xi and xj of the missense DNMs (Equation 
1.), where x represents the position for mutation i and j respectively. Statistical 
significance was determined by performing 1.00E+08 (or N) permutations and 
calculating for each permuted geometric mean distance (δ’g) how many times this 
resulted in the same or smaller geometric mean distance as observed (Equation 2.) 
Permutation p-values were corrected for multiple testing via Bonferroni procedure 
based on the 19,280 genes of the Agilent SureSelect v5 exome enrichment kit. 
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1.
2.
We first validated our method on a dataset of DNMs identified in 2,448 unaffected 
siblings and healthy control studies14 17-22 (Table S3). In this cohort, we failed to 
identify genes for which clustering of de novo missense mutations reached statistical 
significance (Table S4). However, application of our method to the dataset of 4,061 
DNMs, containing 583 genes with more than one de novo missense mutation, 
revealed 15 genes with significant clustering7,8,23-25 (Table 1, Figure 1, Figures S1-
S15). In these genes, a total of 107 de novo missense mutations contributed to 
mutation clustering, ranging from three to 20 mutations per gene with an average 
distance ranging from 0 to 354 bp. To exclude a correlation between the extent 
of clustering and the total number of de novo missense mutations analyzed, we 
applied our method to a cohort of 6,154 de novo missense variants present in de 
novo-db excluding the five studies incorporated in the ID/DD cohort, and found no 
such correlation (Figure S16). To examine whether this set of 15 genes is relevant 
in the context of ID/DD, we compared these genes to a list of 1,541 genes for which 
mutations are known to cause ID/DD (Table S5). This list of genes was a compilation 
of two manually curated lists of disease-associated genes including “confirmed” 
unique genes from DDG2P (n=1,098; see Web Resources) and 1,034 genes offered 
for diagnostic testing in individuals with ID/DD by our in-house diagnostic facility 
(see Web Resources). Among the 15 identified genes with mutation clustering, 
we find 12 genes for which mutations have previously been implicated in ID/DD, 
constituting a significant enrichment (p=3.09E-03; Fisher’s exact test; Tables S6 and 
S7), and confirming that our method is valid for its purpose. The inclusion of exome 
data of two large DDD-studies in both the DDG2P gene list and the ID/DD cohort of 
this study could introduce a potential bias1,7. To exclude such bias, we repeated this 
analysis while excluding the DDD-specific genes identified in the two exome studies 
yielding a significant enrichment (p=3.68E-02; Table S7A-C).
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Figure 1. Examples of identified genes with clustering mutations. Protein domains are annotated 
based on Pfam HMM search26. cDNA locations of de novo missense mutations are depicted by blue 
pins. Genes shown here are: SMAD4 (A), CDK13 (B), PACS2 (C). Figures visualizing the clustering of 
de novo missense mutations in the other 12 genes are provided in Figures S1-S15.
We also identified three genes with clustered de novo missense mutations that 
have not yet been implicated in ID/DD: ACTL6B (MIM:612458), GABBR2 (MIM:607340) 
and PACS2 (MIM:610423). None of these genes would have been identified based 
on enrichment for de novo mutations in this cohort (Table S8). Further systematic 
evaluation of gene function supports a role in (neuro)development for two of these 
genes (Table 2 and Table S9). ACTL6B, encoding Actin-like 6B (also known as BAF53B), 
is a pivotal co-factor for the SWI/SNF neuron-specific chromatin remodeling complex 
nBAF; which is required for neural development and dendritic outgrowth.27,28 Also, 
GABBR2, which is a component of the G protein-coupled GABA receptor, plays a 
critical role in the fine-tuning of inhibitory synaptic transmission,29-31 and other 
members of the GABA receptor family have already been conclusively linked to 
neurodevelopmental disorders.32,33 GABBR2 was very recently also reported by 
others to show significant de novo mutation clustering in a neurodevelopmental 
cohort.6
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Our method might potentially identify clustering based on identical mutations 
in multiple individuals only as a result of issues in the underlying cohort. It could for 
instance be that the same individual was included in multiple studies and therefore 
occurs twice in the cohort. For 99 out of 107 de novo missense mutations (92.5%) 
occurring in the 15 genes with clustering mutations, we could decisively conclude 
that they occurred as unique events in separate individuals based on a combination 
of the gender of the affected individual and the presence of additional de novo 
mutations (Table S10). Nevertheless, it may be possible that siblings of affected 
individuals were included who share a DNM due to parental gonadal mosaicism.34 
Alternatively, DNMs might occur multiple times in disease cohorts as a consequence 
of a locally increased mutation rate. Examples of the latter may for instance incur a 
selective growth advantage (i.e. selfish mutations35) and thereby result in a pattern 
of mutational clustering such as known for FGFR2 (MIM: 176943) mutations in Apert 
syndrome (MIM: 101200).35 However, biological relevance for the mutations in the 
identified genes in the context of ID/DD is suggested by the fact that in our control 
cohort genes with significant clusters were absent, and that for the majority of our 
identified genes experimental evidence in literature supports a NHI mutational 
mechanism (Table S11).
We hypothesized that the clustering de novo missense mutations of the 15 genes 
might exert their effects through mechanisms other than haploinsufficiency. To 
validate this hypothesis, we compiled a set of 116 genes known for mutations that 
exert disease through non-haploinsufficient (NHI) mechanisms. Hereto, we selected 
for genes that have a “confirmed” status in the DDG2P list, or are present on both 
the Radboudumc ID/DD diagnostic testing and DDG2P lists (irrespective of the 
DDG2P status). Furthermore, genes were selected to be dominant (mono allelic), 
with the pathophysiological mechanism being either “activating”, “all missense/in 
frame” and/or “dominant-negative” (Table S12). In addition, we generated a set of 
183 haploinsufficient genes for which mutations are associated with ID/DD from 
the DDG2P gene list by selecting “loss-of-function” as the “mutation consequence” 
and “mono allelic” for the “allelic requirement” in the DDG2P gene list (Table S13). 
Interestingly, for eight of the 12 genes for which mutations are known to cause 
ID/DD and for which we identified mutation clustering, the disease mechanism on 
the constructed gene list was reported to be NHI. For these eight genes, it is either 
gain-of-function or dominant-negative, thereby showing statistical enrichment for 
NHI mechanisms (p=2.66E-03, Fisher’s exact test; Table S14 and S15). For two of 
the three remaining genes (GRIN2B [MIM:138252] and SMAD4 [MIM:600993]) both 
HI and NHI consequences have been reported,36-39 suggesting that for mutations in 
these genes more complex genotype-phenotype relations may exist, where HI and 
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NHI mechanisms cause clinically distinct ID/DD-related disorders. For KCNQ2 (MIM: 
602235), the reported mutational mechanism is HI although a literature search also 
revealed cases with dominant-negative effects.40 We also investigated the extent 
of the evidence for NHI mechanisms and found that extensive functional work of 
mutations supporting NHI mechanisms has been previously published for eight of 
the 12 known genes (Table S11).
Gene name Summary of gene function Interactions
ACTL6B
Belongs to the neuron-specific chromatin 
remodeling complex (nBAF complex) and is 
required for postmitotic neural development 
and dendritic outgrowth. 
Complex formation with 
ACTB, ARID1A, SMARCA2, 
SMARCA4, SMARCE1, 
SMARCC1, SMARCC2, 
SMARCD2, SMARCB1
GABBR2
Postsynaptic GABAB receptor activity 
regulates excitatory neuronal architecture 
and spatial memory.
Heterodimerization is 
required for the formation 
of a functional GABA-B 
receptor.
PACS2
Multifunctional sorting protein, controling 
endoplasmic reticulum-mitochondria 
communication and Bid-mediated apoptosis.
 N/A
Table 2. Gene function for candidate genes with clustered mutations. Third column indicates whether the 
encoded protein has physical interactions with other proteins. (See Table S9 for extended information).
Further we hypothesized that NHI genes should be depleted for truncating 
mutations in individuals with ID/DD, i.e. mutations resulting in premature translation 
termination, whereby the mRNA is targeted for nonsense-mediated decay. In our 
initial analyses focusing on de novo missense mutations only, we excluded truncating 
mutations from our dataset. Retrospectively, we searched for truncating DNMs in 
the 15 identified genes with clustering de novo missense mutations. We found only 
three predicted truncating mutations in two of 15 genes, which is significantly less 
than expected based on the total number of DNMs found in the total cohort for all 
HI genes (p<1.00e-05; Permutation test). 
We have previously hypothesized that genes with mutations acting through 
NHI mechanisms might be more intolerant to normal variation than genes with 
mutations acting though a HI mechanism for ID/DD.8 To test for tolerance to 
variation, existing scores like pLI15 are not useful because these capture tolerance to 
mRNA truncating variation rather than tolerance to variation in general. Therefore, 
we measured tolerance to variation as the ratio of missense over synonymous 
variation ‘’dN /dS,” which has been used by us and others previously for predicting 
disease genes.2,41,42 We downloaded all PASS-filtered single nucleotide variants 
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(SNVs) from ExAC (n=9,035,134) and constructed a ‘’dN /dS” measure by counting the 
unique missense SNVs missenseobs, and the unique synonymous SNVs synonymousobs 
, while correcting for sequence composition using the total possible unique missense 
and synonymous SNVs (missensebg and synonymousbg respectively): 
dN /dS = ((missenseobs / missensebg ) / (synonymousobs / synonymousbg )) (Table S16).
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Figure 2 Intolerance to missense variation. Violin plots show the distribution of the gene-based 
dN /dS  (y-axis) per gene set (x-axis). The median dN /dS is indicated by a red horizontal line. The NHI 
genes are more intolerant to missense variation than HI genes (HI genes median: 0.460; NHI genes 
median: 0.428; p=2.24e-03). In addition, the identified genes with clustering mutations are more 
intolerant to missense variation than HI genes (genes with clustering mutations median: 0.352; 
p=8.45e-03).
 
Based on calculations of these scores for the sets of 116 NHI, and 183 HI genes, 
we indeed find that genes with mutations acting through a NHI mechanism are 
significantly more intolerant to missense variation than genes with mutations acting 
though a HI mechanism (p=2.24e-03; permutation test, Figure 2). In line with our 
hypothesis, also our set of 15 genes with clustered DNMs was significantly less 
tolerant to missense variation compared to the set of 183 genes with mutations 
acting through a HI mechanism (p=8.45e-03; permutation test, Figure 2). 
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Modeling of missense mutations in a 3D protein structure is helpful to gain 
more insight into the possible structural and functional effects.43 Conceptually, 
mutations in the core of the protein structure are more likely to prevent proper 
folding than mutations on the protein surface.44 The impact of a surface change, 
however, depends entirely on the spatial context and is therefore less likely to result 
in misfolding and subsequent protein degradation.45 Consequently, de novo disease-
causing missense mutations preventing proper folding cause protein degradation, 
and thus indirectly lead to HI, similar to protein truncating mutations in such 
genes. To test the hypothesis that our clustered de novo missense mutations do 
not generally result in HI due to protein misfolding, we modeled mutations onto 
the 3D protein structure using YASARA & WHAT IF Twinset.46,47 A (partial) protein 
3D structure was available or could be created via homology modeling25 for 10 of 
the 15 identified genes. We assessed 48 missense mutations on the 3D structure 
(i.e. buried, at the surface, or semi-buried) and whether the mutation was likely to 
affect protein folding (no effect, local effect, or large effect; Figure 3, Table S17). 
To compare the results of 3D modeling of clustered mutations, we also modeled 
75 de novo disease-causing missense mutations in 25 genes with mutations acting 
though HI (Table S13) for which a structure was available (Table S17). For the HI 
genes, 42% of missense mutations were buried and 34% of mutations were located 
at the protein surface. In the 10 genes for which a mutational NHI effect is proposed, 
only 11% of mutations was buried whereas 61% was located at the protein surface 
(p=1.26E-03, chi-square test; Table S17). Even more strikingly, only 19% of the 
clustering de novo missense mutations were likely to result in a large structural 
change that would affect protein function whereas this was observed for 63% of de 
novo missense mutations in HI genes (p = 8.43E-06, chi-square test). These results 
support the notion that the majority of clustered de novo disease-causing missense 
mutations do not result in haploinsufficiency at the protein structure level, but 
exert their effect through other mechanisms. Possibly this could be through the 
functional impairment of protein-protein interactions, as we noted that two of the 
three candidate ID/DD-associated genes require complex formation or joining of 
protein subunits (e.g. multimerisation) to be functional (Table 2).
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Figure 3. Examples of modeling of missense mutations on 3D protein structures. Wild type residues 
are marked in blue; de novo mutations are indicated as red globes or lines (Tables S17). (A) 3D 
structure of GNA1, acting through HI, showing that the modeled missense mutations are buried and 
likely to disrupt protein folding. (B) Structure of PPP2R5D, acting though NHI, where the modeled 
missense mutations are mostly surface residues and are expected to have no or only local struc-
tural effects. (C) Zoom-in of known missense mutations p.Arg496Cys and p.Ile500Val in SMAD4 
known to act through a gain-of-function mechanism. These variants are located on the surface of 
the monomer and in contact with another SMAD4 monomer.38 (D) Zoom-in of the missense variant 
p.Gly343Arg in ACTL6B, which is located at the surface. The side-chain points towards the solvent, 
therefore the larger Arginine will fit. (E) Zoom-in of the missense variant p.Pro65Leu in PCGF2 close 
to the interaction site with other molecules.
In conclusion, we developed a method for the identification of disease-associated 
genes based on the significance of spatial mutation clustering within a gene. We 
show that our method successfully identifies genes previously implicated in ID/DD. 
Moreover, we identified three genes with similar clustering patterns that we propose 
as candidate ID/DD-associated genes. Our findings support the concept that these 
mutations mostly exert their pathogenic effect through disease mechanisms other 
than haploinsufficiency. Thus, our findings might indicate a larger contribution of 
non-haploinsufficient mechanisms to ID/DD than previously thought.
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Web Resources
DDG2P:    
https://www.ebi.ac.uk/gene2phenotype/downloads
Genome diagnostics gene list:  
https://www2.radboudumc.nl/Informatievoorverwijzers/
Genoomdiagnostiek/en/Pages/Intellectualdisability.aspx
YASARA:    
http://www.yasara.org/
OMIM:     
https://www.omim.org/
97
De novo missense mutation clustering identifies candidate neurodevelopmental disorder genes
SUPPLEMENTAL DATA
Supplemental Tables
Supplementary Tables 5, 6, 9-13, 16 and 17 were not included in this thesis an can 
de found online at the following link: https://www.cell.com/ajhg/fulltext/S0002-
9297(17)30326-9 
Number of variants remaining
ID and DD set Control set
Unfiltered 9,770 35,632
Variants in coding regions and canonical 
splice-sites (±2 bp)
9,202 2,749
ExAC number of heterozygous variants less 
than 2 and no homozygous variants.
6,495 1,961
Variant identified in exome of genome 
sequencing study
6,495 1,948
Table S1. Filtering of de novo mutations used in study. Overview of filters that were applied to specific 
columns of the annotated de novo variants used in the analysis (left column). The middle and right 
columns indicate the number of variants left after the filtering for the ID and DD set and control set 
respectively.
Study Trios Disorder Coding Missense LoF
McRae et al.7 4,293 DD 5,375 3,375 961
Lelieveld et al. 8a 820 ID 948 579 177
de Ligt et al.24 100 ID 56 35 10
Rauch et al.23 51 ID 90 54 31
Halvardson et al.25 38 ID/EE 26 18 4
Total 5,302 6,495 4,061 1,183
Table S2. Dataset composition of intellectual disability and developmental disorders cohort (ID + DD). 
Columns indicate (from left to right), the study reference, number of trios included from the study, the 
disorder that was studied (DD= Developmental disorders, ID = Intellectual disability and EE = Epileptic 
Encephalopathies), and the number of coding, missense and loss-of-function de novo mutations after 
filtering. aIncluding 100 de novo mutations (median GATK quality score of 241) not included in the original 
publication.
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Study Trios Disorder Coding Missense LoF
Iossifov et al.19
1.786 Sibs. (ASD)
1,267 805 139
Krumm et al.20a 323 220 30
GONL18 250 Control 102 67 5
Turner et al.21 43 Sibs. (ASD) 28 18 1
Gulsuner et al.48 84 Sibs. (SCZ) 50 28 9
Besenbacher et al.17b 283 Control 178 135 15
Total 2,448 1,948 1,273 199
Table S3. Dataset composition of cohort of healthy controls (Control). Columns (from left to right) indicate 
the reference to the studies, number of trios that were included from the study, the disorder that was 
studied (Sibs. = siblings, ASD = Autism spectrum disorder and SCZ = Schizophrenia), the number of coding, 
missense and loss-of-function de novo mutations that were included from the study. aThe study by Krumm 
et al20. performed a re-analysis on existing data of Iossifov et al.19 bVariants in the study of Besenbacher 
et al.17 are annotated to reference genome HG18. We used LiftOver to convert the HG18 coordinates to 
HG19 coordinates (See .web resources).
Gene name Gene ID Miss. DNMs
Avg. 
distance p-value Adj. p-value
SYNE1 ENST00000367255.5 2 36 0.0027 1
TMPRSS15 ENST00000284885.3 2 9 0.0061 1
MAPK8 ENST00000374189.1 2 6 0.0101 1
FAT4 ENST00000394329.3 2 86 0.0116 1
SPOCK3 ENST00000357154.3 2 14 0.0220 1
PRPS2 ENST00000398491.2 2 15 0.0299 1
Table S4. Results from clustering analysis on the control cohort. Columns from left to right indicate 
the gene name, used GENCODE gene identifier, number of de novo missense variants, average distance 
between de novo variants, permutations test based p-value and Bonferroni corrected p-value. None of 
the genes reach statistical significance after multiple testing correction.
Genes with sig. cluster Other genes Total
Known ID/DD genes 12 187 199
Other genes 3 381 384
Total 15 568 583
Table S7A. Enrichment of genes have previously been implicated in ID/DD. Data used to calculate statistical 
enrichment of genes associated to ID/DD based on the associated ID/DD genes on the combined list of the DDG2P 
and RUMC. The dataset contained in total 583 genes that were recurrently mutated of which 15 genes contained 
clustering de novo variants. 13 of the 15 genes were associated to ID/DD. Enrichment was tested with a two-sided 
Fisher’s Exact test and yielded a significant p-value of 3.09E-04.
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Genes with sig. cluster Other genes Total
Known ID/DD genes 11 162 173
Other genes 4 406 410
Total 15 568 583
Table S7B. Enrichment of genes have previously been implicated in ID/DD solely on RUMC diagnosis list. 
Data used to calculate statistical enrichment of genes associated to ID/DD based on the associated ID/
DD genes solely on the RUMC list (see web resources). Enrichment was tested with a two-sided Fisher’s 
Exact test and yielded a significant p-value of 5.13E-04.
Genes with sig. cluster Other genes Total
Known ID/DD genes 8 153 161
Other genes 7 415 422
Total 15 568 583
Table S7C. Enrichment of genes have previously been implicated in ID/DD excluding two large DDD exome 
studies. To completely remove the weight of the DDD exomes we have extended the enrichment test by 
excluding a set of genes based on the following criteria:     
1. Novel genes enriched for de novo mutations found in the two large scale exome data studies  
 of the DDD7,49         
2. Complement to the genes found enriched for de novo variants in Lelieveld et al. 8
Analysis via a two-sided Fisher’s Exact test yielded a significant P-value of 3.68E-02
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Gene name De novo missense p-value Adj. p-value
ACTL6B 3 8.48E-04 1
ALG13 3 3.66E-03 1
CDK13 12 4.34E-14 7.93E-10
COL4A3BP 6 1.28E-07 2.33E-03
GABBR2 3 6.82E-03 1
GRIN2B 11 4.22E-11 7.71E-07
KCNH1 7 1.36E-07 2.49E-03
KCNQ2 20 3.60E-28 6.59E-24
KIF5C 3 3.22E-03 1
PACS1 9 1.95E-10 3.57E-06
PACS2 3 5.88E-03 1
PCGF2 3 2.99E-04 1
PPP2R1A 4 9.88E-05 1
PPP2R5D 16 2.89E-24 5.28E-20
SMAD4 4 4.40E-05 8.04E-01
Table S8. Statistical significance of enrichment for de novo mutations for all identified genes. P-values are 
calculated based on Gene Specific Mutation Rates from Samocha et al.50 and corrected for multiple testing 
by the Bonferroni correction (for 19,280 genes). Only some of the previously known genes reached statistical 
significance. Genes identified by our clustering analysis would not have been identified as candidate genes 
based on a statistical approach for the enrichment of de novo mutations.
Gene name Allelic requirement Mutation consequence
ALG13a x-linked dominant all missense/in frame
CDK13 monoallelic all missense/in frame
COL4A3BP monoallelic activating
GRIN2Ba monoallelic loss-of-function / all missense/in frame
KCNH1 monoallelic activating
KCNQ2 monoallelic loss-of-function
KIF5C monoallelic all missense/in frame
PACS1 monoallelic activating
PCGF2 monoallelic activating
PPP2R1A monoallelic dominant-negative
PPP2R5D monoallelic dominant-negative
SMAD4a monoallelic loss-of-function / all missense/in frame
Table S14. Identified known genes and their mutational consequence. Allelic requirement and mutational 
consequence according to DDG2P. aIn the statistical analysis we excluded genes for reasons mentioned 
in the main text .
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Hi genes NHI genes Total
Genes with significant cluster 1 8 9
Other genes 182 108 290
Total 183 116 299
Table S15. Enrichment of genes based on their mutational consequence. Statistical enrichment testing 
of disease mechanisms of the genes identified in this study. Of the 15 identified genes, 9 are annotated 
with a disease mechanism after filtering based on the DDG2P and RUMC lists. Analysis via Fisher’s Exact 
test yielded a significant P-value of 2.66E-03.
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SUPPLEMENTAL FIGURES
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Figure S1. Schematic representation of ACTL6B (ENST00000160382). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S2. Schematic representation of ALG13 (ENST00000394780). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S3. Schematic representation of CDK13 (ENST00000181839). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S4. Schematic representation of COL4A3BP (ENST00000380494). The locations of the mis-
sense de novo variants are indicated by blue pins. Recurrent de novo missense mutations are 
indicated by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and 
are illustrated by colored squares.
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Figure S5. Schematic representation of GABBR2 (ENST00000259455). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S6. Schematic representation of GRIN2B (ENST00000609686). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S7. Schematic representation of KCNH1 (ENST00000271751). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S8. Schematic representation of KCNQ2 (ENST00000354587). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S9. Schematic representation of KIF5C (ENST00000435030). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S10. Schematic representation of PACS1 (ENST00000320580). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S11. Schematic representation of PACS2 (ENST00000458164). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S12. Schematic representation of PCGF2 (ENST00000360797). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S13. Schematic representation of PPP2R1A (ENST00000322088). The locations of the mis-
sense de novo variants are indicated by blue pins. Recurrent de novo missense mutations are 
indicated by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and 
are illustrated by colored squares.
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Figure S14. Schematic representation of PPP2R5D (ENST00000485511). The locations of the mis-
sense de novo variants are indicated by blue pins. Recurrent de novo missense mutations are 
indicated by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and 
are illustrated by colored squares.
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Figure S15. Schematic representation of SMAD4 (ENST00000398417). The locations of the missense 
de novo variants are indicated by blue pins. Recurrent de novo missense mutations are indicated 
by stacked blue pins. Protein domains are annotated based on Pfam HMM search26 and are illus-
trated by colored squares.
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Figure S16. Number of missense variants and the extend of clustering. We have studied the possi-
bility of a correlation between the number of missense variants and the extend of clustering. Hereto, 
we have analysed a much larger set of 6,154 de novo missense variants from various patient cohorts 
present in the denovo-db version 1.314 (other than the five selected ID/DD cohorts presented in 
this manuscript). The variants were filtered as described in Table S1. Correlation analysis (Kendall 
rank correlation coefficient) between the number of de novo missense variants per gene (x-axis) 
and the corresponding p-values based on the spatial clustering signal (y-axis) yielded a correlation 
coefficient of -0.04 indicating there is no correlation.
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SUPPLEMENTAL WEB RESOURCES
DDG2P:      
https://www.ebi.ac.uk/gene2phenotype/downloads
RUMC Genome diagnostics gene list:  
 https://www2.radboudumc.nl/Informatievoorverwijzers/
Genoomdiagnostiek/en/Pages/Intellectualdisability.aspx
Lift Over tool: 
https://genome.ucsc.edu/cgi-bin/hgLiftOver
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ABSTRACT
Statistical approaches to identify novel dominant disease genes from exome 
sequence data have been very successful. Methods for identifying recessive 
genes have relied on public datasets or in-house control samples, both of which 
present their own challenges. Here we developed a new approach based on cross-
cohort comparisons, which we applied to exome data from 6,257 patients with 
four different genetic disorders. We show that our method successfully identifies 
known disease genes but also suggests novel recessive candidate disease genes 
for further investigation.
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INTRODUCTION
Statistical approaches have been very successful to identify novel dominant 
disease genes from exome data of large patient-parent cohorts, especially for 
neurodevelopmental disorders1-4. These statistical models rely on identifying genes 
enriched for de novo mutations based on predicted mutation rates of genes that are 
estimated based on gene length, sequence context, and sequence divergence compared 
to primates5. Gene identification studies based on de novo mutations (DNMs) in large 
exome cohorts have identified hundreds of novel disease genes in the last ten years.
By contrast, research into autosomal recessive causes of neurodevelopmental disorders 
by exome sequencing has lagged behind6. This may be due to ascertainment bias. Studies 
on homozygosity mapping in consanguineous families have so far served as the best source 
for identifying novel recessive disease genes7,8. In Western societies where most of the 
genetic research takes place, consanguinity is not very common and families are usually 
small, which has hampered the mapping and identification of the underlying gene defects9.
In addition, the statistical models used for the detection of dominant de novo 
mutations are not applicable for the identification of recessive disease. Models for 
recessive gene identification rely on a comparison of mutational burden between 
cases and controls. However, technical differences in sequencing instruments and 
chemistry, capture methods and data analysis typically hamper a direct comparison 
and differences in the variation burden between populations further complicates this10.
One study on recessive genes in neurodevelopmental disorder showed that 
ExAC data could be used to compute for each gene the expected number of biallelic 
variants10,11. The study identified four new genes recurrently mutated in affected 
siblings utilizing this approach in a cohort of 4,125 families. However, such an approach 
is only feasible when affected siblings are available. Another study on quantifying the 
contribution of recessive coding variation to developmental disorders found that the 
total number of biallelic synonymous genotypes in ExAC was dramatically higher than 
in the patient data indicating differences in sequence coverage, quality control, and 
ancestry12. Instead, the authors used the variants present in the unaffected parents 
rather than ExAC to estimate the biallelic mutability of genes. However, for many patient 
cohorts, parental exome data is not available and/or too expensive to obtain.
Here we developed a statistical burden analysis using a cross-disorder comparison 
scheme where the genetic burden is assessed for each disorder individually, using 
exomes of patients with different disorders, examined on the same sequencing platform, 
as controls. We used this method to identify recessive disease genes for four different 
genetically heterogeneous disorders and assess the contribution of recessive disease 
genes to intellectual disability (ID). In total, we used data from 6,257 exomes of patients 
with four different monogenic disorders in a largely outbred population.
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METHODS
An overview of the analysis workflow is depicted in Figure 1.
Select ion of  pat ients wi th genet ic d isorders
The Department of Human Genetics from the Radboud University Medical Center 
(RUMC) is a tertiary referral center for clinical genetics. All patients included in the 
study were seen as part of routine genetic testing by exome sequencing. All samples 
were anonymized prior to inclusion in the study.
The assignment of individuals to any of the four cohorts was based on: I) 
Initial assignment by the clinician to one of four disorders: movement disorders, 
blindness disorders, deafness disorders or neurodevelopmental disorders, 
the latter consisting of patients with intellectual disability, epilepsy or multiple 
congenital abnormalities II) no overlap with any of the three other disorders 
included in the study (e.g. a patient with an indication of movement disorders and 
intellectual disability was excluded) III) DNA was sequenced to 75x median coverage 
on a Hiseq2000 or Hiseq4000 platform in combination with an Agilent V4 or V5 
enrichment kit respectively and IV) Families gave informed consent for both the 
diagnostic procedure as well as for forthcoming research that could result in the 
identification of new genes by meta-analysis, as presented here.
For the individuals with unexplained ID, a trio-based WES approach is used 
which allows the identification of DNMs as well as variants segregating according 
to other types of inheritance, including recessive mutations and maternally 
inherited X-linked recessive mutations in males 2. To increase the power to detect 
novel candidate disease genes we splitted the ID cohort based on the diagnostic 
outcome (e.g. patients with a molecular diagnosis and those without). For the other 
patient cohorts, information of the diagnostic outcome was not available due to 
anonymization. No parental sequencing data was available for the samples of the 
movement, blindness, and deafness disorders.
Mapping and cal l ing
Mapping of the reads and calling of the variants was performed identically for all 
samples included in the study. Mapping was done using BWA version 0.7.1313, and 
variant calling using the GATK14 haplotypecaller version 3.4-46 on the sequencing 
targets (as provided by the manufacturer) extended on each side with 200bp.
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Variant f i l tering:  Qual i ty-based.
Variants obtained by the analysis pipeline were filtered for quality by excluding 
variants with a GATK quality score below 400. The quality score threshold of 400 
was previously found to result in a 100% validation rate based on re-sequencing of 
variants by Sanger sequencing4,15.
Variant f i l tering:  Coverage-based.
To correct for the use of two enrichment kits (Agilent V4 and Agilent V5), a coverage-
map was constructed that allowed us to I) remove variants located in regions 
targeted by only one of the two enrichment kits and II) to remove variants in poorly 
or inconsistently captured regions across the samples (Supplementary Figure 1 
and 2). The coverage-map was based on a set of 100 randomly selected samples 
sequenced with an Agilent V4 enrichment kit and 100 randomly selected samples 
sequenced with an Agilent V5 enrichment kit. Coverage on a base pair resolution 
of each sample was computed by the BedTools coverage16 function for the target kit 
regions (as provided by the manufacturer extended by flanking regions of 200bp). 
For each sample, regions covered by at least 20 reads were computed, based on the 
Agilent V4 and V5 targets. For the 100 V4 samples this yielded a total of 62,919,285bp 
and for the 100 V5 samples a total of 77,687,639bp that were well covered. The 
final coverage-map was constructed by intersecting the V4 and V5 coverage-maps, 
yielding a total of 53,274,802bp that had at least 20x coverage in 90% of the samples 
(Supplementary Figure 1). Variants that were located outside these highly covered 
regions were discarded.
Variant annotat ion
The variants in the VCF-files were annotated by the variant effect predictor (VEP) 
version 91.117. The effect of the variants was annotated based on all Ensembl transcripts 
version 9118. Variants were annotated with I) Frequencies from the GnomAD exomes 
and genomes11, Genome of the Middle East19, In-house-frequencies, and frequencies 
computed over the complete cohort of 6,257 individuals. II) Combined Annotation 
Dependent Depletion32 (CADD) and III) in the case of protein truncating variants, the 
Loss Of Function Transcript Effect Estimator (LOFTEE) version 0.3 add-on for VEP was 
used to predict whether stop, splice site disrupting, and frameshift variants cause LoF 
by disruption of normal splicing patterns20.
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Variant grouping
Three different categories of variants were made based on the following filtering 
settings:
1. Rare synonymous: All variants were filtered based on the frequency-
 threshold of 0.1% in the five datasets (GnomAD exomes, GnomAD  
 genomes, in-house frequencies, and cohort-specific frequencies).
2. Rare damaging missense: frequency-threshold of 0.1% in the five datasets 
 and a CADD score of 20 or above.
3. Rare high-quality loss-of-function: frequency-threshold of 0.1% in the five 
 datasets and the predicate “HQ” (High-quality) predicted by the LOFTEE 
 add-on with default settings. The default settings and definitions can be 
 found at the LOFTEE-website20.
Variant count ing
The statistical burden analysis was performed on the variants located on the 
autosomes only (i.e. variants located on the chromosomes X and Y were discarded). 
For each Ensembl transcript, the number of variants of the three categories (rare 
synonymous, rare damaging missense, and rare high-quality loss-of-function) was 
counted. To reduce redundancy the transcript with the most variants was selected 
for the statistical analysis.
The compound heterozygous counts were based on the assumption that two 
variants within one transcript are in trans-configuration. In the situation where a 
sample contains more than two heterozygous variants within one transcript the 
most impactful combination of two variants was used for the statistical analysis.
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Annotation-based filtering
- Frequencies < 0,1%
- CADD-score >= 20 (Missense variant)
- LOFTEE prediction (Truncating variant)
Statistical analysis
- Patient cohort vs. control cohort
- Two-sided Fisher’s Exact test
- Bonferroni correction
VCF-based filtering:
- GATK quality score >= 400
- Located in well-covered regions
- Located in protein-coding regions
Variant annotation
Variant counting
Sample selection:
- Disease based
- Sequencer: HiSeq2000 or HiSeq4000
- Enrichment kit: Agilent V4 or V5
Mapping/Calling
pipeline
Well-covered 
regions
Cohort specific 
frequencies
Figure 1. Overview of the data filtering and statistical analysis. Depicted are the four main steps 
used in the analysis: sample selection, variant filtering, functional filtering, and statistical analy-
sis. The well-covered regions were computed on a subset of 200 BAM-files (100 Agilent V4 and 100 
Agilent V5 samples) and used as one of the quality based criteria for the filtering. The cohort-spe-
cific frequencies were based on the variants of all samples and used as one of the criteria to filter 
variants based on specific annotations.
Stat ist ical  analys is
Variant counts were compared between one patient cohort and those from the 
other three disease cohorts added together as controls. We performed a burden 
analysis of synonymous variants, which served as a negative control of the analysis. 
We expected to find no genes enrichment for rare synonymous variants these in 
any of the cohorts. The statistical burden analysis was then performed on the rare 
damaging missense and rare high-quality loss-of-function variants located in the 
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protein-coding regions. For each gene, we applied a Fisher’s Exact test to test for two 
separate scenarios: (1) enrichment for potential biallelic mutations (i.e. homozygous 
and potential compound heterozygous) and (2) enrichment for single heterozygous 
mutations. The latter case allowed us to identify potential dominant disease genes, 
but also accounted for cases in which the second allele was missed because of 
lack of sequence coverage, or was filtered out because of our filtering criteria. The 
p-values for both scenarios were subsequently combined into a single enrichment 
p-value using Fisher’s method. P-values were then corrected for multiple testing by 
the Bonferroni procedure for the number of genes with at least one variant across all 
exomes. We used the RUMC diagnostic department gene lists of the four disorders 
to compare the inheritance patterns and disease association21-24.
Manual inspect ion of  variants
For each gene, with a significant enrichment, we manually inspected the variants 
that were identified in the patient cohort and the control cohort. Based on the 
type of variants, and the number of different variants in cases and controls we 
assessed whether the gene was likely to be a candidate disease gene. Variants that 
were directly adjacent to each other were considered as an artefact and therefore 
not treated as potential biallelic. Genes with such events were discarded after the 
analysis if the omission of the adjacent variants resulted in a non-significant p-value.
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RESULTS
In total, our cohort contained 6,257 patients of four different monogenic genetic 
disorders (Table 1). After correcting for differences in exome capture kits (See 
Methods), we identified a median of 19,986 variants in the protein-coding regions 
of 18,135 genes. To identify candidate recessive genes in the four disease cohorts, all 
extreme rare protein-altering variants were classified into three groups of predicted 
functional consequences: I) rare synonymous variants, II) rare damaging missense 
variants and, III) rare high-quality loss-of-function variants. This yielded a median of 
86 variants per sample after selection for all three mutation categories per cohort 
(See Methods and Supplementary Figures 3-4). We found no significant difference 
between the median number of these variants identified per sample in the different 
disease cohorts (Table 1 and Supplementary Figures 2-4)
Cohort Cohort size Filtered variants per sample (median)
Empirical P-value 
(corrected)
Movement 1,513 85 1.00
Blindness 1,148 88 0.1
Deafness 1,177 86 1.00
ID (diagnosed) 1,099 86 1.00
ID (undiagnosed) 1,320 87 1.00
Table 1. Overview of the four disease cohorts. The first two columns indicate the number of patients 
in each of the genetic disorder cohorts. The third column indicates the median number of variants 
per individual included in the three mutation categories. Empirical P-values are computed based on a 
permutation test with 100,000 permutations and corrected for the number of tests by the Bonferroni 
procedure. There is no significant difference in the number of variants between the cohorts.
To further validate our method we initially performed our analysis only on rare 
synonymous variants and found no genes to be enriched for these variants in any of 
the four patient cohorts. This is in line with what we would expect for synonymous 
variants that are known to contribute only rarely to Mendelian diseases. We then 
performed our analysis on the rare damaging missense and rare high-quality loss-
of-function variants present in the four genetic disorder cohorts, which yielded a 
total of nine genes that were significantly enriched after combining the p-values and 
correction for multiple testing by the Bonferroni procedure (Significance p-value 
threshold < 2.76E-6; Table 2, Supplementary Table 2).
All of the genes that were identified are well-known disease genes for the disorder 
in which they were identified (p = 1.12E-10; Supplementary Table 3) and all are known 
to cause disease in an autosomal recessive fashion (p = 0.03; Supplementary Table 
4), showing that our method is able to identify recessive disease genes successfully.
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Gene Cohort OMIM P-value
(uncorrected)
AR/AD
Phenotype Number AR/AD
RP1 Blindness Retinitis pigmentosa 1 603937 AR, AD 3.29E-12 AR
PDE6A Blindness Retinitis pigmentosa 43 180071 AR 1.17E-08 AR
PDE6B Blindness Retinitis pigmentosa 40 180072 AR 3.10E-07 AR
USH2A Blindness Usher syndrome, type 2A 608400 AR 5.37E-07 AR
EYS Blindness Retinitis pigmentosa 25 612424 AR 7.31E-07 AR
ABCA4 Blindness Retinitis pigmentosa 19 601691 AR 1.76E-06 AR
Stargardt disease 1 AR
MYO7A Deafness Deafness, autosomal 
dominant 11
276903 AD 2.16E-13 AR
Deafness, autosomal 
recessive 2
AR
Usher syndrome, type 1B AR
MYO15A Deafness Deafness, autosomal 
recessive 3
602666 AR 2.76E-10 AR
CDH23 Deafness Deafness, autosomal 
recessive 12
605516 AR 8.46E-08 AR
Usher syndrome, type 1D AR, AD
Table 2. Overview of the nine genes that were significantly enriched for mutations in a patient cohort. 
All nine genes are known to cause autosomal recessive disorders consistent with the cohort in whom they 
were identified. The Cohort column indicates in what disease-cohort the genes were found enriched. We 
have extended the annotation of the genes with information from OMIM, however the disease gene lists 
of the RUMC diagnostic department were used to determine disease association (See Methods). The 
OMIM columns contain the Phenotype, OMIM gene number, and inheritance from the OMIM database25. 
The column P-value (uncorrected) contains the final, uncorrected p-value of the statistical analysis. The 
most right columns indicate if the lowest p-value was calculated for the biallelic (AR) or nonbiallelic (AD) 
variant counts, (See Supplementary Table 2 for variant counts and biallelic and non-biallelic p-values).
Notably, our analysis did not identify any novel candidate disease gene with a 
significant enrichment for mutations. We, therefore, investigated for each disorder 
the genes with a suggestive p-value smaller than 1.00E-3, before multiple testing 
correction, excluding genes that already reached genome-wide statistical significance 
after multiple testing correction (i.e. genes with a p-value within the range of [1.00E-
3 – 2.76E-6]). This gene set (which we call hereafter genes with suggestive statistical 
evidence) contained a total of 28 genes (Methods, Table 3, Supplementary Table 
5). We found a total of 19 out of 28 genes to be already associated with the relevant 
disease (p-value: 3.14E-15; Fisher’s Exact test; Supplementary Table 6) of which 
14 with a recessive inheritance pattern (Table 3). The remaining 9 genes have not 
previously been implicated with these disorders (Table 3).
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Gene Cohort OMIM P-value
(uncorrected)
AR/AD
Phenotype Number AR/AD
LAMA1 Movement Poretti-Boltshauser 
syndrome
615960 AR 4.11E-6 AD
EHMT2* Movement 1.87E-5 AD
CYP7B1 Movement Spastic paraplegia 5A 270800 AR 8.66E-5 AR
PCDHGC5* Movement 9.5E-4 AD
ATP1A3 Movement Dystonia-12 128235 AD 9.5E-4 AD
RPGRIP1 Blindness Cone-rod dystrophy 13 608194 AR 1.28E-5 AR
RPE65 Blindness Retinitis pigmentosa 20 613794 AR 4.2E-4 AR
PRPF31 Blindness Retinitis pigmentosa 11 600138 AD 2.4E-4 AD
NLRX1* Blindness 3.4E-4 AR
WDR43* Blindness 1.85E-5 AR
MFRP Blindness Microphthalmia 606227 AR 3.51E-4 AR
HARS2 Deafness Perrault syndrome 2 614926 AR 7.14E-6 AR
GJB2 Deafness Deafness 601544 
220290
AD, AR 4.01E-5 AD
OTOA Deafness Deafness 607039 AR 2.9E-4 AR
OTOGL Deafness Deafness 614944 AR 6.1E-4 AR
TPRN Deafness Deafness 613307 AR 9.9E-4 AR
OTOG Deafness Deafness 614945 AR 2.5E-4 AR
PALD1* Deafness 9.9E-4 AD
LARS2 Deafness Perrault syndrome 4 615300 AR 2.8E-4 AR
KCNQ4 Deafness Deafness 600101 AD 8.6E-5 AD
CRYBB3* Deafness Cataract 22 609741 AD, AR 6.6E-4 AD
PTPRQ Deafness Deafness 603317 AD, AR 3.1E-4 AR
PPP2R5D ID (diagnosed) ID 616355 AD 3.1E-4 AD
DOCK6 ID (diagnosed) ID/Adams-Oliver 
syndrome 2
614219 AR 7.5E-4 AR
C16orf62* ID (diagnosed) 8.7E-4 AR
LIN9* ID (diagnosed) 9.3E-4 AR
POGZ ID (diagnosed) ID 616364 AD 9.5E-4 AD
DNAH5* ID 
(undiagnosed)
Ciliary dyskinesia, 
primary, 3
608644 AR 3.6E-4 AR
Table 3. Overview of the 28 genes with suggestive statistical evidence. The Cohort column indicates what 
disease-cohort the genes were found enriched. We have extended the annotation of the genes with information 
from OMIM, however the disease gene lists of the RUMC diagnostic department were used to determine disease 
association (See Methods). The OMIM columns contain the Phenotype, OMIM gene number, and inheritance 
from the OMIM database25. The column P-value uncorrected contains the final, and uncorrected p-value of 
the statistical analysis (See Supplementary Table 7 for variant counts and biallelic and nonbiallelic p-values). 
The most right column indicates whether, based on the two separate p-values for biallelic and heterozygous 
enrichment, the gene is likely to act in autosomal recessive (AR) or autosomal dominant (AD) fashion.
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We examined the 19 known disease genes with suggestive evidence and the variants 
identified therein and found that enrichment in these genes was consistent with 
their known inheritance patterns (Table 3). For example, for the gene CYP7B1, 
associated with movement disorders in an autosomal recessive fashion, we 
found that enrichment was driven mostly by biallelic mutations (Supplementary 
Table 7; p = 1.16E-05) whereas there was no signal for a dominant inheritance 
pattern (Supplementary Table 7; p = 0.58). Conversely, for the known dominant 
gene ATP1A3, the enrichment was driven purely by mono allelic (heterozygous) 
mutations (Supplementary Table 7; p =9.22E-05) and not by biallelic mutations 
(Supplementary Table 7; p = 1).
We also investigated all candidate genes and examined the types of variants 
identified in the patients and the control cohort. This revealed that some of the 
candidates are likely to be false positives due to the lack of multiple testing correction 
(Supplementary Table 8). We found three genes to be potential candidate disease 
genes: WDR43 and NLRX1 for blindness disorders and PCDHGC5 for movement 
disorders.
For WDR43 (AR) we found two large sequence insertions potentially compound 
heterozygous occurring in three patients with blindness. Both variants affected 
the splice donor site of an exon (exons 1 and 5) and visual inspection showed that 
these variants are more likely a deletion than a sequence insertion. Three other 
large deletions occurred in a fourth patient, affecting the donor splice sites of exon 
8, 14 and 17. Although it is striking that all variants are large deletions that affect the 
donor splice site of different exons, none of these variants was present in the control 
cohort. Sanger sequencing in the patient and parents would be needed to confirm 
these variants and show that they reside on different alleles. Only five missense 
variants were identified in the control cohort none of which occurred in a biallelic 
fashion. Biallelic loss-of-function mutations in WDR43 have been associated with a 
Treacher Collins syndrome33 (MIM #154500), in which coloboma (MIM #120200) is 
a characteristic phenotype.
For the gene NLRX1 (AR) we found eight different loss-of-function mutations and 
two missense variants within the blindness cohort. Two patients showed the same 
potential compound heterozygous loss-of-function variants, of which one nonsense 
mutation and one 8bp deletion. Conversely, in the control cohort we identified 
mostly heterozygous missense variants but also six loss-of-function mutations. 
However, none of these variants occurred together in a single patient. The protein 
encoded by this gene is a member of the NLR family and localizes to the outer 
mitochondrial membrane. The encoded protein is a regulator of mitochondrial 
antivirus responses34.
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For PCDHGC5 (AD) enrichment was driven by one frameshift mutation and three 
heterozygous missense variants occurring in ten patients. All previously mentioned 
prediction scores predicted the missense variants to be pathogenic with few 
exceptions. All variants were located in highly conserved protein residues. In the 
control cohort only three variants were identified: a coding splice site mutation, 
a nonsense mutation and a missense mutation. This gene is a member of the 
protocadherin gamma gene cluster, one of three related clusters tandemly linked 
on chromosome five. These neural cadherin-like cell adhesion proteins most likely 
play a critical role in the establishment and function of specific cell-cell connections 
in the brain. Mouse knock-outs of this gene are known to give rise to ataxia26.
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DISCUSSION
Recessive disease may explain a significant fraction of undiagnosed rare disease 
cases. However, the discovery of recessive disease genes with the use of statistical 
methods is lacking behind6. Here, we developed a statistical burden analysis using 
a cross-disorder comparison scheme where the genetic burden is assessed for each 
disorder individually, using exomes of patients with different disorders as controls. 
We applied the statistical method to identify genes with an enrichment of rare 
and deleterious variants from 6,257 exomes of four different monogenic genetic 
disorders and identified nine recessive genes that have been previously associated 
to disease. In addition, we investigated for each disorder, genes with suggestive 
statistical evidence. This set contained a total of 28 genes of which we found 19 
genes to be associated with the relevant disease. Further investigation of the eight 
unknown genes with suggestive statistical evidence revealed three candidate genes: 
WDR43 and NLRX1 for blindness disorders and PCDHGC5 for movement disorders.
Although the sample sizes of our cohorts are relatively large, we found relatively 
few significantly enriched genes using stringent statistical criteria. This was 
particularly the case for the ID and movement disorders cohorts in which we found 
no significant genes. This may be because genetic diseases have differences in the 
contribution of recessively inherited variants. Exome-based sequencing studies 
have shown that autosomal recessive genes are more often found to be the cause in 
deafness27 (77%) and blindness28 (88%) compared to for example severe ID12 (3% in 
an outbred population) which has a much larger contribution of de novo mutations 
and copy number variants29 (62%).
We also found a clear enrichment of known disease genes among the set of 
genes identified with a more lenient p-value cut-off (p<1.0E-3), indicating that our 
study is still likely underpowered. Lowering the p-value obviously does go at the cost 
of more false-positive findings, which is also what we observed, when we discarded 
five of the eight genes after manual inspection of variants in these additional genes. 
To increase our power to detect novel candidate disease genes we investigated the 
possibility to separate the cohorts based on the diagnostic outcome. In this study 
we could only separate the patients with ID based on receiving a positive genetic 
diagnosis. Doing this for the other cohorts is likely to increase our statistical power 
but will also allow us to use a more lenient method for multiple testing correction.
The fact that our method mostly identified genes with a recessive mode 
of inheritance is likely due to the fact that variants occurring on two alleles of a 
gene within a single patient are less likely than the occurrence of a single allele. 
Nevertheless, our method also identified known dominant disease genes. For 
example, the gene PRPF31, which is only known to cause disease in a dominant 
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fashion, is enriched based on heterozygous mutations only. Furthermore, the gene 
PPP2R5D, was found to contain seven heterozygous missense variants in patients 
with (diagnosed) ID and no mutations in any of the other cohorts. The gene PPP2R5D 
encodes a B56 regulatory subunit of protein phosphatase-2A (PP2A) and de novo 
mutations are a known to cause ID30.
Although the main driver of enrichment was always consistent with the known 
inheritance pattern, for some genes with a known autosomal recessive inheritance, 
there was also some putative signal for dominant inheritance. For example, for the 
recessive gene ABCA4 the enrichment came from biallelic mutations (p = 3.1E-4; 
Supplementary Table 2) but there was also a clear signal for the enrichment of 
heterozygous mutations (p = 3.3E-4; Supplementary Table 2). This may indicate 
that other inheritance modes are possible, but it is perhaps more likely that in some 
cases the alternative allele was not identified because of technical issues such as 
lack of sequence coverage.
The strength of our method is that by using other patient cohorts sequenced 
alongside, we do not need to rely on public datasets of healthy individuals for 
controls. Although public cohorts are much larger, it is very challenging to correct 
for differences in sequencing, target kit, coverage, and ancestry. Such differences 
will always bias potential findings and make a robust statistical analysis challenging. 
Another advantage is that our control cohort is likely to be ethnically better matched 
as most samples are likely to be of Dutch ancestry, whereas this is not the case for 
public population databases. A small disadvantage of our approach, however, is 
that because the controls that we use are patients with different disorders this can 
potentially lead to problems for genes involved in multiple disorders. In this study 
we found for example that the well-known recessive disease gene USH2A was not 
identified for deafness disorders because mutations also occurred in our blindness 
cohort31.
In our study, samples were analyzed anonymously as this allowed us to include as 
many patients as possible to increase our statistical power. This approach, however, 
limits the possibilities to determine whether patients with particular variants already 
had a diagnosis, or to verify that patients were unrelated. We know that very few 
related samples are included in the cohort, but such samples may cause some of 
the likely false positive associations that we identified. Indeed, we found that two 
patients with a very rare homozygous missense mutation in LIN9 had consecutive 
patient identifiers, making it likely that these patients are related and that this 
drives the suggestive enrichment for mutations in LIN9. Furthermore, the use of 
anonymized and unphased variants, prohibited us to validate whether variants are 
truly inherited in a compound heterozygous fashion. The compound heterozygous 
5
128
Chapter 5
counts in the analysis were based on the assumption that two or more rare variants 
within one transcript were in trans-configuration.
While developing our method we observed a large impact of the selection of 
variants for the enrichment analysis. Because of our limited sample size, we choose 
to be relatively strict in variant selection. For future studies we would suggest being 
less strict on pathogenicity prediction of variants while excluding variants that are 
larger deletions and insertions, which are more likely to represent false positive 
variant calls. In addition, here, we made no distinction for loss-of-function and 
missense variants in our counting statistics in order to avoid overburdening of the 
analysis by multiple testing corrections. However, from a biological point of view it 
would be prudent to distinguish these events in future analyses.
CONCLUSIONS
Our study shows that we can identify recessive disease genes by performing 
statistical burden analysis between different patient cohorts analysed alongside 
each other in the same sequencing center. Although statistical power remains 
a challenge, our method provides a statistical approach to the identification of 
candidate disease genes that can then be confirmed by other means.
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SUPPLEMENTARY DATA
Supplementary Tables
Patient cohort Control cohort
Cohort N Mutations M
ov
em
en
t
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s
ID
 (d
ia
gn
os
ed
)
ID
 (u
nd
ia
gn
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)
N
Movement 1,513
Synonymous X X X X
4,744
Damaging X X X X
Blindness 1,148
Synonymous X X X X
5,109
Damaging X X X X
Deafness 1,177
Synonymous X X X X
5,080
Damaging X X X X
ID (diagnosed) 1,099
Synonymous X X X X 5,158
Damaging X X X 3,838
ID (undiagnosed) 1,320
Synonymous X X X X 4,937
Damaging X X X 3,838
Supplementary Table 1. Overview of the patient cohort sizes and control cohort sized. The cross-disorder 
comparison scheme for each disorder using exomes of patients with different disorders as controls. The 
“Patient cohort” column indicates the name of the disorder and the number of samples included (N). The 
“Control cohort” column indicates the composition of the cohorts used in the cross-disorder comparison.
Gene Cohort
Biallelic Non biallelic Combined
P-valueC P P-value C P P-value
RP1 Blindness 0 16 1.58E-12 22 10 0.067423 3.29E-12
PDE6A Blindness 0 10 4.25E-08 31 16 0.012241 1.17E-08
PDE6B Blindness 0 10 4.25E-08 43 13 0.385121 3.10E-07
USH2A Blindness, 0 8 1.27E-06 22 12 0.023001 5.37E-07
EYS Blindness 8 14 3.42E-06 114 41 0.011868 7.31E-07
ABCA4 Blindness 4 8 0.00031 71 35 0.000333 1.76E-06
MYO7A Deafness 6 22 1.16E-11 75 36 0.00055 2.16E-13
MYO15A Deafness 2 16 2.45E-10 49 20 0.042811 2.76E-10
CDH23 Deafness 2 12 1.19E-07 149 49 0.034907 8.46E-08
Supplementary Table 2. Overview of genes found to be statistically enriched. All genes are known to 
cause autosomal recessive disorders consistent with the cohort in which they were identified. The columns 
Biallelic and Non-biallilic show the number of mutated alleles in the control cohorts (C) and patient cohort 
(P) and corresponding P-value. The combined P-value column indicates the combined Biallelic and Non-
biallelic P-values. All genes are significant according to the p-value cut-off for multiple testing based on 
the Bonferroni method (Significance p-value threshold < 2.76E-6).
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Disease-associated Other genes Total
Enriched 9 0 9
Not enriched 1,417 16,709 18,126
Total 1,426 16,709 18,135
Supplementary Table 3: Contingency table for the enrichment of genes that have previously been 
implicated in disease. Contingency table for the Fisher’s Exact test to test the 9 genes enriched for biallelic 
variants for enrichment of disease associated genes. The Fisher’s Exact test yields a significant p-value 
of 1.12E-10. The disease gene set is based on the gene lists used by the diagnostics department of the 
Radboud UMC for the four disorders (See Methods section).
Disease-associated 
AR gene
Disease-associated 
non AR gene
Total
Enriched 9 0 9
Not enriched 946 471 1.417
Total 955 471 1.426
Supplementary Table 4. Contingency table for the enrichment of genes that have previously been implicated 
in diseases with a recessive inheritance. Contingency table for the Fisher’s Exact test to test the 9 genes enriched 
for biallelic variants for enrichment of disease associated genes with an AR inheritance pattern. The Fisher’s 
Exact test yields a significant p-value of 0.03. The disease gene set, including inheritance pattern, is based on the 
gene lists used by the diagnostics department of the Radboud UMC for the four disorders (See Methods section).
Gene name Comment Conclusion
E2F7 The same combination of variants in two patients at adjacent 
positions on the same allele.
False positive
CPSF3L One patients with different potential compound heterozygous 
missense mutations that are not found in the controls. One patient 
with missense mutations at adjacent positions on the same allele.
False positive
Supplementary Table 5. List of genes that were removed post-analysis based on adjacent variants. For 
some genes we observed that variants were directly adjacent in the same patients. These are most likely 
single mutational events and should therefore not be treated as potential biallelic. Genes with suggestive 
p-values with such events were discarded post enrichment analysis. The Comment and Conclusion column 
describes the comments and conclusion based on the manual inspection of the variants.
Disease-associated Other genes Total
Enriched 19 9 28
Not enriched 1,405 16,702 18,107
Total 1,424 16,711 18,135
Supplementary Table 6. Contingency table for the enrichment of genes that have previously been 
implicated in disease. Contingency table for the Fisher’s Exact test to test the 28 genes with suggestive 
statistical evidence for enrichment of disease-associated genes. The Fisher’s Exact test yields a significant 
p-value of 3.14E-15. The disease gene set is based on the gene lists used by the diagnostics department 
of the Radboud UMC for the four disorders (See Methods section).
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Gene Cohort
Biallelic Non biallelic Combined
P-valueC P P-value C P P-value
ATP1A3 Movement 0 0 1 3 10 9.22E-05 9.48E-04
CYP7B1 Movement 0 8 1.16E-05 12 5 0.58 8.66E-05
EHMT2* Movement 0 2 5.85E-02 1 9 2.19E-05 1.87E-05
LAMA1 Movement 0 4 3.41E-03 39 33 7.44E-05 4.11E-06
PCDHGC5* Movement 0 0 1 3 10 9.22E-05 9.48E-04
MFRP Blindness 0 6 3.79E-05 24 6 0.81 3.51E-04
NLRX1* Blindness 0 6 3.79E-05 19 5 0.79 3.43E-04
PRPF31 Blindness 0 0 1 4 10 2.06E-05 2.43E-04
RPE65 Blindness 0 6 3.79E-05 13 3 1 4.24E-04
RPGRIP1 Blindness 0 8 1.27E-06 7 2 0.67 1.28E-05
WDR43* Blindness 0 8 1.27E-06 5 1 1 1.85E-05
CRYBB3* Deafness 2 0 1 18 17 6.19E-05 6.62E-04
GJB2 Deafness 0 0 1 9 15 2.92E-06 4.01E-05
HARS2 Deafness 0 6 4.41E-05 16 11 1.04E-02 7.14E-06
KCNQ4 Deafness 0 2 3.54E-02 10 12 1.88E-04 8.60E-05
LARS2 Deafness 0 6 4.41E-05 16 2 0.55 2.84E-04
OTOA Deafness 0 6 4.41E-05 15 5 0.56 2.88E-04
OTOG Deafness 4 10 2.59E-05 91 19 0.81 2.46E-04
OTOGL Deafness 0 4 1.25E-03 50 20 0.05 6.07E-04
PALD1* Deafness 0 2 3.54E-02 9 9 2.73E-03 9.88E-04
PTPRQ Deafness 2 8 4.85E-05 36 6 0.56 3.11E-04
TPRN Deafness 2 6 8.70E-04 11 6 0.11 9.95E-04
C16orf62* ID (diagnosed) 0 6 1.21E-04 27 9 0.69 8.67E-04
DOCK6 ID (diagnosed) 0 6 1.21E-04 58 19 0.58 7.46E-04
LIN9* ID (diagnosed) 0 4 2.45E-03 1 3 3.67E-02 9.28E-04
POGZ ID (diagnosed) 0 0 1 5 11 9.19E-05 9.46E-04
PPP2R5D ID (diagnosed) 0 0 1 0 7 2.69E-05 3.10E-04
DNAH5* ID (undiagnosed) 0 6 2.80E-04 92 43 0.11 3.55E-04
Supplementary Table 7. Overview of genes with suggestive statistical evidence. Columns depict (from 
left to right) the gene name of the identified gene, the patient cohort in which an enrichment was identified, 
known associated disease according to OMIM, corresponding OMIM identifier, inheritance pattern of the 
disease according to OMIM, statistical p-value for enrichment, most likely inheritance pattern according 
to our analysis. * Indicates genes that are not currently associated with the disease corresponding to the 
patient cohort in which the gene was found to be enriched.
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Gene 
name Inheritance Comment Conclusion
EHMT2 AD Single missense variant identified in five patients and 
additional stop and splicesite mutations.
Unclear
CRYBB3 AD Heterozygous missense variants in patients. three in 
singletons and three recurring mutations, none seen in 
controls. nine singleton missense mutations in controls only, 
and one frameshift. Gene associated with catteracts.
Unclear
PALD1 AD Three loss-of-function mutations not seen in controls and 
three missense mutations, not seen in controls. In controls 
one frameshift and seven singleton missense
Unclear
WDR43 AR Two large deletions in three patients seemingly compound 
heterozygous. Not seen in controls. Three different 
deletions in another single patient, also not seen in controls.
Possible
NLRX1 AR Different compound heterozygous loss-of-function 
mutations in two patients and a homozygous missense 
variant in a third patient that is no present in controls. No 
biallelic mutations in the controls.
Possible
PCDHGC5 AD Single frameshift and nine missense variants in patients. 
Only two missense variants and one nonsense in controls, 
one of which overlapping with the patients.
Possible
C16orf62 AR The same two compound heterozygous missense variants 
identified in two patients. One homozygous missense. No 
biallelic individuals were identified in the control cohort. 
Only the homozygous missense occurred heterozygously 
in the control cohort.
Unclear, 
patients 
already have 
a diagnosis
LIN9 AR Two homozygous missense variants with consecutive 
patient identifiers. Likely samples are related
False 
positive
DNHA5 AR Three different compound heterozygous mutations that 
also occur heterozygously in controls. No other biallelic 
mutations in controls. Many variants overall. Gene linked 
to a different disease
Unclear
Supplementary Table 8. Manual assessment of genes with suggestive p-values after variant inspection. 
For each gene we inspected the variants that were identified in the patient cohort and control cohort. 
Based on the type of variants, and the number of different variants in cases and controls we assessed 
whether the gene was likely to be a candidate disease gene. The gene name columns depict the name of 
the gene. The inheritance column indicates if the lowest p-value was calculated for the biallelic (AR) or 
nonbiallelic (AD) variant counts. The comment column contains the result of the manual inspection. The 
Conclusion column indicates the conclusion based on the manual inspection of the variants
133
Mutational burden analyses in large-scale exome data identifies novel candidate recessive disease genes
SUPPLEMENTARY FIGURES
BAM-files 
Agilent V4 
BAM-files Agilent 
V5 (N=100)
coverage-files 
Agilent V4 
Coverage-map
Agilent V4 
coverage-files 
Agilent V5 
Coverage-map
Agilent V5 
Coverage-map
Agilent V4 ∩ V5 
Supplementary Figure 1. Flowchart of the steps to create the coverage-map of reliably covered 
regions. 100 samples were randomly selected from the set of Agilent V4 and V5 exomes. For the 
set of Agilent V4 and V5 samples the coverage was computed on a base-resolution and for the two 
sets a coverage-map was created based on the regions that had a coverage of at least 20 reads in 
90% of the samples. The resulting Coverage-maps based of the Agilent V4 ad Agilent V5 set were 
intersected to form the final coverage-map covering a total of 53,274,802bp.
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Supplementary Figure 2. Violin plots of the number of filtered variants for the different cohorts, 
subdivided by exome sequencing kit, after defining well-covered regions. No statistically significant 
differences remain between the two exome kits after correcting for well-covered regions.
5
134
Chapter 5
Blindness Deafness ID (diagnosed) ID (undiagnosed) Movement disorders
17500
20000
22500
25000
Number of coding variants per cohort
N
um
be
r o
f c
od
in
g 
va
ria
nt
s 
pe
r s
am
pl
e
Supplementary Figure 3. Violin plots of the distribution of the number of coding variants for the 
5 different patient cohorts. We found no statistical differences between the cohorts.
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Supplementary Figure 4. Violin plots of the distribution of the number of variants after filtering 
for likely pathogenic mutations for the 5 different patient cohorts. We found no statistical differ-
ences between the cohorts.
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ABSTRACT
For next-generation sequencing technologies, sufficient base pair coverage 
is the foremost requirement for the reliable detection of genomic variants. We 
investigated whether whole genome sequencing (WGS) platforms offer improved 
coverage of coding regions compared to whole exome sequencing (WES) platforms, 
and compared single-base coverage for a large set of exome and genome samples. 
We find that WES platforms have improved considerably in the last years, but at 
comparable sequencing depth, WGS outperforms WES in terms of covered coding 
regions. At higher sequencing depth (95x-160x), WES successfully captures 95% of 
the coding regions with a minimal coverage of 20x, compared with 98% for WGS at 
87-fold coverage. Three different assessments of sequence coverage bias showed 
consistent biases for WES but not for WGS. We found no clear differences for the 
technologies concerning their ability to achieve complete coverage of 2,759 clinically 
relevant genes. We show that WES performs comparable to WGS in terms of covered 
bases if sequenced at two to three times higher coverage. This does, however go at 
the cost of substantially more sequencing biases in WES approaches. Our findings 
will guide laboratories to make an informed decision on which sequencing platform 
and coverage to choose.
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INTRODUCTION
Whole exome sequencing (WES) has been adopted as a standard approach within 
genetic research, however the implementation in clinical settings has been much 
slower. This is in part due to the fact that clinical applications are more demanding 
in terms of quality and robustness of the experiment than research applications. 
Novel clinical tests are typically required to perform as well or better than existing 
clinical tests on sensitivity and specificity. A major concern for the implementation 
of WES in the clinic is the reduced sensitivity compared with gold-standard Sanger 
sequencing at particular regions 1. Although WES is much more sensitive on an 
exome-wide scale, the sensitivity may be low at particular regions due to locus-
specific features or sequencing bias 2. Fine-tuning or improvements of mapping 
and variant calling software can resolve some of these false negatives 3,4. However, 
the most prominent reason for not calling variants is a lack of sufficient sequence 
coverage 5-7, which cannot be resolved by improved algorithms.
Early comparisons of whole exome capture kits showed that all were able to 
capture around 80% of the human consensus coding sequence regions at a minimal 
coverage of 20x 7. For the majority of low coverage regions this could be attributed to 
an extreme GC content of the captured region as these regions are both difficult to 
capture as well as sequence 8,9. This initial lack of sequence coverage for a significant 
proportion of the exome has spurred clinical laboratories to develop custom gene 
panels, or custom exome captures in order to achieve better capture performance, 
especially for known disease genes 10. Current day exome enrichment designs try to 
circumvent the problem of capturing difficult regions by designing capture probes 
close to the region of interest. In combination with long paired-end reads, this allows 
one to also sequence regions adjacent to the capture targets, that is, the actual 
region on interest. Comparisons performed for earlier capture kits are therefore not 
representative of current day standards in sequencing and capture technologies. 
Moreover, most of the published studies have compared coverage of capture targets 
rather than coding regions which is more relevant to clinical applications 7,11.
The cost of whole genome sequencing (WGS) is becoming less prohibitive for 
applying WGS as a clinical test 12, and pilot studies have already been performed 13-16. 
Although the major advantage of WGS over WES is its ability to sequence also non-
coding DNA, WGS is also expected to outperform WES in the coding regions as WGS 
does not involve capture methods that can introduce bias. This improved coverage 
may make WGS a more suitable clinical test than WES. However, whether WGS 
indeed does perform better than WES remains unclear. Jiang et al. performed one of 
the first direct comparisons of sequence coverage between WGS and WES. However, 
this study included only 10 WGS and 10 WES samples from a single platform and 
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compared average exon coverage 16. A comparison of two WGS platforms for 56 
genes concluded that current WGS platforms are unable to cover 10%-19% of genes 
to acceptable standards for SNV discovery 6. However a direct comparison to current 
day exome sequencing was omitted. A comparison of WES and WGS for variant 
calling showed that both current WES experiments as well as WGS are unable to 
identify all variants 11. It remained unclear however what proportion was due to 
intrinsic lack of sequence coverage, and which proportion may be amendable by 
improved variant detection.
Here we focus on the coverage capability of the latest WES and WGS technologies 
in protein-coding regions and investigate different technological biases. In particular, 
we look at the potential for clinical application by comparing the ability of WES 
and WGS to fully cover clinically relevant disease genes at a depth sufficient for 
reliable variant calling (≥20x). We provide a comprehensive comparison of base-pair 
coverage and read distribution of the human exome of a wide array of high-coverage 
samples generated by the most commonly used WES and WGS platforms.
Materials and Methods
Whole exome sequenc ing
Exome sequencing samples were collected for two current mainstream technologies. 
We selected 2 x 12 exome libraries captured with the Agilent SureSelect V4 kit 
sequenced by the Beijing Genomics Institute (BGI) in Copenhagen on an Illumina HiSeq 
system with 101bp paired-end reads. The first set contained samples sequenced to 
an average coverage of 78x and the second set were different samples sequenced 
at 160x. An additional 12 libraries were captured with the latest Agilent SureSelect 
V5 capture kit and sequenced by the Charité university clinic Berlin to an average 
coverage of 100x on an Illumina HiSeq system using 100bp paired-end reads. For 
NimbleGen we selected 12 libraries captured by the latest NimbleGen SeqCap V3 
and sequenced on an Illumina HiSeq using 101bp paired-end reads at 95x average 
coverage at the Duke Genome Centre (Table 1). DNA from all samples was derived 
from blood.
Whole genome sequenc ing
Samples for whole genome sequencing were likewise collected for three mainstream 
sequencing platforms. We selected 12 whole genomes of four parent-child trios that 
were sequenced by Complete Genomics to an average coverage of 87x using 35bp 
paired-end reads 17 and were additionally down-sampled to 44x. We obtained 11 
additional WGS samples sequenced on an Illumina HiSeq at Duke genomics core at 
28x using 101bp paired-end reads. For coverage comparisons the single base pair 
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coverage counts of these samples were merged into 5 samples to resemble an 
average of 56x coverage. Additionally we gathered 12 WGS samples from the Charité 
university clinic Berlin sequenced on an Illumina xTen system at Macrogen Inc. with 
the TruSeq Nano DNA (350) to an average coverage of 40x using 150bp paired-end 
reads (Table 1).
Sequencing 
platform
Enrichment/
Library
Avg. Exome 
Coverage
Coverage 
Range
# Samples
Illumina HiSeq Agilent SureSelect V4 77.92 70-90 12
Illumina HiSeq Agilent SureSelect V4 159.92 151-170 12
Illumina HiSeq Agilent SureSelect V5 100.17 81-117 12
Illumina HiSeq NimbleGen SeqCap V3 94.50 92-97 12
Complete Genomics Whole genome 44.17 41-48 12
Complete Genomics Whole genome 87.42 83-95 12
Illumina HiSeq Whole genome 28.09 26-30 11
Illumina HiSeq Whole genome 56.20a 56-57 5
Illumina X Ten Whole genome 39.58 30-47 12
Table 1. Overview of tested datasets, average coverage, used sequencing systems and enrichment kits. 
Columns depict (from left to right) the sequencing platform that was used; The exome enrichment kit or 
library preparation that were used; the average coverage across the RefSeq exome; the range of coverage; 
the number of samples used in the analysis. a For comparison the 28.09x genomes sequenced on the 
Illumina HiSeq system are merged to resemble five samples sequenced to 56.20x coverage.
Mapping of  the reads
All exome samples were aligned to the hg19/GRCh37 assembly of the human 
reference genome by the Burrows Wheeler Aligner (BWA) 18 by the respective 
sequencing center. Illumina HiSeq samples were aligned by BWA version 0.5.9; 
Illumina xTen samples were aligned with ISAAC version 1.0 and Complete Genomics 
samples were aligned using Complete Genomics assembly software version 2.4.0.43. 
We did not take into account whether duplicate reads were excluded during the 
mapping process.
Defin i t ion of  the exome and gene sets
In order to compute coverage of human protein-coding regions we defined a 
consensus exome by merging locations of protein-coding regions using the hg19 
assembly transcripts of the NCBI RefSeq database (Release 60) 19. As an alternative 
to the more conservative RefSeq regions we used the EMBL-EBI Ensembl (Release 77) 
20 regions, which contains more gene models from multiple sources. The RefSeq and 
Ensembl transcripts were downloaded from the UCSC table browser (http://genome.
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ucsc.edu/) 21 and converted by a custom Java program to bed format. The merging 
of overlapping regions was done by the merge function from the BEDTools software 
package v.2.19.1 22. Only protein-coding regions annotated to chromosomes 1 to 22 
and X were used in the coverage comparison. This resulted in a 33.3 Mb RefSeq and 
a 35.1 Mb Ensembl based consensus exome (Supp. Table S1).
The computation of transcript coverage was based on two sets of disease genes. 
The first set consisted of 56 genes recommended by the American College of Medical 
Genetics (ACMG) for pathogenic variant discovery 23. The second set, named hereafter 
OMIM+, consisted of 2,759 genes derived from the Online Mendelian Inheritance in Man 
(OMIM) Morbid Map 24 and the Clinical Genome Database (CGD) 25. The OMIM Morbid 
Map and CGD are manually curated databases and catalogue disease genes published 
in literature. Only genes with the highest OMIM level of evidence were included (entries 
with a known molecular basis of the disorder). For both gene sets, rather than calculating 
consensus-coding regions, we selected the longest transcript of each gene. This provides 
a biologically more meaningful and practically more relevant comparison. The regions 
of the transcripts were extracted from the RefGene transcript list (downloaded from 
the UCSC table browser, http://genome.ucsc.edu/) 21. The base pair coverage for each 
transcript at different coverage intervals was calculated using custom java programs.
Coverage calculat ion of  the exome
Single base pair coverage was calculated, based on the BAM-files, with the use of 
the coverage function of the BEDTools package v.2.19.1 22. For Complete Genomics 
the reference coverage files were converted to tabix format and the coverage of 
the regions was extracted via the tabix tool from the SAMtools package v0.1.19 26.
Coverage calculat ion of  HGMD mutat ions
To analyze coverage of known pathogenic mutations, 96,377 single nucleotide 
mutations from the Human Gene mutation Database (HGMD, professional version) 
were downloaded on 09-2014 27. Mutations were then intersected with RefSeq 
(82,076 SNVs) and Ensembl (82,353) coding regions covered at ≥20x using the 
BEDTools software package v.2.19.1 22.
Assessment of  systemat ic b iases
First, we calculated three different metrics in order to assess potential technological 
biases. The evenness score describes the uniformity of the base coverage over 
target regions and was calculated according to the method by Mokry et al. 28. The 
score is normalized to the average coverage and therefore depicts the quality of 
a targeted genome section. The evenness score is 100% for completely uniform 
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coverage where an extreme non-uniform distribution approaches a score of 0%. 
The average coverage for the exome was computed using a custom Java program.
Second, we evaluated coverage-bias for genes located on the positive and 
negative strand. We extracted the orientation for all genes from the NCBI RefSeq 
database (Release 60) 19. Consistent with the transcript analysis, we selected the 
longest transcript of each gene. For each transcript we computed the percentage of 
base pairs not covered at a coverage level ranging from 20-40-fold and tested for 
coverage bias based on DNA strand (Mann-Whitney non-parametric U-test).
Finally, we evaluated bias in the allele distributions of common heterozygous 
single nucleotide polymorphisms (SNPs). The list of protein-coding single SNPs, 
based on the dbSNP database (build 138) 29, was downloaded from the UCSC table 
browser (http://genome.ucsc.edu/) 21. SNPs annotated with a population-frequency 
above 10% were considered as common. In total, our set contained 15,153 common 
SNPs in protein-coding regions. With the mpileup function from SAMtools v0.1.19 
26 the nucleotide counts for each SNP location were extracted from the BAM-files. 
SNPs with less than 16 reads were discarded to rule out distribution bias caused 
by low coverage. SNPs were considered heterozygous when the allele ration was 
between 10 and 90% based on the raw nucleotide counts. Difference in coverage 
was determined by the Mann-Whitney non-parametric U-test and p-values were 
corrected for multiple testing by the Benjamini-Hochberg procedure. On average 
4,307 (range [2,690-5,096]) heterozygous SNPs of our set were found per sample. 
For this analysis we excluded the 5 Illumina genomes that were merged together to 
resemble 56.2x coverage. For the Complete Genomics data the nucleotide counts 
for the common protein-coding SNPs were extracted from the masterVarBeta files.
GC content of  low covered regions
Based on the single base pair coverage the RefSeq regions covered with less than 
5x, between 5x and 10x and between 10x and 20x were selected. With the use of the 
nuc function from the BEDTools software package v.2.19.1 22, the percentage G and 
C nucleotides of these regions could be extracted based on hg19 assembly of the 
human genome. The exome kit regions were corrected for targeted regions based 
on the capture probes locations as provided by the manufacturers.
RESULTS
For our comparison we evaluated three widely used exome capturing kits: Agilent 
SureSelect version 4 (Agilent V4), Agilent SureSelect version 5 (Agilent V5) and 
NimbleGen SeqCap version 3 (NimbleGen V3). Libraries for all aforementioned 
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enrichment kits were sequenced on the commonly used Illumina HiSeq sequencer. 
Additionally, three whole genome-sequencing platforms were examined: Complete 
Genomics, Illumina HiSeq and Illumina xTen (Table 1). For all platforms we evaluated 
the percentage of sufficiently (≥20x) covered protein-coding regions based on RefSeq 
19 and Ensembl 20 annotated exons. Furthermore, the coverage in two clinically 
relevant transcript sets was assessed to study the potential for clinical application. 
Next to coverage, systematic biases such as nonuniform mapping of reads, unequal 
strand coverage, and deviations in allele distributions of common heterozygous 
SNPs were assessed.
Newer exome capture ki ts show a c lear improvement in exome 
coverage
First, we compared the coverage of sequence libraries constructed by the exome 
kits (Table 1). We observed that libraries of the most recent Agilent V5 kit are able to 
capture on average 94.57% of RefSeq and 93.58% of Ensembl defined exome at ≥20x 
coverage whereas the Agilent V4 libraries achieved 88.75% and 87.41% (Figure 1 and 
Supp. Table S2). The difference between Agilent V4 and V5 is in part due to missing 
coding regions in the V4 capture design (Supp. Table S3). Deeper sequencing, on an 
Illumina HiSeq system, of the Agilent V4 libraries to 160x average depth increased 
the ≥20x-covered exome to 94.10% for the refSeq exome and 92.79% for the Ensembl 
exome. However, by deeper sequencing the average coverage did not surpass that 
of the Agilent V5. The NimbleGen V3 capture kit performed similar to the Agilent 
V5 with 95.83% and 94.49% covered at ≥20x. These results represent a marked 
improvement compared to previous generations of sequencing platforms that were 
able to capture at most 80.50% of the human consensus coding sequence regions 7.
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Figure 1. Coverage of the Ensembl and RefSeq annotated protein-coding regions and (full) coverage 
of 2,759 clinically relevant OMIM+ genes. A The percentage of base pairs of Ensembl (in yellow) 
and RefSeq (in blue) annotated protein-coding regions covered by at least 20 reads for the tested 
platforms. B Percentage of base pairs covered by at least 20 reads for the longest OMIM+ transcripts 
(in green). The red bars depict the percentage of the (longest) OMIM+ transcript base pairs that are 
fully covered by at least 20 reads.
WGS provides a bet ter exome coverage than WES
Next, we assessed whether WGS indeed provides a better coverage of the RefSeq 
and Ensembl defined exomes. Both the 44x Complete Genomics and 56x Illumina 
HiSeq genomes achieved a much higher fraction of the exome covered at ≥20x 
than the 70x Agilent V4 (Figure 1 and Supp. Table S2). Only at a deeper average 
coverage of 160x the results from the Agilent V4 libraries were comparable to 
much lower sequenced WGS (44-56x). Both Agilent V5 and NimbleGen V3 libraries 
achieved similar performance compared to the WGS, although be it at the cost 
of about two times more average coverage. Complete Genomics sequencing at 
high coverage (87x) outperformed all exome libraries with 98.40% and 98.58% 
coverage (Figure 1 and Supp. Table S2). Similar results were obtained when we 
compared only the coverage of 96,377 HGMD mutations between the different 
platforms (Supp. Table S4) 27.
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Figure 2. Overview of 56 genes and the percentage of coding bases not covered at 20x. The Box-
plots depicting the percentage of bases not covered by at least 20x reads. For each of the 56 ACMG 
recommended genes the coverage of the longest RefSeq transcript was analyzed. A: Shows the 
performance of all tested exome capture libraries. B: Shows the performance of the tested whole 
genome sequencing platforms.
Complete coverage of  c l in ical ly relevant genes
From a clinical point of view it is important to cover the sequence of disease genes as 
complete as possible. We analyzed the coverage for a set of 56 genes, recommended 
by the American College of Medical Genetics and Genomics (ACMG) for pathogenic 
variant discovery 23. This transcript-set covers 198,482 nucleotides divided over 1,169 
exons. We assessed the percentage of transcripts that are completely sequenced 
to a depth of ≥20x (Figure 2 and Supp. Table S5). With an average of 48.21%, the 
NimbleGen V3 libraries, achieved the highest average of fully covered transcripts 
captured for the enrichment-kits. Genome performance was not obviously better 
than the exomes with on average 54% and 43% of fully covered transcripts for 
Complete Genomics 87x genomes and Illumina 56x genomes. The difference 
between the Complete Genomics 44x and 87x genomes was striking, with an 
average percentage of fully covered transcripts of 6.25% and 54.46% respectively. 
Interestingly, for these genes the difference in percentage of exome fraction covered 
at ≥20x was only 4.44%.
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We extended our analysis to the coverage of 2,759 transcripts from the OMIM+ 
set (Figure 1 and Supp. Table S5). This set is much larger than the ACMG set and 
includes overall 6,374,161 nucleotides distributed across 38,498 exons. Due to the 
higher number of transcripts, a lower average number of nucleotides were covered 
at ≥20x compared to the ACMG set. However, for all platforms the percentage 
of transcripts fully covered at ≥20x increased compared to the ACMG set. This 
may indicate that some of the ACMG genes are particularly difficult to sequence 
compared to other disease genes.
In addition we explored GC ratios of insufficiently covered regions. The GC-
ratio of these regions was computed for regions with minimal (<5x), poor coverage 
(between 5x and 10x) and intermediate (between 10x and 20x) coverage (Supp. 
Table S6). Based on the genomic sequence of the RefSeq protein-coding region, 
the average GC content is 51%. The mean GC-content for annotated regions with 
minimal coverage, poor and intermediate coverage was however 73.13%, 70.48% 
and 64.43% respectively on average for exomes, and 72.78%, 70.40% and 65.20% 
on average for Complete Genomics and Illumina HiSeq genomes.
Systemat ic b iases in sequence coverage
To investigate systematic biases in coverage we compared the evenness of 
mapped reads across targets. As noted by Lam et al. 30 less uniform coverage 
requires more overall sequencing to achieve a certain level of coverage for most 
of the genome. Moreover, uniform coverage is not only important in economic 
terms, but also for applications such as the detection of copy number variation 
(CNV) and somatic variation. The evenness score of exome capture technologies 
was on average 74.6% (range [67.67%-78.32%]). Scores for Illumina HiSeq, xTen 
and Complete Genomics were very similar around 85% (range [78.39%-90.31%]) 
(Figure 3A and Supp. Table S7).
To assess the observed reduction in evenness further, we evaluated whether 
transcripts on either the plus or minus strand were covered at equal proportions. 
The exome capture libraries provided significantly less coverage for genes on 
the minus strand compared to those on the plus strand (Figure 3B). This effect 
becomes more apparent at higher exome coverage and was not present in the whole 
genome sequencing data (Figure 3C and Supp. Table S8). To further assess this, 
we studied the distribution of reads for heterozygous SNPs (minimal coverage of 
≥20 reads) to see whether there was a systematic deviation from the ideal 50-50% 
allele-distribution. Exomes showed on average a deviation of 2.3% to the optimal 
50%, while the whole genome datasets distribution deviated only 1.43% (P=0.04; 
Two-sided Student’s t-test) (Figure 3D and Supp. Table S9).
6
150
Chapter 6
DISCUSSION
High-throughput sequencing techniques have shown a rapid development and 
made a significant impact on how genetic research is conducted. Scanning all genes 
simultaneously has led to the identification of a vast number of disease-causing 
genes. Various studies have tried to determine what amount of sequence coverage is 
sufficient to reliable identify single-nucleotide variants 5,11,31,32. A challenge for this is 
that a comprehensive golden standard for variant calling is still under development 
1,33, and that results may depend on the choice of variant caller and settings thereof. 
However, a prerequisite for reliable variant calling is sufficient sequence coverage.
In this study, we examined the latest WES and WGS platforms in terms of coverage 
of RefSeq 19 and Ensembl 20 annotated regions (Table 1 and Supp. Table S1). To increase 
robustness of our results, we used multiple replicates per approach. Although all of 
the samples were sequenced using standard sequencing protocols, site-specific 
implementations may have an influence on the actual results. We conducted our 
comparison at a single base pair resolution and assessed biases in coverage for all 
technologies. We find that exome capture technology has significantly improved and 
that, at high average coverage (≥95x), the latest exome libraries are able to reliably cover 
close to 95% of the protein-coding regions to a sequencing depth of at least 20x (Figure 
1 and Supp. Table S2). Our choice of 20x coverage for reliable coverage stems from 
various published studies as well as our own experience. However, although results 
change for different thresholds, the overall differences between the platforms remains 
the same (Supp. Table S2)
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Figure 3. Assessments of three different sequence coverage biases. A: Evenness scores (a measure 
for uniform read mapping) for the different platforms based on the RefSeq annotated protein-cod-
ing regions. B: The difference in average coverage at 20x of WGS libraries for RefSeq transcripts 
grouped by strand. The symbols + and – indicate average coverage level at the plus and minus 
strand. C: Idem for WES libraries. D: Density plot of allele ratio distribution for heterozygous SNPs. 
The green line depicts the ideal heterozygous allele ratio of 0.5.
We note that the definition of the exome naturally affects the outcome of this 
comparison 34. The absence of probes in enrichment kits restricts sequencing 
yield of regions when a more comprehensive exome definition is used. However, 
we find that in all but few exome-libraries, a region will be sufficiently covered if 
a capture probe is in the vicinity. Exceptions to this occur in extreme GC-regions, 
where genome sequencing may also suffer from loss of sequence coverage (Supp. 
Table S6). The differences in GC bias that we observed may be directly correlated 
to the number of PCR steps of the sequencing protocols that were used.
Full transcript coverage for clinically relevant disease genes was quite variable 
between replicate samples. Some platforms performed poor due to lower average 
coverage, but performed better with a lower coverage threshold for fully covered 
transcripts (Figures 1 and 2 and Supp. Table S5). Unexpectedly, the high-coverage 
Agilent V5 samples also performed poor in this analysis. We suspect this may be due 
to performance differences between individual sequencing runs, rather than being 
intrinsic to the platform itself. Dewey et al. previously reported 10% and 19% of 56 
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disease genes were not fully covered at an acceptable coverage of ≥10x by Illumina 
and Complete Genomics respectively 6. In this study a comparable 21% of the genes 
were not completely covered by at least 10 reads by Complete Genomics at 87.42x 
average coverage. However, this representation of the results does not do credit to 
the actual performance of these technologies as Illumina and Complete Genomics 
genomes achieve ≥10x coverage for 98.71% and 99.8% of the coding bases of this 
gene set (Supp. Table S10).
Next to sequence coverage, we also investigated several other important features 
to identify systematic biases. We found that genome sequencing performed better 
than exome sequencing in all of these comparisons, providing a more even coverage, 
no strand bias, and a higher proportion of transcripts covered completely (Figure 
3). Although these features may seem secondary to sequence coverage, they may 
have implications in a clinical setting where reliability and reproducibility of results 
is crucial. Also for applications other than the identification of normal SNVs these 
features are of importance. A more even coverage increases the sensitivity for 
detecting copy number variants 35,36, and allele biases may hamper the detection 
of somatic variation.
The imperfect performance of previous generations of exome captures has 
spurred clinical laboratories to develop custom gene panels, or custom exome 
captures, to boost coverage of relevant disease genes. Recently published studies 
of gene panels show that these libraries are generally sequenced much deeper 
than WES and WGS libraries and cover in the range of 92.0 - 98.7% of the regions by 
10 or more reads (Supp. Table S11) 37-41. In comparison, the ACMG (56 genes) and 
OMIM+ (2,759 genes) disease gene sets tested in this study shows comparable or 
better performance coverage for WES (ACMG range [95.95%-99.01%]; OMIM+ range 
[95.60%-98.02%]) and WGS (ACMG range [95.24%-99.80%]; OMIM+ range [93.00%-
99.51%]) platforms at ≥10x (Supp. Table S10). This illustrates the potential of WES 
or WGS approaches for more generic clinical testing 15.
CONCLUSION
In conclusion, both high-coverage WES and WGS are able to generate sufficient 
coverage for reliable variant calling of 95% of the coding regions. Sequencing 
biases are however more prominent in WES data, and may hamper more advanced 
applications. WGS however offers the additional advantages that it allows more 
reliable detection of structural variants 13 and the identification of non-coding 
variation 42. Although currently the costs of WES and WGS only differ by a factor 
2-4 (depending on coverage), the additional data storage and computational burden 
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may still make WES a convenient pre-screening technology. Our findings will help 
laboratories to make an informed decision on which sequencing platform and what 
sequencing coverage to chose for their experiments.
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SUPPLEMENTARY DATA
Supplementary Tables
Reference Assembly Number of transcripts
Number of 
regions
Number of 
nucleotides
RefSeq hg19 52,078 194,908 33,383,722
Ensembl hg19 204,941 209,612 35,123,365
Supplementary Table 1. Overview of the RefSeq and Ensembl datasets used to define the human exome.
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Reference
RefSeq Ensembl
bp Percentage bp Percentage
Agilent V4 target list 28,298,818 84.77% 29,131,331 82.94%
Agilent V5 target list 29,577,104 88.59% 30,587,010 87.08%
Supplementary Table 3. Difference in Agilent SureSelect version 4 and 5 target regions. The difference 
in targets between Agilent SureSelect V4 and V5 overlapping with the protein-coding regions in RefSeq 
and Ensembl.
Reference
Percentage HGMD SNVs covered at ≥20x
RefSeq Ensembl
Library Cvg. Mean Range Mean Range
Agilent V4 78x 77.92 90.40 86.71-92.84 90.40 86.69-92.85
Agilent V4 160x 159.92 96.03 95.14-96.51 96.03 95.14-96.51
Agilent V5 100x 100.17 96.23 94.55-97.61 96.23 94.56-97.60
Nimblegen v3 99x 94.50 97.39 96.70-98.05 97.37 96.67-98.02
Complete Genomics 44x 44.17 93.46 89.51-96.44 93.46 89.51-96.44
Complete Genomics 87x 87.42 98.97 98.40-99.39 98.97 98.39-99.39
Illumina HiSeq 28x 28.09 70.31 55.44-79.67 70.28 55.43-79.63
Illumina HiSeq 56x 56.20 95.79 95.33-96.62 95.78 95.31-96.61
Illunima xTen 40x 39.58 91.61 77.61-99.11 91.62 77.66-99.11
Supplementary Table 4. Coverage summary of HGMD single nucleotide variants. The percentage of SNVs 
overlapping the Human Gene mutation Database (HGMD, professional version; downloaded: 09-2014) 
and the RefSeq (82,076 SNVs) and Ensembl (82,353) based coding regions covered at ≥20x.
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Reference Coverage ACMG transcripts 
≥20x
Coverage OMIM+ transcripts 
≥20x
Library Cvg. Avg.
 % fully covered
Avg.
% fully covered
Mean Range Mean Range
Agilent V4 77.92 90.15 10.12 0.00-16.07 89.89 17.76 8.55-26.65
Agilent V4 159.92 96.11 42.86 30.36-51.78 95.98 52.55 42.10-60.55
Agilent V5 100.17 95.62 16.82 7.14-28.57 95.74 27.16 17.36-39.09
NimbleGen V3 94.50 97.70 50.15 44.64-60.71 95.72 58.52 55.80-64.76
Complete 
Genomics
44.17 94.72 6.70 1.78-10.71 92.92 8.27 5.11-13.63
Complete 
Genomics
87.42 99.16 54.32 39.29-66.07 98.56 55.55 48.08-64.87
Illumina HiSeq 56.20a 96.04 43.21 42.86-44.64 94.06 52.59 50.98-54.97
Illumina Hiseq 28.09 73.71 5.03 0-10.71 70.76 8.29 6.13-12.18
Illumina Xten 39.58 95.96 51.79 7.14-51.79 93.77 56.95 17.44-79.91
Supplementary Table 5. Coverage summary of ACMG and OMIM+ transcripts. The Avg. column indicates 
the average percentage of base pairs covered at 20x sequencing depth. The % fully covered column 
contains the Mean and corresponding Range of the fully covered transcripts. Fully covered is defined as 
all base pairs are covered by at least 20 reads.
Reference
GC-ratio
[0-5>x [5-10> x [10-20> x
Library Cvg. Avg. Range Avg. Range Avg. Range
SureSelect V4 77.92 .713 .657-.732 .671 .614-.692 .615 .567-.630
SureSelect V4 159.92 .741 .705-.764 .725 .706-.743 .671 .655-.681
SureSelect V5 100.17 .715 .700-.730 .688 .675-.710 .603 .580-.645
NimbleGen V3 94.50 .756 .733-.769 .735 .711-.746 .688 .679-.701
Complete Genomics 44.17 .718 .701-.738 .692 .678-.708 .615 .597-.632
Complete Genomics 87.42 .725 .712-.739 .722 .706-.735 .700 .686-.714
Illumina HiSeq 28.09 .718 .697-.734 .676 .653-.693 .608 .590-.626
Illumina HiSeq 56.20a .750 .742-.760 .726 .721-.728 .685 .679-.692
Illumina xTen 39.58 .544 .500-.578 .583 .449-.656 .572 .440-.666
Supplementary Table 6. GC-content of refSeq annotated regions per sequencing system. The average 
GC-content for the RefSeq-annotated regions for assembly hg19 is 0.51. For each set the averaged GC-
content of the coverage interval of [0-5>, [5-10> and [10-20> are depicted. The WES regions were corrected 
for targeted regions based on the capture probes locations as provided by the manufactures.
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Reference Average Evenness Score
Library Cvg. Avg Range
Agilent V4 77.92 73.61% 67.67-75.32
Agilent V4 159.92 75.03% 73.99-75.91
Agilent V5 100.17 76.04% 74.19-77.30
NimbleGen V3 94.50 76.87% 75.55-78.32
Complete Genomics 44.17 85.02% 84.18-85.60
Complete Genomics 87.42 85.74% 85.02-86.28
Illumina HiSeq 28.09 82.18% 78.39-84.49
Illumina HiSeq 56.20a 83.35% 82.56-83.77
Illumina xTen 39.58 87.05% 74.94-90.31
Supplementary Table 7. Average evenness scores of coverage for the RefSeq annotated protein-coding 
regions for the different exome and genome datasets.
Agilent V4 Agilent V5
NimbleGen 
V3
Complete 
Genomics
Illumina 
Hiseq
Illumina xTen
Cvg 159.92x 77.92x 100.17x 94.50x 44.17x 87.42x 28.09x 56.20x 39.58x
20x 0.24 0.04 0.71 0.07 0.40 0.34 0.42 0.29 0.13
25x 0.45 9.48E-03 0.19 0.06 0.40 0.34 0.71 0.29 0.20
30x 0.74 1.81E-03 0.02 0.02 0.51 0.43 0.95 0.26 0.22
35x 0.75 2.97E-04 1.11E-03 3.26E-03 0.72 0.40 0.69 0.36 0.32
40x 0.43 5.30E-05 5.30E-05 1.54E-03 0.98 0.38 0.50 0.43 0.49
Supplementary Table 8. Comparison of the average coverage of genes located on the plus and minus 
strand. The first column indicates the minimal level of coverage. Remaining columns are q-values for the 
comparison of the fraction of covered bases of genes on the plus versus minus strand. For both strands 
the percentage of bases not covered by the intervals is computed for the different datasets. Statistical 
significance is computed by a Student’s T-test and corrected for multiple testing by the FDR procedure. In 
all exome capture kits a significant strand bias is present at higher coverage. Only the Agilent version 4 
exomes that were sequenced at very high coverage did not show this bias. This effect is due to the higher 
coverage and became apparent again when looking at regions covered more than for example 60x. The 
strand bias was not present in the whole genome data for any of the investigated coverage cut-offs.
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Reference
Heterozygous SNP allele ratio
Library Cvg.
Agilent V4 77.92 0.478
Agilent V4 159.92 0.478
Agilent V5 100.17 0.473
NimbleGen V3 94.50 0.479
Complete Genomics 44.17 0.489
Complete Genomics 87.42 0.487
Illumina HiSeq 28.09 0.489
Illumina xTen 39.58 0.478
Supplementary Table 9. The mean ratio between the alleles for heterozygous SNPs for the datasets. 
A theoretical ratio of 0.5 is expected.
Reference Coverage ACMG transcripts 
≥10x
Coverage OMIM+ transcripts 
≥10x
Library Cvg. Avg.
% fully covered
Avg.
% fully covered
Mean Range Mean Range
Agilent V4 77.92 95.95 37.05 19.64-50.00 95.60 48.90 30.09-61.46
Agilent V4 159.92 97.58 68.15 87.14-78.57 97.65 75.78 67.70-82.70
Agilent V5 100.17 98.18 55.06 35.71-69.64 98.53 65.39 52.21-77.88
NimbleGen V3 94.5 99.01 76.19 69.64-80.36 98.02 78.29 71.80-82.38
Complete 
Genomics
44.17 99.09 44.35 32.14-58.93 98.57 47.57 39.01-58.67
Complete 
Genomics
87.42 99.80 78.27 73.21-83.21 99.51 81.86 76.43-86.51
Illumumina HiSeq 56.2a 98.71 71.79 69.64-73.21 97.47 75.94 71.72-79.73
Illumumina HiSeq 28.09 95.24 36.85 28.57-48.21 93.00 44.55 29.26-57.69
Illumina xTen 39.58 99.74 91.67 75.00-96.43 99.15 90.80 77.63-97.28
Supplementary Table 10. Coverage summary of ACMG and OMIM+ transcripts. The Avg. column 
indicates the average percentage of base pairs covered at 10x sequencing depth for the replicates. The 
% fully covered column contains the Mean and corresponding Range of the fully covered transcripts.
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Sequencer Gene-panel size Disease
Average 
coverage
>10x 
coverage
Year 
published
Illumina Hiseq 186 Retinitis pigmentosa 141x 95.1% 2015 37
Illumina 
HiSeq
104 Hereditary hearing loss [188x-264x] [94.1%-96.2%] 2014 
38
Illumina 
HiSeq
80 Non-syndromic hearing loss 311x 98.4% 2014 
39
Illumina 
HiSeq
126
Non-syndromic 
hearing loss 246x 98.7% 2014 
39
Life 
technologies 
SOLiD
105
Hereditary Retina 
Dystrophies
783x 95% 2014 40
Illumina 
HiSeq
103 Usher syndrome Not available 92% 2014 
41
Supplementary Table 11. Overview of coverage achieved by published gene panel sequencing studies. 
For each study the number of genes, the disease, average coverage and percentage of targeted nucleotides 
covered by 10 reads or more are shown. The Hereditary hearing loss study by Vona et al. only described 
the ranges of average coverage for targets covered by at least 10 reads.
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Chapter 7
The introduction of next-generation sequencing (NGS) has made an undeniable 
impact on the field of human genetics. The decreasing prices, increasing quality, and 
throughput of sequencing platforms made large quantities of genomic data available 
to the community1,2. These technological advances introduced the “genotype first” 
approach where an individual’s genotype is characterized first by a molecular test 
prior to extensive clinical phenotyping3. This contrasts the traditional “phenotype-
first” approach, in which molecular tests were ordered based on a clinician’s 
detailed analysis of the patient’s phenotype. The digitalization of genetic data is 
transforming the field of human genetics into a data-driven science. However, with 
this transformation, challenges in the storage, management, and data analysis have 
required the development of novel computational and statistical approaches as 
discussed in the chapters of this thesis.
The approaches described in chapters 3, 4 and 5 show how novel statistical 
methods could be used to identify novel candidate genes associated with genetic 
disorders. In chapter 3 we show how the combination of statistical methods and the 
incorporation of publicly available data into in-house generated datasets identified 
ten novel candidate genes for intellectual disability (ID) based on enrichment of 
functional and loss-of-function de novo mutations. Chapter 4 describes how 
we identified an additional three disease-associated genes based on the spatial 
clustering of de novo missense mutations. In chapter 5 we developed a burden-
analysis method to identify recessive disease genes in large exome sequencing 
cohorts. We show that our method successfully identifies known disease genes but 
also suggests novel recessive candidate disease genes for further investigation. In 
the current chapter, I will assess and discuss the impact of my studies and how future 
technological and methodological advances may lead towards the identification of 
all monogenic causes of neurodevelopmental diseases.
From candidate to disease -associated gene
Statistical analyses, as described in this thesis, are often seen as the first step in the 
process to identify novel disease-associated genes. To prove the relevance of the 
identified mutations in disease requires orthogonal evidence. Such evidence may 
come from additional genetic studies that independently replicate the identification 
of mutations in the candidate genes in non-overlapping patient-cohorts with the same 
disorder. This is then combined with detailed phenotype comparisons of individuals 
with mutations in the same candidate genes as well as functional experiments that 
provide a mechanistic link between the mutations in the gene and the disease.4
For the 13 genes that we identified as novel candidate ID genes in chapters 3 and 
4 we did not provide any additional evidence in the form of replication or functional 
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experiments at the time of publication. In the meantime, clinical follow-up studies 
for eight of the genes have been published which include additional patients and 
extensive phenotype comparisons (Table 1). For two genes, DLG4 and SYNCRIP, 
detailed studies are ongoing and for the gene SOX5 multiple case-reports have 
now been published5,6. For the two remaining genes, SMAD6 and ACLT6B, no further 
studies have been published at this time. In summary, additional evidence for the 
involvement in ID is available for 11 out of the 13 candidate ID genes identified in 
chapters 3 and 4. This is quite remarkable given that my studies were only published 
in 2016 and 2017. The candidate genes identified in chapter 5 have not yet been 
published to-date and currently no additional evidence for their involvement in 
disease is available.
Gene Number of patients
Number of patients 
follow-up Reference follow-up Predicate
DLG4a 5 Patient follow-up in progress (in preparation) Established
PPM1Da 3 14 Jansen et al.7 Established
RAC1a 3 7 Reijnders et al.8 Established
SMAD6a 2 Candidate
SONa 3 20 Kim et al9 Established
SOX5a 3 Multiple case reports5,6 Established
SYNCRIPa 2 Patient follow-up in progress (in preparation) Established
TCF20a 4 6 Schäfgen et al.10 Established
TLK2a 5 39 Reijnders et al.11 Established
TRIP12a 4 9 Zhang et al. 12 Established
ACTL6Bb 3 Candidate
GABBR2b 3 7 Yoo et al.13 Established
PACS2b 3 14 Olsen et al.14 Established
Table 1. Current status of the candidate ID genes identified in this thesis. This table shows the overview of 
clinical follow-up studies that have been published for eight of the genes that include additional patients 
and extensive phenotypic comparison. Genes identified based on gene-specific mutation rates in chapter 
3 are annotated with a. Genes identified based on the cluster analysis of chapter 4 are annotated with b.
Diagnost ic contribut ion
To determine the diagnostic contribution of the 11 ID genes identified in chapters 3 
and 4 with a clinical follow-up study, I have retrospectively investigated how many 
non-synonymous de novo mutations have been identified in an independent cohort 
of 1,620 trios of patients with neurodevelopmental disorders sequenced at the 
RadboudUMC (Figure 1). A total of 17 patients have been identified in the cohort of 
1,620 trios with a non-synonymous de novo mutation in one of the 11 genes resulting 
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in an additional diagnosis of 1.05% or a diagnostic increase of 4.00%. Based on 
estimated global demographics, with almost 400,000 children born per year with 
developmental disorders, this would mean that approximately 4,000 additional 
diagnoses per year could be made based on these 11 genes on a global scale15.
Other genes
N = 1,132
(69.88%)
Disease-associated 
genes
N = 471
(29.07%)
Novel genes
N = 17
(1.05%)
Figure 1. Assessment of non-synonymous de novo mutations in an unbiased cohort of 1,620 pa-
tients with neurodevelopmental disorders from the department of genetics of the RadboudUMC. 
Of the 1,620 patients, 471 had a non-synonymous de novo variant in a gene associated with neu-
rodevelopmental disorders. 17 patients carried a non-synonymous de novo variant in one of the 
11 novel genes identified in chapters 3 and 4.
Towards all  ID -associated genes
As can be seen in Figure 1, for ±31% of the 1,620 patients a non-synonymous de novo 
mutation could be identified based on diagnostic exome trio sequencing. This is in line 
with the current diagnostic yield of 31-42% reported in the literature for exome, or 
even genome, sequencing in patients with neurodevelopmental disorders and ID15-17. 
Many more autosomal ID genes may still await discovery in the fraction of patient’s 
exomes that currently have no diagnosis. However, it is difficult to reliably predict how 
many ID genes are still to be discovered and when all ID genes will be identified18.
Estimates on the total number of ID associated genes, based on X-linked genes 
that are associated with ID, are not unanimous. Estimates range from a total of 
1,500-2,000 genes that cause ID19 to thousands of associated genes that are yet 
to be discovered20. Based on the gene list of 1,514 neurodevelopmental disorder 
associated genes that we have constructed in chapter 4, these estimates would 
suggest that at least five hundred autosomal ID genes are yet to be discovered. 
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However, there are several factors that are currently hampering the identification 
of these remaining genes involved in ID that I will discuss below:
• Lack of statistical power
• Limited ability to read the genome
• Limited ability to identify structural variation
• Mutational mechanisms
• Interpretation of non-coding variants
Stat ist ical  power
One challenge of the studies described in chapters 3, 4 and 5 is the limited 
statistical power. A study by Fitzgerald et al. calculated that studying ±1,000 trios 
has an estimated 5–10% power to detect an averagely mutable haploinsufficient 
developmental-disorder-linked gene17. Furthermore, the authors state that 
the power to detect novel genes that operate recessively or by gain-of-function 
mechanisms is lower than for haploinsufficient genes17. Based on the modelling 
of the statistical power by Fitzgerald et al. we can estimate the statistical power of 
the patient-parent trios based studies of this thesis. The meta-study in chapter 3, 
with a total cohort size of 2,104 trios, has an estimated statistical power of 10 to 
20% to detect an averagely mutable haploinsufficient NDD gene. The meta-study 
to identify spatial clustering of de novo missense mutations described in chapter 
4 was based on 5,302 trios. However, since this study aims to identify clusters of 
de novo mutations within genes that operate by a non-haploinsufficient (e.g. gain-
of-function dominant-negative) mechanisms, the statistical power is expected to 
be lower than the estimated 10-20% for chapter 3. These estimates highlight the 
limited statistical power for the cohorts used in chapters 3 and 4 and emphasize 
the need to create larger cohorts.
The question remains how long it will take before all genes that are involved 
in neurodevelopmental disorders will be identified. A reliable estimate for this is 
very difficult to make. However, it might be possible to extrapolate the findings 
of current large-scale exome studies on neurodevelopmental disorders. Based 
on the power estimates as described in Fitzgerald et al. it would require roughly 
20,000 patient-parent trios to reach complete statistical sensitivity for the averagely 
mutable haploinsufficient neurodevelopmental disorder gene17. Currently, GeneDx, 
the Deciphering Developmental Disorders study, and Radboud University Medical 
Center have aggregated a cohort of 22,518 NDD trios21. The results of the statistical 
analysis of this cohort are soon to be expected and will likely reveal a large number 
of the remaining haploinsufficient genes involved in neurodevelopmental disorders. 
In order to identify all haploinsufficient genes, including the ones with a less than 
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average mutability, even larger cohorts will be needed, up to 100,000 of patients. 
Given the current trend of increasing cohort sizes and international data sharing22, 
I estimate that such cohorts will be available within the next 2.5 – 5 years, and that 
these will reveal the full spectrum of haploinsufficient NDD genes.
Sequenc ing qual i ty
Adequate base pair coverage is the most important requirement for the detection of 
genomic variants. In chapter 6 I describe a comprehensive comparison of coverage 
of the protein-coding regions of samples that underwent whole genome sequencing 
(WGS) or whole exome sequencing (WES). Chapter 6 shows that WES has improved 
over the years but at comparable sequencing depth, WGS outperforms WES regarding 
covered coding regions. This better coverage may result in an improved diagnostic 
yield of as much as 42% based on a direct comparison of 50 individuals with ID who 
were sequenced on both a WES and WGS platform16. This analysis was, however, 
based on a very early version of exome sequencing, and current comparisons would 
likely show less dramatic differences. In addition, WGS has the ability to reliably call 
copy number variants (CNVs) by providing more equal sequence coverage due to 
the absence of an enrichment step, and the ability to accurately detect genomic 
breakpoints that fall outside of the coding region covered by the exome. Particularly 
ID, where 10 – 21% of the patients a de novo CNV is the underlying cause of disease23,24, 
would benefit from one comprehensive test in the clinic.
If WGS provides significantly better results, why is WES considered as the de facto 
standard? In chapter 6 the monetary aspects of the comparison between WES and 
WGS were omitted. Recently published studies estimate prices to sequence an entire 
genome, without clinical interpretation of the variants, to be in the range of $1,696 
to $1,906 and WES in the range of $555 to $79225,26. Based on the prices mentioned 
in these studies, roughly three whole exomes could be sequenced for the price of 
one whole genome. However, WES and WGS prices are dropping and the price of 
WGS is approaching $1,000, lowering an important barrier for widespread clinical 
applications. The first initiatives to explore the possibility to develop infrastructure 
for routine WGS in the clinics are already ongoing. The Genomics England 100,000 
Genomes Project (100,000GP) offers routine WGS for rare genetic diseases and 
cancer.27 It is clear that WGS will be the universal genetic test of the future. However, 
there may still be a niche for WES as long as it remains cost-effective compared to 
WGS, for example in deep sequencing and detection of mosaic mutations. Moreover, 
some significant improvements are still being made in WES, such as the improved 
capture of regions and improvements in the evenness of coverage (Chapter 6).
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Structural  variat ion
NGS can generate high sequence coverage for most regions of the human genome. 
However, paired-end short read sequencing technology is limited in its ability to resolve 
complex and repetitive regions of the genome28,29. New technologies, so-called third 
generation sequencing techniques, are appearing on the horizon and are drastically 
different from current platforms. These third-generation techniques no longer 
require cloning or amplification of the native DNA, and read lengths typically exceed 
5 kb whereas reads from short-read sequencing technology generally are 150-300 
bp. Despite overall lower individual read accuracy, longer read lengths facilitate high 
confidence mapping across a greater percentage of the genome30. In a publication 
of single-molecule, real-time (SMRT) sequencing data, the authors close or extend 
55% of the remaining interstitial gaps in the human reference genome (GRCh37). The 
authors resolve the complete sequence of 26,079 euchromatic structural variants at 
the base pair level, including inversions, complex insertions and long tracts of tandem 
repeats30. Their findings suggest a higher complexity of the human genome in the form 
of variation of longer and more complex repetitive DNA that can now be largely resolved 
with the application of this longer-read sequencing technology. It is expected that the 
ability to sequence repetitive regions, inversions and complex insertions will help in the 
assessment of disease-associated genes and contribute to an improved diagnostic yield. 
The first small successes have already been achieved, where a causal 2.2 kb deletion 
of the first exon of PRKAR1A was identified through long read sequencing, resulting in 
a diagnosis of Carney complex in a previously unresolved patient31.
Mutat ional  mechanisms
The underlying mutational mechanism is an essential factor in the discovery of 
the remaining ID genes. Figure 2 shows the genes with most de novo mutations 
identified in the cohort of 2,418 ID samples (as described in chapter 5) and their 
composition of missense and loss-of-function mutations. Most genes contain 
truncating mutations that are expected to result in disease via a haploinsufficiency 
(HI) mechanism. However, for the genes KCNQ2 and PPP2R5D only missense de novo 
mutations have been identified, suggesting a disease mechanism other than HI.32,33
As shown in chapter 4, very particular mutations might give rise to disease. In 
chapter 4 we identified seven genes where all de novo mutations were affecting one 
single base pair. The most extreme example we found was PACS1 where we identified 
nine recurrent de novo missense mutations. All currently known mutations in PACS1 
that give rise to disease affect only one single base pair position34. A study by McRea et 
al. estimated the number of mutations that act through such mutational mechanisms, 
other than haploinsuficiency. McRea et al. used the ratio of truncating and missense 
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de novo mutations and pLI (probability that a gene is intolerant to a loss-of-Function) 
distribution within haploinsufficient developmental disorder associated genes to 
estimate the proportion of the excess missense de novo mutations that likely act by 
haploinsufficient and non-haploinsufficient mechanisms15. The pLI score is based on 
the loss-of-function variants identified in the protein-coding regions of 60,706 healthy 
individuals and estimates the probability that a gene is intolerant to loss-of-function 
variation, and thus the probability that a gene is haploinsufficient35. The authors 
estimate that 57 – 59% of excess missense and truncating de novo mutations act via 
a haploinsufficient mechanism, and about 43% by a different mechanism15.
Pathogenic mutations in non-haploinsufficient genes will be much rarer than 
pathogenic mutations in haploinsufficient genes, and therefore it will be much more 
difficult to identify these genes by statistical enrichment approaches. However, 
specialized methodology such as the identification of mutational clustering 
as described in chapter 4 will yield greater sensitivity for the detection of such 
events, and cohorts of 100,000 patients may prove sufficient. For example, the 
three candidate genes identified in chapter 4 would not have reached statistical 
significance based on the use of gene-specific mutation rates used in chapter 3.
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Figure 2. The most commonly mutated genes in a cohort of 2,418 patients with neurodevelopmental 
disorders. This figure shows the composition of loss-of-function (green) and missense mutations (blue).
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Mosaic de novo mutat ions
The timing at which de novo mutations arise impacts their phenotypic 
consequences36. Typically de novo mutations occur in the germline, but they may 
also appear post-zygotically, resulting in embryonic mosaicism, where two or more 
genetically different cell populations that developed from a single fertilized egg 
are present in a single individual37. In the most extreme case, only mutations that 
occur post-zygotically result in disease, presumably because germline mutations are 
incompatible with life. An example of the importance of de novo mosaic mutations 
is shown in the case of Proteus syndrome that is caused by activating mosaic 
mutations in the gene AKT1, occurring in the skin38.
Post-zygotic mutations may be tissue-specific, and thereby elude identification 
based on the sequencing of blood samples37. Moreover, post-zygotic mutations 
are much more difficult to detect than germline mutations. This is why post-zygotic 
mutations have only recently been shown to be an unrecognized source of de novo 
mutations that also have severe clinical implications on recurrence risk of the 
disease. Based on a set of 107 de novo mutations in 50 parent-offspring trios one 
study found that seven (6.5%) of these assumed germline de novo mutations were 
present as mosaic mutations in the blood of the offspring and were therefore likely 
to have appeared post-zygotically37. In the case of a post-zygotic mutation, parents 
will have an increased risk of recurrence compared to a germline de novo mutation, 
where recurrence is unlikely.
Post-zygotic mutations may explain part of undiagnosed ID patients. Evidence for 
this comes from studies on neurologic disorders such as autism spectrum disorders 
(ASD) and epileptic encephalopathies (EE). Breuss et al. employed single molecule 
genotyping on de novo mutations identified in a cohort of ASD cases. They found 
that four out of 14 fathers were germline mosaic for a putatively causative mutation 
transmitted to the affected child39. In addition, the authors reported that one of these 
mutations, a de novo mutation in GRIN2A, the cause of diverse neurodevelopmental 
conditions, was transmitted to three affected children. Furthermore, a study by Myers 
et al. found a parental mosaicism in 8.3% of parents who had a child with a diagnosis 
of an apparently de novo mutation in a disease associated gene40. However, the true 
extent to which mosaic de novo mutations contribute to ID remains currently unknown.
Extending to the non-coding DNA
Clinical diagnostic sequencing currently focuses on identifying causal mutations in 
the protein-coding regions of an individual, where most disease-causing mutations 
are currently known to occur41. Extending diagnostic sequencing to the complete 
human genome will, in addition to better coverage of the protein-coding region 
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as discussed before, reveal mutations located in the non-coding regions of the 
human genome. However, extending to the non-coding DNA of the human genome 
introduces a new hurdle: interpretation of the sheer number of variants located in 
98% of the human genome.
Intronic variants
The most apparent form of non-coding variants are mutations in the intronic 
regions of genes. Such mutations may result in alterations in pre-mRNA splicing 
and are increasingly recognized as a cause of monogenic disorders42,43. The 
introduction of NGS has enabled the identification of pathogenic variants located 
deep in intronic regions. The integration of whole genome sequencing data in 
combination with the integration of RNA sequencing (RNA-seq), may provide direct 
insight into transcriptional perturbations caused by genetic changes44-46. RNA-seq 
utilises next-generation sequencing (NGS) technology to reveal the presence and 
quantity of RNA of all genes of the human genome. RNA-seq can help to detect 
aberrant transcriptional events genome-wide and resolve the effect of variants on 
transcription. Analysis of the RNA of single genes has proven useful on a case-by-
case basis to provide diagnoses to patients with Mendelian disorders44-46.
A recent study demonstrated how RNA-seq identified a range of aberrations 
caused by both protein-coding and non-coding variants. The authors performed 
RNA-seq on muscle tissue of 50 patients with genetically undiagnosed rare muscle 
disorders and identified splice-altering variants in both exonic and deep intronic 
regions, yielding an overall diagnosis rate of 35%44. The authors also report the 
discovery of a highly recurrent de novo intronic mutation in COL6A1 that results in 
a dominantly acting splice-gain event. Furthermore, the authors identified splice 
site–creating hemizygous deep intronic variants in the DMD gene that resulted in the 
creation of a pseudo-exon and led to a premature stop codon in the coding sequence 
that would have been missed without the addition of RNA splicing information44.
However, these approaches ideally require the availability of relevant patient 
tissue because RNA expression profiles are known to show a high degree of 
variability between different cell types44,47. Furthermore, obtaining the relevant 
tissue for patients with neurodevelopmental or neurodegenerative disease is 
however often not feasible. In addition, the brain consists of a variety of different 
types of cells, and it is not clear which cell type would be relevant for the different 
forms of ID48. Induced pluripotent stem cells may provide a partial remedy for these 
challenges, allowing one to differentiate patient-derived cells such as lymphocytes 
or fibroblasts into more disease-relevant tissue types such as neurons49,50.
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Regulatory regions
Another important part of the non-coding genome consists of regions regulating 
gene expression. Regulatory regions of the human genome are estimated to 
comprise more than four times (8.2% of the human genome) the size of the protein-
coding regions51. SNVs and structural variations located in regulatory elements have 
been identified as the cause of several Mendelian diseases52,53. Regulatory elements 
are notoriously difficult to identify and may reside at considerable distances from 
the transcription units on which they operate and may be incorporated into the 
structure of neighbouring genes54. For example, pathogenic variants affecting the 
expression of the gene SHH were identified in an intronic region of a different gene, 
1Mb away from SSH itself54. However, the relationships between these elements 
and distal target genes remain largely unknown. A recent systematic genome-wide 
assessment showed that 7% of distal elements establish contact with the nearest 
promoter indicating that genomic proximity is not a simple predictor for long-range 
interactions55.
Specialized techniques, such as Hi-C, are able to assess the 3D configuration 
of folded DNA inside the nucleus of a cell and quantify the number of interactions 
between loci that are located in the neighbourhood56. Hi-C revealed that the 
genome is partitioned into condensed structures, or topologically associated 
domains (TADs)57. TADs are thought to represent regulatory domains and contain 
many preferentially interacting sub-regions and very few interactions across 
their boundaries. Disruption of TADs may lead to disease because changing the 
3D organization of the chromosome disrupts gene regulation, whereby genes are 
expressed in the wrong tissue or at the wrong time-points during development58. 
Recent studies of particular mouse loci have implicated disrupted regulatory 
architecture in developmental disorders and engineered mouse mutations have 
been seen to alter TAD boundaries and affect the expression of nearby genes59. 
The discovery of TADs and knowledge on the spatial conformation of nuclear DNA 
will help us better interpret non-coding CNVs and variants identified through WGS.
However, the contribution of such non-coding events remains unclear. In a recent 
study by Short et al. it was shown that de novo mutations in highly evolutionarily 
conserved fetal brain-active elements are significantly and specifically enriched in 
neurodevelopmental disorders. These authors estimate that genome-wide, only 
1–2.8% of patients without a diagnostic coding variant carry pathogenic de novo 
mutations in fetal brain-active regulatory elements60. In addition, the authors 
highlight an urgent need for improved tools to stratify benign and damaging variants 
within non-coding elements and to annotate gene targets for regulatory elements60.
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Polygenic contribut ions
Whereas most patient-oriented studies into neurodevelopmental disorders have 
focussed on Mendelian genetics, advances have also been made towards the 
identification of polygenic causes of disease. Genome-wide association studies 
(GWAS) of common variants have identified thousands of susceptibility loci in 
disease61,62. However, the effect sizes of identified common SNPs are generally 
very small63. Therefore the term risk factor is used to indicate that among 
polygenic disorders any individual sequence variant acts in a statistical rather than 
deterministic fashion. This is in contrast to the monogenic or Mendelian inheritance 
model where the presence of one variant gives rise to the phenotype.
Polygenic contributions have already been identified in large neurodevelopmental 
disorder cohorts. It has been estimated that about 3-5% of autism spectrum 
disorders (ASD) cases may arise from non-complementing genetic variants at 
dozens of different loci64. Weiner et al. , using a novel approach called the polygenic 
transmission disequilibrium (PTD) test and data from 6,454 families with a child with 
ASD, showed that polygenic risk for ASD is over-transmitted to children with ASD 
65. The authors find that polygenic variation contributes additively to risk in ASD 
cases that carry a strongly acting de novo mutation. Application of the PTD test to 
a cohort of 6,987 children with neurodevelopmental disorders revealed that 7.7% 
of NDD risk could be explained by polygenic effects in disorders widely presumed 
to be monogenic66.
A recent study by Kheira et al. on five more common diseases development and 
validation of genome-wide polygenic scores for five common diseases identified 
effect sizes of 1.5 – 8.0% of the population at greater than threefold increased 
risk67. These risks are comparable to those from rare Mendelian variants, perhaps 
indicating that the use of polygenic risk scores in the clinic is becoming feasible.
For neurodevelopmental diseases, a polygenicity inheritance model may still 
be too complex because of the much greater underlying biological complexity. 
Therefore much larger cohorts may be required to identify a sufficient number of 
common variants that give rise to a valuable polygenic risk score. Perhaps, the GWAS 
studies that analyze single nucleotide polymorphisms of hundreds of thousands of 
individuals resemble a comparable complexity68,69. This could mean that hundreds 
of thousands of genomes might be required to provide a cohort with the required 
statistical power to measure the effect of all variant for polygenic models for 
extreme heterozygous disorders such as ID. Such a cohort will represent the next 
milestone for the field of human genetics with its own challenges and needs for 
computational methods.
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CONCLUSION
My thesis has revealed many novel candidate genes for intellectual disability by 
analysing available large-scale genomic datasets with novel statistical approaches, 
without doing a single experiment in the laboratory myself. The available datasets 
and computational and statistical approaches as described in this thesis represent 
a larger trend in the field of human genetics that is evolving in an increasingly 
data-driven discipline, rather than a purely experimental/laboratory field. 
These approaches combined with ongoing international data sharing initiatives 
greatly contribute to finding all genes for intellectual disability and other 
neurodevelopmental disorders. I predict that more than 95% of all monogenic 
causes of neurodevelopmental diseases will be identified within a period of 5 to 10 
years. Novel “omics” technologies will continue to generate more and more complex 
biological data, and integration of various sources of “omics” data will allow us to 
move ahead with the interpretation of non-coding mutations and more polygenic 
causes of these disorders, allowing us to determine their contribution to disease 
causation and phenotypic variability. This development will undoubtedly continue 
to increase the demand for expertise in data-analytics and bioinformatics in medical 
genomics.
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Chapter 8
SUMMARY
Identifying the genes in which genetic mutations are responsible for a specific 
disease is of paramount importance. The identification of novel disease genes 
contributes to our understanding of gene functions and biological pathways 
underlying health and disease. In addition, the identification of a novel disease gene 
allows for the diagnosis of patients for this gene. Such a genetic diagnosis provides 
patients with information on the disease-prognosis, potential therapy, and provides 
the patient’s parents with a risk of recurrence. 
The introduction of next-generation sequencing (NGS) enables the reading of 
DNA, and thus the detection of mutations, much faster and more cost-efficient 
than before. In particular exome sequencing (i.e. reading only the DNA that is 
translated into proteins) has quickly become a standard within the repertoire of 
genetic laboratories for both research and diagnostics in human genetics. This 
new technique has accelerated the identification of new genes that are associated 
with human diseases. The large quantities of data that are generated by NGS are 
slowly transforming the field of human genetics into a data-driven science. Solutions 
from different fields, such as computer science and statistics, had to be introduced 
to solve these challenges and thereby firmly established a role for bioinformatics 
within the field of genetics. 
The scale at which exome sequencing data is now being generated has given rise 
to novel challenges in bioinformatics to store, analyze and interpret exome data 
of this magnitude. In chapter 2, I discuss these challenges and possible solutions. 
Chapter 3 describes how I collected a dataset of de novo mutations (i.e. mutations 
that are present in the DNA of the offspring while being absent in the DNA of the 
parents) from 2,104 patients with intellectual disability (ID) and applied a statistical 
model to identify genes that are enriched for mutations in the patient cohort. We 
found that ten genes (DLG4, PPM1D, RAC1, SMAD6, SON, SOX5, SYNCRIP, TCF20, TLK2 
and TRIP12) harboured more de novo mutations than expected and are therefore 
novel candidate ID genes. Analyses on gene function, genetic intolerance and patient 
phenotype provided additional support for the causative nature of the mutations 
in the majority of the candidate genes.
In addition to analysing the absolute numbers of de novo mutations, novel 
candidate genes can also be identified based on specific patterns of mutations. In 
chapter 4, I change perspective and show how spatial clustering of de novo mutations 
in genes can be used to discover new genes that are associated to disease. We 
successfully identified 15 genes with a cluster of mutations, of which three novel 
candidate ID/DD-associated genes (ACTL6B, GABBR2 and PACS2). We also show that 
the mutations in the clusters likely exert disease through a mutational mechanism 
185
Miscellaneous
other than haploinsufficiency (e.g. gain-of-function or dominant-negative). In line 
with this, I observed that, when we map the de novo mutations onto 3D structures of 
the proteins, these mutations are less likely to affect the overall structural integrity 
of the protein, compared to other known haploinsufficient mutations. 
Besides de novo mutations, also inherited mutations are also known to cause 
disease. In chapter 5, I developed a method that aims to assess the genetic burden 
for each gene, based on rare variants. We applied our new approach to the rare 
variants of 6,257 patients with four different genetic disorders to identify recessive 
disease genes by cross cohort-based comparison. We show that our method 
successfully identifies known disease genes, but also suggests novel recessive 
candidate disease genes for further investigation. 
The computational methods that I used in previous chapters are limited by the 
genetic variants that can be identified in the patient’s DNA. In chapter 6, I compare 
different NGS platforms and their capability to read the DNA. I investigated whether 
whole genome sequencing (WGS) platforms are better at reading the protein-coding 
regions of the human genome, compared to exome sequencing platforms. I found 
that exome sequencing platforms have improved considerably in the last years. 
However, at comparable sequencing depth, WGS outperforms exome sequencing 
in terms of covered coding regions. These findings will guide laboratories in making 
an informed choice on sequencing platform and coverage.
Computational analyses, as described in this thesis, are often seen as the 
first step in the process to identify novel disease-associated genes. In chapter 
7, I performed a retrospective literature analysis on the current status of the 13 
candidate genes that where identified in chapters 3 and 4 of this thesis. Additional 
evidence for the involvement in ID is available for 11 out of the 13 candidate ID genes 
identified, which is quite remarkable given that my studies were only published in 
2016 and 2017. Furthermore, based on these genes, we can expect an additional 
diagnosis for 1.05% of the patients, or an increase of the diagnostic yield of 4.00%. 
The final part of the discussion provides perspectives for future research on how 
we may be able to resolve the genetic cause of disease in patients for whom we 
currently cannot provide a genetic diagnosis.
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SAMENVATTING
Het is van groot belang dat we alle genen identificeren waarin mutaties 
verantwoordelijk zijn voor het ontstaan van een specifieke ziekte. Het identificeren 
van nieuwe ziektegenen draagt bij aan het beter begrijpen van de onderliggende 
biologische processen die ten grondslag liggen aan een specifiek ziektebeeld. 
Ook maakt de identificatie van een nieuw ziektegen het mogelijk om patiënten 
te diagnosticeren. Een genetische diagnose geeft patiënten informatie over de 
prognose van de ziekte, mogelijke behandeling, en geeft ouders van jonge patiënten 
inzicht in het risico op herhaling bij toekomstige kinderen. 
De introductie van next-generation sequencing (NGS) maakt dat het lezen van 
het DNA, en dus het detecteren van mutaties, veel sneller en efficiënter kan dan 
voorheen. Met name exome sequencing (het uitlezen van enkel het DNA dat codeert 
voor eiwitten) is in korte tijd de standaard geworden binnen het repertoire van 
genetische laboratoria en onderzoeksinstituten. Deze nieuwe techniek heeft de 
identificatie van nieuwe, aan ziekten gerelateerde genen bij de mens aanzienlijk 
versneld. De grote hoeveelheden gegevens die door middel van NGS worden 
gegenereerd veranderen het veld van humane genetica langzaam in een door data 
gedreven wetenschap. Vanuit verschillende vakgebieden, waaronder informatica 
en statistiek, zijn methoden geïntroduceerd om hier mee om te kunnen gaan. 
Hierdoor is de rol voor bioinformatica binnen het veld van genetica inmiddels stevig 
verankerd.
De enorme schaal waarop exoom sequencing data nu wordt gegenereerd heeft 
geleid tot nieuwe uitdagingen binnen de bioinformatica om data van deze omvang 
efficiënt te bewaren, analyseren en te interpreteren. In hoofdstuk 2 bespreek ik 
deze uitdagingen en mogelijke oplossingen. 
Hoofdstuk 3 beschrijft hoe ik een dataset van de novo mutaties (de mutaties 
die aanwezig zijn in het DNA van de nakomeling, maar afwezig zijn in het DNA van 
de ouders) heb verzameld van 2.104 patiënten met een verstandelijke beperking 
(ID). Vervolgens heb ik een statistisch model toegepast om nieuwe ziektegenen te 
identificeren gebaseerd op de verrijking van mutaties binnen de patiëntengroep. We 
constateerden dat tien genen (DLG4, PPM1D, RAC1, SMAD6, SON, SOX5, SYNCRIP, TCF20, 
TCF20, TLK2 en TRIP12) meer de novo mutaties bevatten dan verwacht, en daarom 
nieuwe kandidaatgenen voor ID zijn. Analyses op genfunctie, genetische intolerantie 
en patiëntfenotypes leverden extra ondersteuning op voor de causatieve aard van 
de mutaties in de meeste kandidaatgenen.
In hoofdstuk 4 verander ik van perspectief en laat ik zien hoe specifieke clusters 
van de novo mutaties gebruikt kunnen worden om nieuwe ziektegenen te vinden. 
Op deze manier vinden we 15 genen met zulke mutatie clusters, waarvan drie 
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nieuwe kandidaat ziekte genen voor ID. We tonen ook aan dat de mutaties in deze 
clusters waarschijnlijk een ziekte veroorzaken via andere mutatiemechanismen 
dan haploinsufficiëntie, bijvoorbeeld via gain-of-function of dominant-negatief. In 
lijn hiermee constateer ik dat, wanneer we de de novo mutaties in kaart brengen in 
de 3D-structuren van deze eiwitten, de algemene structurele integriteit aanzienlijk 
minder beïnvloedt wordt in vergelijking tot  andere bekende haplosufficiënte genen.
Behalve de novo mutaties kunnen ook erfelijke mutaties ziekten veroorzaken. In 
hoofdstuk 5 heb ik een methode ontwikkeld om de genetische belasting van elk gen 
te beoordelen op basis van zeldzame varianten. We hebben deze nieuwe methode 
toegepast op de zeldzame varianten van 6.257 patiënten die zijn onderverdeeld in 
groepen van vier verschillende genetische aandoeningen. Op basis van onderlinge 
vergelijkingen van de vier groepen tonen we aan dat onze methode met succes 
bekende ziektegenen identificeert. Daarnaast worden ook nieuwe recessieve 
kandidaat-genen voor verder onderzoek gesuggereerd. 
De effectiviteit van de computationele methoden die ik in de vorige hoofdstukken 
van dit proefschrift beschrijf, kunnen worden beperkt doordat genetische varianten 
gemist worden bij het uitlezen van het DNA. In hoofdstuk 6 vergelijk ik verschillende 
NGS platformen en hun vermogen om het DNA te lezen. Ik heb onderzocht of 
genoom sequencing  platformen beter zijn dan exoom sequencing platformen in het 
uitlezen van de eiwit coderende regio’s van het menselijk genoom. Ik concludeer dat 
exoom sequencing platformen in de laatste jaren aanzienlijk zijn verbeterd. Echter, 
voor vergelijkbare sequencing-specificaties presteert genoom sequencing beter dan 
exoom sequencing in het aflezen van eiwit coderende regio’s. Deze bevindingen 
kunnen laboratoria helpen in het maken van een afgewogen keuze voor het 
sequentieplatform en de bijbehorende specificaties.
Computationele analyses, zoals beschreven in dit proefschrift, worden vaak 
gezien als de eerste stap in het proces om nieuwe, aan ziekte gerelateerde genen, 
te kunnen identificeren. In hoofdstuk 7 heb ik een retrospectieve literatuuranalyse 
uitgevoerd voor de 13 kandidaatgenen die in de hoofdstukken 3 en 4 van dit 
proefschrift zijn geïdentificeerd. Aanvullend bewijs voor de betrokkenheid bij 
mentale beperkingen is beschikbaar voor 11 van de 13 geïdentificeerde kandidaat 
genen, wat opmerkelijk is gezien het feit dat mijn studies pas in 2016 en 2017 
werden gepubliceerd. Bovendien kunnen we op basis van deze genen een diagnose 
verwachten voor een additionele 1,05% van de patiënten en een toename van de 
diagnostische opbrengst van 4,00%. Het laatste deel bediscussieert perspectieven 
voor toekomstig onderzoek om de genetische oorzaak van ziekten te vinden bij 
patiënten waar we momenteel geen genetische diagnose kunnen stellen.
8
188
Chapter 8
DANKWOORD / ACKNOWLEDGEMENTS
Dit proefschrift heeft nooit tot stand kunnen komen zonder de hulp en bijdrage 
van mijn geweldige collega’s, vrienden en familie. Vandaar dit hoofdstuk, een ode 
aan jullie.
Christian, je durfde het aan om mij, als jouw eerste PhD-student, aan te nemen 
op je Veni beurs en de dagelijkse begeleiding op je te nemen. Als ik terugdenk aan 
hoe we het eerste jaar samen als “Gilissen groep” begonnen, zie ik wat een mooie 
weg wij beiden hebben afgelegd. Volgens mij heb jij nog heel wat kratjes bier van 
mij tegoed van alle weddenschappen die ik heb verloren. Je bent een hele fijne 
mentor voor mij geweest tijdens mijn periode als PhD-student. Je hebt mij weten te 
inspireren met je enthousiasme, passie voor wetenschap, werkethiek en capaciteit 
om knopen door te hakken en projecten af te ronden (waar het bij mij nog wel eens 
aan ontbrak). Ik wil je bedanken voor alle tijd en energie die je in mij hebt gestoken 
als wetenschapper, supervisor en vriend.
Joris, ik had me geen betere promotor kunnen wensen. Jouw sterke 
wetenschappelijke visie is voor mijn projecten van enorm belang geweest.  Ondanks 
dat je geen achtergrond hebt in bioinformatica wist je altijd precies de juiste vragen 
te stellen. Je bent zoals je zelf altijd zegt “heel normaal gebleven”, wat ik kan beamen. 
Je bent heel toegankelijk en altijd wel in voor een feestje. Jij voelde altijd perfect aan 
wanneer projecten wat meer sturing nodig hadden en bent in staat om problemen, 
die voor mij onoplosbaar leken, toch te kunnen fixen. Dat alles zelfs vanaf de andere 
kant van het kanaal, zo bleek na jouw verhuizing naar Newcastle. 
Han, bedankt voor de intrigerende de brainstormsessies, die leidden tot ideeën 
om projecten naar een hoger niveau te tillen. Jouw volharding bij het opstellen van 
de rebuttals voor de meta-study en de clusteranalyse papers hebben mij laten ziet 
dat de aanhouder toch echt wint. Bij de voorbereidingen van congrespresentaties 
wist jij precies hoe we de complexe materie op een eenvoudige en begrijpbare 
manier konden overbrengen. 
Lisenka, al vanaf het begin was jij betrokken bij mijn promotietraject. Jouw fijne 
oog voor detail heeft mij al regelmatig gered. Om nog maar te zwijgen over de keren 
dat jij moest bijspringen omdat mijn gebrek aan time-management weer eens voor 
problemen zorgde. We noemden jouw altijd grappend mijn surrogaat supervisor, 
want als ik ergens mee zat en een luisterend oor nodig had, stond je altijd voor mij 
klaar. 
Alex, jouw enthousiasme voor wetenschap was altijd zeer aanstekelijk. Je 
nam altijd de tijd om mijn vragen over de laatste sequentietechnieken of lastige 
mutatiemechanismes te beantwoorden. Daarnaast was je altijd bereid om naar mijn 
oefenpresentaties te luisteren om ze te kunnen perfectioneren. En als er weer eens 
189
Miscellaneous
treinstoring was, en ik niet meer vanuit Nijmegen naar Utrecht kon komen, kon ik 
altijd in de logeerkamer terecht. Ook tijdens de Vierdaagse was ik jaarlijks te gast 
bij Hotel Alex. Dankjewel voor je gastvrijheid en lekkere snacks!
Het was een waar genoegen om deel te mogen uitmaken van de Genomics 
Disorder groep en de humane genetica afdeling van het Radboud UMC. Ik heb 
gedurende mijn periode daar de eer gehad om met heel wat geweldige collega’s te 
mogen werken. 
Ik begon als de eerste PhD-student in de groep van Christian, maar werd 
gelukkig al snel vergezeld door (vader) Jakob en Laurens en later door Bregje. 
Drie bioinformatica PhD-studenten waarmee je kunt sparren over hoe processen 
het beste kunnen lopen en welke algoritmen de taak het beste kunnen voltooien 
is van enorme waarde. Daarnaast was het heel fijn om met jullie het PhD-traject 
te kunnen doorlopen. Laurens ik ben trots op hoe onze samenwerking voor het 
cluster-project een mooie paper opleverde. Rocío, senior-PhD-guru, thank you 
for your scientific discussions, coffees, and cup-tumbling cockatoos. Peer, jouw 
optimisme, doorzettingsvermogen en Brabantse humor lieten mij inzien dat een 
PhD doen ook best leuk kan zijn. Manon en Sinje, bedankt voor jullie input en 
wetenschappelijke discussies. Mijn kamergenoten Suus, Stephanie, Laurens, Jacob, 
Bergje, Jard en Simone, naast jullie feedback en discussies over wetenschap en 
andere zaken, was de dag beginnen met een kopje koffie en goed gesprek een vast 
en belangrijk ritueel. Na werk verruilden we de koffie vaak voor wat sterkers, we 
hebben samen heel wat mooie avonden beleefd.  
Rolph, als ik vragen had over de diagnostiek nam jij altijd de tijd om te helpen, 
hoe druk je het ook had. Voor last minute Sanger validaties draaide jij je hand niet 
om, jij regelde het. Margot, gedurende mijn PhD was jij mijn vraagbaak over de 
patiënten en cohorten. Ik ben altijd onder de indruk geweest hoe jij de stapels 
dossiers doorwerkte om te bekijken of er consent was om geïncludeerd te kunnen 
worden in de meta-studies. Het koste veel tijd, maar jij deed het!
Voor de hoofdstukken van dit proefschrift staat het analyseren van genoomdata 
van patiënten centraal. De bioinformatici van de diagsnotiek afdelingen, Djie, 
Steven, Galuh, Jordi, Jordi, Rick, Marisol, Nienke en Marc stonden altijd klaar 
om te helpen met data gerelateerde problemen. Dimitra, the little dictator, thank 
you for being my office-mate and joining me on those long train-rides, commuting 
between Utrecht and Nijmegen. Maartje, bedankt voor de analyses die je hebt 
gedaan voor de NGS platformvergelijking in hoofdstuk 6. Van jouw effectiviteit kan ik 
nog wat leren. Steven, alle projecten begonnen met brainstormsessies en discussies 
waarin duidelijk werd hoe we de computationale processen moesten laten lopen. 
Mieke, bedankt voor de samenwerking en de zelf gebakken chocolade taart. Last, 
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but not least, Jayne, thank you for your input and discussions during the train-rides, 
commuting between Utrecht and Nijmegen. I’m happy to be your colleague again! 
Zeer belangrijk voor dit proefschrift waren de zorgvuldig geselecteerde 
patiëntengroepen. Mijn dank hiervoor aan de diagnostiek en clinici, Helger, Marcel, 
Erik-Jan, Rolph, Hannie, Frans, Connie, Lonneke, Bert, Margot, Marjolein, Bregje, 
Tjitske, Ernie, Tuula, Janneke en Han. En het fantastische lab team bestaande uit 
Marloes en Petra die veel van de Sanger validaties voor hun rekening hebben 
genomen. 
Naast werk had ik ook het geluk om met collega’s internationale congressen te 
mogen bezoeken waarbij veel voorbereiding kwam kijken. Daar heb ik belangrijke 
ervaring opgedaan waarvoor ik mijn dank graag wil uitspreken. Zo liep ik op de 
ESHG (European Society of Human Genetics) 2015, samen met Lot en Margot, als 
verloren brugklasser die voor het eerst mag presenteren, zoekend naar de plek 
om onze presentaties te kunnen uploaden. Daarna heb ik nog de ESHG 2016 en 
2017 mogen meemaken in het gezamenlijke Airbnb-huis, inclusief Nijmegenfeest, 
samen met Alex, Christian, Lisenka, Jakob, Laurens, Margot, Lot, Marloes, Peer, 
Rocío, Judith, Manon, Richarda and Gael. ASHG 2017, met Ilia, Rosa en Sinje, dat 
getypeerd werd met een koelkast vol bacon. Die tripjes waren geweldig!
Maar niet alle tripjes waren werkgerelateerd. Met Alex, Marloes, Martijn, 
Michael, Petra, Richarda en Simon naar Sölden, ik kom de Willlie mit birne-
zwaardjes zo nu en dan nog tegen. Ik heb de eer gehad om samen met Adinda, 
Petra, Lonneke, Margot, Michiel en Jordi het jaarlijkse dagje uit met de afdeling 
genetica te mogen organiseren. 
Tot slot, mijn vrienden en familie. Mark, Jesse, Linda, Adinda, Daniel, Rosalie, 
Gerben, Mark, Martine, Bjorn, Gijs, Rik, Charlie, Michiel, Karel, Fabian ,Valentina, 
Matías, Ali en Nicola, wat fijn om in het weekend lekker met jullie drankjes te doen, 
op stap te gaan, bbq-en in het park of festivals te pakken en even los te komen van 
het harde werken. Mark en Maarten, bedankt dat jullie mij willen begeleiden als 
paranimfen en veel organisatorisch werk uit handen genomen hebben. Daniel, 
gebaseerd op een van de eerste proefversies heb jij de schilderingen gemaakt voor 
de kaft en hoofdstukpagina’s, waardoor dit proefschrift letterlijk een kunstwerk 
geworden is. En Linda, dankjewel voor je hulp bij het digitaliseren daarvan. Mijn 
broer Laurens, die vaak als “leek”-lezer diende voor de hoofdstukken van dit 
proefschrift en altijd klaar staat voor een goede discussie. Mijn zus Marjolein, 
voor de fijne, speciale broer-zus relatie die we hebben en dat jouw vriend mijn 
paranimf kon zijn, mede op aanraden van jou. Mijn oma, die het geld van haar 
verjaardag doneerde aan de Hersen Stichting om zo bij te kunnen dragen aan mijn 
wetenschappelijk werk. Mijn schoonouders, Fred en Dorette, mijn grootste fans, 
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dank voor jullie support. Lieve ouders, Jan en Marja, jullie zijn de architecten van 
dit werk. Dat jullie mij altijd hebben vrijgelaten in alle keuzes die ik heb gemaakt 
en jullie onvoorwaardelijke ondersteuning, heeft geresulteerd in waar ik nu ben. 
Lieve Ellemijn, mijn steun en toeverlaat, en sinds een jaar ook mijn verloofde. 
Tijdens de vijf jaar van mijn PhD heb je heel wat te verduren gekregen. Jouw 
geloof en vertrouwen is wat mij, met name aan het einde van de rit, op de been 
heeft gehouden. Als ik het even niet meer wist en de Zuurbert (een toepasselijk 
pseudoniem van mijn tweede naam, Hubertus) in mij tevoorschijn kwam, was jij 
altijd in staat om mij te kalmeren en te motiveren om door te gaan. Ik bewonder je 
om jouw eindeloze geduld met mij en ik kijk uit naar de tijden samen die nog voor 
ons liggen.
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 - Paper reviewing scientific journal (EJHG/Human Mutation)
2014-2016
2014-2018
2015-2017
2015-2016
2016-2017
3.0
2.0
3.0
2.0
0.3
TEACHING ACTIVITIES Year(s) ECTS
e)      Lecturing
 - Assisting practical in the Personal genomics course
 - Assisting practical in the NGS course MMD master
2014-2015
2016-2017
1.0
1.0
f)      Supervision of internships / other
 - Supervision bioinformatics bachelor intern: (S. Boersma)
 - Supervision bioinformatics bachelor intern: (M. Stegeman)
2016
2017
2.0
2.0
TOTAL 35.15
8
